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Abstract
The dynamics of monoclonal antibody production by CLC LT14 cells were characterized
in perfusion bioreactors. The cell line, a Sp2/0-derived transfectoma, secretes a chimeric
human-mouse IgG1 directed against an antigen found on colorectal carcinomas. In order to grow
cells to high density, part of this research project included the design and characterization of
a novel conical cell separator to effect cell recycle in the perfusion bioreactor. The use of this
cell separator permitted facile growth to densities in excess of 107 viable cells/ml.
A marked cell-density dependent decline in the specific rate of antibody production from
about 0.2 pg/c-hr at densities < 3 x 106 viable cells/ml to 0.02 pg/c-hr at a cell density of 107
viable cells/ml was observed during growth in perfusion bioreactors. Removal of cells from
bioreactors at high density showed that this downregulation of antibody production was
reversible. Cells regained their high productivity after two days of growth at low density.
In order to explore the basis of this downregulation of antibody productivity, I measured
the rates of transcription, translation, synthesis, and secretion at high and low antibody
productivity. This was done by measuring steady-state heavy and light chain mRNAs,
distribution of mRNAs on polysomes, and intracellular IgG and secreted IgG.
Analysis of steady-state immunoglobulin mRNA levels showed that heavy and light
chain mRNAs decreased coordinately to 1/3 of the levels seen at high specific productivity at
cell densities in excess of 3 x 106 viable cells/ml. Immunoglobulin mRNAs per cell remained at
these levels as the specific productivity slowly decreased to less than 1/10 the level seen at
densities < 3 x 106 viable cells /ml.
Examination of polysome loading of immunoglobulin mRNAs showed that the average
polysome size for light and heavy chain mRNAs decreased coordinately from full loading at
high productivity. Comparison of the heavy chain polysomes at high and low specific
productivity showed a 2.4-fold reduction in polysome loading in the fractions containing 68%
of the heavy chain signal at high productivity; the light chain polysomes showed a 2.4-fold
decrease in loading in the fractions containing 62% of the light chain signal at high
productivity. The average number of ribosomes associated with mRNAs decreased 2.3-fold for
heavy chain mRNA and 1.4-fold for light chain mRNA.
Rates of translation of a-tubulin, a cellular "housekeeping" protein also decreased;
comparison of the a-tubulin polysomes at high and low specific productivity showed a 2.6-fold
reduction in polysome loading in the fractions containing 66% of the a-tubulin signal at high
productivity, and the average number of ribosomes associated with a-tubulin decreased 2.6-
fold.
The product of the 3-fold reduction in transcription of immunoglobulin mRNAs and the
2.3-fold decrease in translation of immunoglobulin heavy chain, by itself, would result in a 7-
fold decrease in synthesis and secretion. This decrease, coupled with a 1.4-fold decrease in
cellular processing rates, is sufficient to account for the 10-fold observed decrease in
immunoglobulin synthesis and secretion.
The finding that the synthesis of not only immunoglobulin, but a-tubulin were reduced at
high density implied that the decrease in rates of transcription and translation were part of a
global downregulation of protein synthesis at high cell density.
Thesis Supervisor: Dr. William G. Thilly
Title: Professor of Applied Biology and Civil Engineering
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I. Introduction
A. Monoclonal Antibody Technology
1. Immunoglobins
Immunoglobulins are molecules secreted by B cells which have an
antigen-binding variable region and a constant effector region. There are five
classes of immunoglobulins (IgG, IgM, IgA, IgD, and IgE), differing in the
structure of the heavy chain constant region (designated as y, g, a, 8, and C,
respectively) and two classes of light chains, kappa (I) and lambda (k). An
immmunoglobulin G (IgG) molecule, shown schematically in Figure I-1,
consists of two identical heavy (H) and two identical light (L) chains, of
approximate molecular weight 50,000 and 25,000, respectively, which are held
together by inter and intrachain disulfide bonds as well as by noncovalent
interactions to form a bivalent H2L2 (Fougereau and Edelman, 1965). The
heavy chain polypeptide consists of approximately 440 amino acid residues
and the light chain of approximately 220 amino acids, and each chain is folded
into domains of 110 amino acids.
Both chains have an amino terminal variable (V) region and the light
chain has one carboxy-terminal constant (C) region, while the heavy chain
has three constant regions (CH 1-3). The antigen binding site is formed by the
variable region, which differs among antibodies reacting with different
antigens (French et al., 1989). The variable region is further subdivided into
three hypervariable complementarity-determining regions (CDR 1-3 in Figure
I-1) which are the sites of antigen contact, and four framework regions (FW 1-
4 in Figure I-1) (French et al., 1989).
The constant regions mediate cell membrane receptor interactions and
complement interactions (Benjamini and Leskowitz, 1988). Each domain of
the variable region is encoded by a series of exons. These are designated
variable (VH), diversity (D) and joining (J) for the heavy chain, and VL and JL
for the light chain. The "hinge" region of the heavy chain is between the first
and second heavy chain domain.
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Figure I-1.
Schematic of the Structure of Immunoglobulin G
CH1
Hinge Reg
CH2
C H3
COOH
H2 2NH
V.
CDR1
CDR2
CDR3 - DJ
L H
The functional domains of the heavy and light chains are shown filled in
with different patterns. Abbreviations are: VL (variable region of light
chain); CL (constant region of light chain); VH (variable region of heavy
chain); CH1-3 (constant regions 1-3 of heavy chain). The variable regions of
the heavy and light chains are further subdivided into three
complementarity-determining regions (CDR1-3) and four framework regions
(FW1-4). For the light chain, FW1-3 and CDR1 and 2 are encoded by the VL
exon and FW4 and CDR3 by the joining (J) exon. For the heavy chain, FW1-3
and CDR1 and 2 are encoded by the VH exon, CDR3 by the diversity (D) exon,
and FW4 by the joining (J) exon.
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In humans, there are four IgG subclasses which are distinguised by
their fine structure, number of glycosidic side chain, number of disulfide
bonds, and a number of in vivo properties such as their half-life in the serum
(Benjamini and Leskowitz, 1988). An N-linked oligosacharide at Asn-297 in
the CH 2 domain of the heavy chain is conserved in all species (Beale and
Feinstein, 1976). Glycosylation of monoclonal antibodies is needed for in vivo
effector functions such as complement binding, binding to the Fc receptor of
macrophages, elimination of antigen-antibody complexes, and induction of
antigen-antibody cellular cytotoxicity (Nose and Wigzell, 1983).
In vivo, B cells undergo a maturing process when exposed to an antigen.
(Melchers et al., 1975). As B lymphocytes mature, immunoglobulin appears
first in the cytoplasm, then on the cell surface, and finally as secreted product
(Melchers, et al., 1975). This transition involves the sequential expression of
multiple forms of immunoglobulin M (g) heavy chain (Melchers, et al., 1975)
and the activation of light chain synthesis.
The expression of immunoglobulin is mediated by rearrangement of
the germ line DNA during B lymphocyte maturation to give functional
heavy and light chain genes (Tonegawa, 1983; Wall and Kuehl, 1983). The
variable region of the heavy chain is formed in pre-B cells by a sequential
two-step process. First, the D region is joined to an JH (joining) region on
both chromosomes, and then a VH is joined to the DJH region. The creation
of an immunoglobulin heavy chain gene involves combining of one of over
100 variable segments with one of 12 diversity segments and one of the four
joining segments, and results in two deletions of intervening DNA sequences
(reviewed by Tonegawa, 1983). The rearranged VDJ portions and the nearby
segment for the constant g chain constitute the gene coding for synthesis of ~L
chain. The configuration of immunoglobulin heavy and light genes in
germline DNA and after rearrangement is shown schematically in Figure 1-2.
Exons are indicated by boxes, and introns by a thin line.
The pre-B cell stage is defined by the presence of the rearranged g gene,
and by synthesis of a low level of cytoplasmic g. chain (reviewed in Whitlock
et al., 1985). Next, the light chain DNA is similarly rearranged to give a
functional light chain, defining the B-cell stage (Nelson et al., 1985, Cooper
and Burrows, 1989). At this point, the B cell synthezises low levels of
membrane-bound IgM. During further B cell maturation, when B
19
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lymphocytes encounter mitogen or antigen stimulation and the appropriate
lymphokines, there is a loss or decrease in membrane IgM (Preud'homme,
1977; Bourgois et al., 1977) and a switch to synthesis of the secretory form of
IgM which is synthesized, polymerized, and secreted as a pentamer (Melchers
and Andersson, 1974). The switch to synthesis from membrane to secreted
IgM is via alternate splicing of the gL chain RNA (Nelson et al., 1983). The
mature B lymphocyte synthesis both heavy and light chain and expresses
surface immunoglobulin, and the terminal plasma cell secretes large
amounts of immunoglobulin (Schibler et al., 1978).
Many B cells undergo a switch from IgM synthesis to IgG, IgA, or IgE
synthesis (reviewed in Honjo et al., 1989), termed "class-switching". This is
mediated by further sequential rearrangements of the heavy chain DNA to
generate a gene encoding 7, e, or a chain. This heavy-chain class switch is
accompanied by deletion of DNA sequences containing the CJg and all other
sequences between the Cg and the C-region gene segment that is expressed
(reviewed in Tonegawa, 1983). This rearrangement is shown schematically in
Figure I-2 (for IgGi expression). Through a process termed allelic exclusion,
only one heavy and one light chain are productively rearranged in each
antibody-forming cell (French et al., 1989).
The production of functional antibody in vivo is restricted to lymphoid
cells (Banerji et al., 1983; Mercola et al., 1983; Gillies et al., 1983; Sen and
Baltimore, 1989). This is due to specific enhancer and promoter elements
which interact with factors specific for lymphoid cells. A conserved octamer
(ATTTGCAT) element is found 60-70 base pairs upstream of the site of
initiation of transcription in all immunoglobulin light chain genes, and the
same element, in an inverse orientation, is found at this site upstream of all
heavy chain immunoglobulin genes (Parslow et al., 1984). This promoter
element is necessary for immunoglobulin transcription. The location of the
promoter is shown schematically in Figure 1-2, labelled as "P".
The second set of essential regulatory elements for expression of
immunoglobulin light and heavy chain expression are tissue-specific
enhancer elements, located in the introns between the JH and Cgt and the JK
and CK exons (reviewed by Sen and Baltimore, 1989). The enhancer elements
are labelled "E" in Figure 1-2. The enhancer activity of the immunoglobulin
heavy chain has been localized to a 700 base pair region, and several specific
20
sequence elements have been defined, each of which bind specific nuclear
factors. The light chain enhancer has been localized to a 475 base pair region,
and several specific sequences, including one which binds nuclear factor KB
(NF-icB), have also been identified. NF-iKB is found only in cells which
express immunoglobulin light chains.
21
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IFigure I-2.
Schematic of Immunoglobulin Light and Heavy Chain Gene Organization
Exons are represented by boxes, and introns by lines (not to scale).
Abbreviations are: L1, L2, Ln: first, second, and nth leader exon of light or
heavy chain genes; V1, V2, Vn: first, second, and nth variable exon of light or
heavy chain genes; VK: variable region of kappa gene (consisting of leader
and variable region); V: variable region of heavy chain constant gene; JK 1-5:joining exons of kappa light chain gene; CK: constant region of kappa light
chain; D1, D2, Dn: first, second, and nth diversity exon of heavy chain gene;
J1-4: joining exons of heavy chain gene; g, 8, 73, 71, y2b, y2a, E, ac: different
heavy chain constant regions; CH1-3: constant exons of yl heavy chain gene.
Open circles labelled P represent promoter regions; filled circles labelled E
represent enhancer regions.
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2. Development of Cells Secreting Monoclonal Antibodies
The production of monoclonal antibodies was revolutionized by the
discovery of K6hler and Milstein (1975) that a mouse myeloma cell could be
fused with a murine B lymphocyte secreting a particular antibody of defined
specificity. While the B lymphocyte has only a limited lifespan, the resulting
cell, a hybridoma, retains the desirable characteristics of both parental cells.
Hybridomas have both the unlimited lifespan of the parental myeloma, and
the ability to secrete a specific, thus monoclonal, antibody, a characteristic of
the parental B lymphocyte. This discovery allowed the production of
antibodies to virtually any antigen. However, one disadvantage of this
technique is that each hybridoma cell line which is isolated is unique and
different for two reasons: first, the hybridoma has some number, not
necessarily all, of chromosomes from each parental cell, and second, the
developmental stage of the B lymphocyte can have a profound effect on the
stability and growth and secretion rates of the hybridoma.
Other approaches to the production of monoclonal antibodies include
their expression in E. coli and yeast (Boss et al., 1984; Cabilly et al., 1984; Wood
et al., 1985). However, the results have been disappointing. No functional
antibody was synthesized in E. coli (Boss et al., 1984; Cabilly et al., 1984). After
solubilization of heavy and light chains from inclusion bodies, produced
separately or together in E. coli, and combining them to allow refolding in
vitro, the best yield obtained was only 3-5% of the total amount of antibody
produced (Boss et al., 1984; Cabilly et al., 1984). When an antibody was
expressed in yeast, the efficiency of assembly and secretion was very low, and
75% of the synthesized mAb was insoluble (Wood et al., 1985).
An additional problem with monoclonal antibodies produced in
bacteria is that they are not glycosylated, and those produced in yeast are not
glycosylated with the same carbohydrate structure as in mammalian cells.
Glycosylation of monoclonal antibodies is needed for in vivo effector
functions (Nose and Wigzell, 1983) which are thought to be important in
antibodies used therapeutically. Thus, monoclonal antibodies are produced
in mammalian cells to obtain correctly assembled and properly glycosylated
immunoglobulins.
For therapeutic applications, it is desirable to have human, rather than
murine, antibodies, as the repeated administration of murine antibodies
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causes patients to develop anti-mouse antibodies (Shawler et al., 1985). The
production of human monoclonal antibodies has been reviewed extensively
(Carson and Freimark, 1986; Teng et al., 1985; Kozbor and Roder, 1983).
Methods for producing human monoclonal antibodies include the isolation
of human B lymphocytes from patients undergoing spleenectomies and
subsequent immortalization either by infection with Epstein Barr virus,
which selectively infects and immortalizes human B cells (Carson and
Freimark, 1986; Crawford, 1985) or by fusion to human or murine myelomas.
However, aside from the ethical problems of immunizing humans so as to
obtain antibodies with the desired specificity, the cell lines obtained produce
antibody at very low levels and tend to be quite unstable, often losing their
production capability after a few months (Kozbor and Roder, 1983).
Another related technology involves isolation of peripheral B
lymphocytes from blood, incubation with an antigen, and immortalization by
infection with Epstein Barr virus or by fusion with a human or mouse
myeloma. However, immortalization of cell with Epstein Barr virus
frequently results in polyclonal populations which are unstable and difficult
to clone (Carson and Freimark, 1986, Posner et al., 1987), and also results in a
very low percentage of immortalized cells synthesizing antibody of the
desired specificity. The resulting monoclonal cell lines also suffer from low
productivity and are unstable (Carson and Freimark, 1986). Improvements in
the in vitro activation of human peripheral B lymphocytes to produce
antibody-secreting cell lines have also been recently described (Borrebaeck,
1989).
An important development in monoclonal antibody technology for in
vivo use in cancer therapy and imaging is the construction of chimeric
antibody genes. These recombinant chimeric monoclonal antibodies have a
murine variable region and a human constant region, usually for both the
heavy and light chain gene, and provide an alternative to human
monoclonal antibodies. Mouse-human chimeric immunoglobulin genes are
created by joining murine variable regions and human constant regions for
both the heavy and light chain gene. These are then cloned into expression
vectors with dominant selectable markers, and transfected into non-
immunoglobulin-producing murine myeloma cell lines such as Sp2/0.
Antibody-producing clones are then selected using the selectable markers
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(Morrison and Oi, 1984). The resulting recombinant line is termed a
transfectoma.
Boulianne et al. (1984) and Morrison et al. (1984) were the first to
construct chimeric human-mouse monoclonal antibodies. Boulianne et al.
(1984) constructed a chimeric IgM using human g and K constant regions and
mouse variable regions directed against the hapten trinitrophenyl. The
heavy and light chain gene constructs were separately cloned into vectors
bearing the neo or gpt genes (coding for resistance to G418 and mycophenolic
acid, respectively). These were sequentially transfected into Sp2/0 cells and
transformants selected via resistance to G418 and mycophenolic acid. Stable
transformants which secreted about 5 gg/ml pentameric IgM were obtained,
and the chimeric IgM had the same affinity for trinitrophenyl as the parental
antibody.
Others (Nishimura et al., 1987) also constructed a human-mouse
antibody that contained human heavy (yl) and light K constant regions and
murine heavy and light chain variable domains. The genes were transfected
into the mouse myeloma line X63Ag8.653, and produced 10-30 gg/ml mAb,
which in this case was similar to the productivity of the parental hybridoma.
Interestingly, the amounts of immunoglobulin mRNAs in the transfected
myeloma were 3 to 4 times higher than those in the parental hybridoma,
although the amounts of antibody produced were similar.
The uses and production of chimeric antibodies have recently been
reviewed (Ahmed, 1987; Morrison and Oi, 1989; Verhoeyen and Riechmann,
1988). In all the cases tested to date, the chimeric antibody has retained the
binding specificity of the original murine antibody (Ahmed, 1987; Sun et al.,
1987; Sahagan et al., 1986), while exhibiting the effector function of the novel
constant region (Sun et al., 1987; Shaw et al., 1988a). The advantages of
chimeric antibodies is that they can be of any desired specificity, yet are much
less immunogenic than murine mAbs (Boulianne et al., 1984). For example, a
chimeric antibody with murine variable regions and human constant
regions, designated chl7-1A, had a six-fold longer circulation time in patients
than the parental murine antibody (LoBuglio et al., 1989). Only 1 of 10
patients treated with the chimeric antibody made anti-murine antibodies (to
the murine variable region) while 3 of 4 (Sears et al., 1982) and 10 of 20 (Sears
26
I __
et al., 1985) patients treated with the parental murine antibody mounted an
anti-murine response.
Chimeric antibodies are expected to replace murine antibodies for in
vivo applications such as anticancer therapy and tumor imaging because of
their reduced immunogenicity (Morrison and Oi, 1989; Sun et al., 1987;
Sahagan et al., 1986). The repeated administration of murine antibodies
causes patients to develop antimouse antibodies (Sears et al., 1982; Shawler et
al., 1985) which decreases therapeutic effects and can lead to anaphylactic
reactions (Chatenoud et al., 1986; Levy et al., 1983; LoBuglio et al., 1986; Sears et
al., 1982). In addition, the mouse antibodies have a much shorter circulating
half-life in man (LoBuglio et al., 1986) as compared to what would be expected
with human IgG.
However, a problem with all transfectomas described to date is their
relatively low (to a level of 10-30 gg/ml in batch culture) level of antibody
secretion as compared to the amount of antibody secreted by many mouse-
mouse hybridomas. Secretion of 50-150 gg/ml in batch culture is very
common for mouse-mouse hybridomas (de St. Groth, 1983), while mouse-
human (mouse myeloma/human B cell) hybridomas also generally only
secrete at the same level seen for transfectomas. The reasons for these lower
levels of antibody production are not known.
More recent technologies for the production of monoclonal antibodies
includes their production in chinese hamster ovary (CHO) cells. Weidle et al.
(1987) reported stable IgG production by dhfr- CHO cells transfected with
dhfr+ plasmids for iK and y chain, and amplified with methotrexate, at 5 x 10-4
pg/c-hr; however, this is 3 orders of magnitude lower than obtainable in
high-producing hybridomas. Recently, Wood et al. (1990) demonstrated high
level expression of polymeric IgM in CHO cells up to a maximum of 1.25
pg/c-hr. The immunoglobulin genes were linked to different amplifiable
markers, DHFR and ADA (adenosine deaminase), which were separately
transfected into dhfr- CHO cells, and were amplified in the presence of either
methotrexate and 2'deoxycoformycin. Immunoglobulin producing cells were
made by fusing one clone expressing the immunoglobulin light chain to
another clone expressing the immunoblobulin heavy chain.
Another approach to the engineering monoclonal antibodies is by
using homologous recombination to replace certain gene domains. Fell et al.
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(1989) showed that the CH 1 domain of the heavy chain of a murine
hybridoma can be replaced by the CH 1 of a human IgG by homologous
recombination, and suggest that homologous recombination could be used to
develop chimeric and novel immunoglobulins.
3. Applications of Monoclonal Antibodies
Most monoclonal antibodies (mAbs) are produced by hybridomas, and
a few by transfected myeloma cell lines. Hybridomas may be grown in mouse
ascites or in cell culture. For the production of large amount of mAbs,
production in cell culture is the best option. An average of 10-100 mg of
monoclonal antibody per mouse is obtained by growth of hybridomas in the
peritoneal cavity of the mouse (Hoogenread and Wraight, 1986). If one
assumes that on the average, approximately 50 mg of a monoclonal antibody
can be obtained from one mouse, then production of one kilogram of a
monoclonal antibody would require 20,000 mice. In addition, production in
cell culture is a reproducible and consistent process, and has the advantages
that much lower levels of extraneous antibodies and proteins are present,
both of which present purification problems when mAbs are to be used for
therapy.
Monoclonal antibodies and monoclonal antibody-derived products
comprise a valuable group of products with many applications, ranging from
in vivo tumor imaging to biosensors, which are shown in Table I-1. These
have been reviewed by Tami et al. (1986). Some of the uses of monoclonal
antibodies in the area of diagnostic assays include the testing of blood for
infectious agents and testing of blood and urine for the presence of hormones
and steroids.
In vivo, mAbs are used for tumor imaging, cancer therapy for pancreatic
and colorectal carcinomas, and as therapy for speticemia. The need for
kilogram quantities of mAbs for therapeutics is anticipated. For example, it is
estimated that at least 5000 patients per year in the US would be eligible for
colorectal cancer immunotherapy. A conservate estimate for the course of
treatment is four infusions each of 400 mg pure mAb (Shawler et al., 1985),
which translates into a yearly need for eight kilograms of mAb. If losses
during purification and the testing of the product are considered, then at on
the order of twice this amount of crude mAb needs to be produced.
Antisepsis mAbs are another large market, with the need estimated on the
order of 100 kg/year (Leist et al., 1990).
Table I-1.
Applications of Monoclonal Antibodies
Estimated 1990 US Marketa:
$ million/year
in vitro
* Diagnostic Assays 500
* Affinity Chromatography 100
* Biosensors
* Tissue Typing
* Novel methods for probing the B-cell repertoire
in vivo
* Therapeutics 500
cancer therapy
prevent graft rejection
* Delivery of lethal agents to cells via conjugated antibody 400
toxins
anti-cancer drugs
radioisotopes
* Prophylaxis 150
passive therapy for infections
* Imaging 250
Other
* Antibodies with enzymatic activity
aBoston Biomedical Consultants, Inc.
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B. Molecular Studies of Immunoglobulin Transcription and Synthesis
1. Studies on Immunoglobulin mRNAs
The regulation of RNA synthesis in cells is complex, as the rates of
transcription and the stability are dependent on many parameters such as the
state of differentiation of the cell and its growth rate (Berberich and Schimpl,
1990; Jack and Wabl, 1988; Rao and Slobin, 1988). The steady-state level of a
particular mRNA is a function of its rates of synthesis and degradation, with
the steady-state amount of any particular mRNA setting an upper bound for
the amount of protein which it codes for that can be synthesized (Jackson and
Standart, 1990; Hendricks et al., 1989).
A number of workers have measured the stability of immunoglobulin
mRNAs in myelomas and hybridomas. A striking feature of these results is
that while the stability of immunoglobulin mRNAs varied in different cell
lines, and with the experimental protocol which was used, the stability of H
and L mRNAs within each experiment was always similar, suggesting that
the same regulatory mechanism(s) governs their stability.
Cowan and Milstein (1974) measured the half-life of heavy and light
chain immunoglobulin mRNAs via UTP pulse-chase in a mouse myeloma ,
and found that both the heavy and light mRNAs have half-lives of 12-14
hours. Storb (1973) found that the half-life of immunoglobulin light chain
mRNA was about 12 hours in another myeloma line, in agreement with the
results of Cowan and Milstein.
Other workers used actinomycin D, an inhibitor of mRNA synthesis,
treatment to estimate the stability of immunoglobulin mRNAs by
monitoring the production of immunoglobulin protein (Namba and
Hanaoka, 1969; Scharff and Laskov, 1970; Shutt and Krueger, 1972). In
contrast to the results obtained with uridine labelling, these workers found
that the half-lives of immunoglobulin heavy and light chain mRNA were
only 2-5 hours. This discrepancy may be due to the deleterious effects of
actinomycin D on cellular metabolism, or may reflect differences among
different cell lines.
Jack and Wabl (1988) studied immunoglobulin heavy chain (4) mRNA
stability in different lines of B cells representing various stages of B
lymphocyte differentiation, the pre-B, B, and plasma cell stages. They had
previously found that the transcription rates for the heavy chain mRNA
were about the same for the cells tested, and suggested that the increased level
of heavy chain mRNA at the plasma cell stage is due to increased stability.
Using two different inhibitors of RNA synthesis, actinomycin D or
(5,6)dichloro-benzimidazole (DRB), the measured half-lives of g mRNA were
about the same. Most of the detectable g chain mRNA was gone after 4
hours of treatment in three pre-B cell lines; in two plasma cell lines, the half-
life of p. chain was about 4 hours; for two hybridomas, FH and KH, there was
almost no decay of g chain after 7-8 hours.
Bibila and Flickinger (1991) measured the halflives of heavy and light
mRNA in a murine hybridoma during exponential growth and during
stationary phase in batch culture, and found that immunoglobulin mRNA
stabilities decreased during stationary phase. The half-lives of
immunoglobulin mRNAs decreased from 12-14 hours in exponential phase
to about 6 hours during stationary phase.
Measurement of the absolute amounts of immunoglobulin heavy and
light chain RNAs was reported by Schibler et al. (1978) for MPC-11 myeloma
cells. The absolute number of heavy and light chain mRNAs was measured
via solution hybridization. They estimated that there are about 30,000 heavy
and 40,000 light cytoplasmic mRNAs, respectively. In addition, they
characterized the primary immunoglobulin RNAs and splicing
intermediates. They found that the primary heterogeneous nuclear (hn) H
RNA transcript is 11 kb in length, and the mature mRNA 1.8 kb, while the
primary light chain transcript is 5.4 kb, and the mature mRNA is 1.2 kb. In
MPC-11 cells, immunoglobulin represents approximately 20% of total cellular
protein synthesis, and immunoglobulin is synthesized at a very high rate,
about 2.5 pg/c-hr.
Gilmore-Hebert and Wall (1979) estimated that there are about 54,000
copies of Kc light chain mRNA per cell in another myeloma cell line, MOPC
21. In these cells, IgG represents approximately 25% of the total cell protein
synthesized (Sherr and Uhr, 1970).
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2. Immunoglobulin Assembly, Processing, and Secretion
Immunoglobulin messenger RNAs are associated with membrane-
associated ribosomes to form the rough endoplasmic endoplasmic reticulum.
The nascent immunoglobulin polypeptide, bearing the signal sequence, binds
to the signal recognition particle (SRP) (Walter et al., 1981). The SRP-
translation complex then binds to a rough endoplasmic reticulum SRP
receptor, the signal docking protein (Gilmore et al., 1982). The
immunoglobulin mRNAs are translated to the H and L peptide chains, which
are inserted into the endoplasmic reticulum (ER) via a hydrophobic 19-20
amino acid signal sequence, which is then cleaved co-translationally (Blobel
and Dobberstein, 1975) by a signal peptidase.
Glycosylation of the heavy chain occurs co-translationally (Bergmann
and Kuehl, 1978); completed H chains cannot be glycosylated post-
translationally. Release of H and L chains from polyribosomes is rapid,
occurring by two minutes chase after a 2.5 minute radioactive pulse (Baumal
et al., 1971; Scharff et al., 1970). Assembly of immunoglobulin occurs in the
ER. The mature IgG consisting of 2 heavy and 2 light chains is held together
by noncovalent interactions and disulfide bonds, with one disulfide bond
linking the heavy and light chains, and two or more disulfide bonds linking
the two heavy chains in the hinge region, depending on the subtype of IgG
(Benjamini and Leskowitz, 1988).
The formation of the disulfide bonds is the rate-limiting step in the
covalent assembly of IgG (Scharff and Laskov, 1970). Scharff and Laskov
(1970) measured the assembly rates in MPC 11 tumor cells and found that
after a 2.5 min pulse of MPC 11 tumor cells with radioactive amino acids, the
halftime for H2L2 assembly is five minutes; 80-90% of H 2L2 was assembled
after 10-20 minutes. Two other tumor lines, MOPC 494 and MOPC 173,
showed similar kinetics.
A number of workers have studied the assembly pathways of
immunoglobulins both in vivo and in vitro. The assembly of murine IgG
subclasses in vivo have been studied using either malignant plasma cells from
tumors or cell lines (myelomas) derived from them. These studies have
shown that the order of formation of disufide bonds varies with the subtype
of IgG, and that more than one pathway may operate in the same cell
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(Baumal et al., 1971; Baumal and Scharff, 1973a; Scharff et al., 1970). The
possible pathways of assembly are shown in Table 1-2.
Table 1-2.
Possible Pathways of Immunoglobulin Assembly
(a) H + H -> H2 (b) H + L -- > HL (c) H + L -> HL
H2 + L > H2L HL + HL -- > H2L2 HL + H -- > H2L
H2L + L -- > H2L2 H2L + H -- > H2L2
Peterson and Dorrington (1974) developed an in vitro system which they
used to assess the sequence and kinetics of interchain disulfide bond
formation under different environmental conditions. Their work suggests
that the sequence of disulfide bond formation is dependent on structural
features of the IgG, such as the number of intra heavy chain disulfide bonds,
while the environmental conditions, such as temperature, pH, and
concentration determine the overall rate of covalent assembly. They showed
that human IgGi and IgG4, which both have two disulfide bonds linking the
heavy chains, showed differences in both the predominant pathway of
assembly and the rate of reoxidation. For two different IgGis (one K, one h)
tested, HL and HHL were intermediates, but for IgG4K, HL was the primary
intermediate, with only negligible amounts of HHL seen. The half-time for
complete reoxidation of IgG1 was 70-95 minutes at 250 C in air; in the presence
of a disulfide interchange system consisting of both oxidized and reduced
glutathione, it was reduced to 25 minutes at 250 C or 10 minutes at 370 C. For
IgG4, the halftime for assembly in air was 16 hours; this was reduced to 30
minutes at 370 C in the presence of oxidized and reduced glutathione.
Sears et al. (1977), using an in vitro system employing air reoxidation,
found that the presence of excess L chain, as is often seen in vivo (Baumal and
Scharff, 1973b), retarded the precipitation of H chains as high molecular
weight aggregates; this suggests a possible function for them in vivo. The
assembly pathways were not changed by the presence of excess L chain. L2
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dimers were incorporated into completely assembled IgG, via disulfide
exchange.
A number of workers have studied the pathways of immunoglobulin
assembly in cells (Baumal et al., 1971; Baumal and Scharff, 1973a; Scharff et al.,
1970). To analyze the pathway(s) of assembly utilized, cells were pulsed with
radioactive amino acids, chased, and then lysed at intervals. Lysates were
immunoprecipitated and electrophoresed under nonreducing conditions.
The intermediates (HL, H2, H2L, etc) were separated on the basis of molecular
weight and quantified. IgG1 (MOPC-31B, MOCP 21) and IgG2a (Adj. PC 5) were
assembled primarily via H2 intermediates (pathway a in Table 1-2), while
IgG2b (MPC 11) was first assembled via HL dimers (pathways b and/or c in
Table 1-2), and IgM mostly via pathway b in Table I-2 (Baumal et al., 1971;
Baumal and Scharff, 1973a). Another IgG2b-producing line, MOPC 195, was
assembled via both HL and H2 intermediates (pathways a and b in Table I-2)
(Baumal and Scharff, 1973a). Other work with MPC 11 tumors indicates that
the formation of HL is a dead end, and the pathway used to make H 2L2 is
pathway a (Scharff et al., 1970). The kinetics of assembly varied between
different tumor lines, with between 39 and 100% of H 2L2 assembled after 18
minutes.
Baumal et al. (1971) studied the kinetics of assembly in 12 mouse IgG-
secreting tumors and two cell lines. As described above, they found that for
IgG2b, the predominant assembly pathway is via formation of HL, while for
IgG1 and IgG2a, it is via H 2 . By injecting mice with radioactive amino acids,
they ascertained that the assembly pathways in tumors in the mice were the
same as in tumor cell suspensions.
An interesting feature of many myeloma cell lines, which is not shared
by hybridomas, is that they synthesize excess light chain. Baumal and Scharff
(1973a) reviewed work from their laboratories and compared 19 mouse
myeloma tumors and cell lines, as well as normal murine immune
lymphoid cells. Eleven of these, including normal murine immune
lymphoid cells, synthesized and secreted an excess of L chains, with L:H ratios
of 1.3-4.2:1. Three myeloma lines synthesized excess L chain, with L:H ratios
of 2.4-3.2:1, but secreted only assembled H 2L2, indicating intracellular
degradation of excess L chain, as was shown by a decrease in the cytoplasmic
L:H ratio over 15 minutes chase. Five lines synthesized H and L chains at a
ratio of 1:1. Similarly, Scharff (1973-74) also reported that of 16 human
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myelomas examined, four synthesized L:H at a 1:1 ratio, while 12 synthesized
excess L chains. It has been suggested that the synthesis of excess light chain
may serve to prevent "toxic" effects of uncomplexed heavy chain, or prevent
aggregation and/or misfolding of heavy chains (Sears et al., 1977; Scharff and
Laskov, 1970).
Two resident proteins of the endoplasmic reticulum (ER) have been
shown to be important in immmunoglobulin assembly. One of these
proteins, important in folding and immunoglobulin assembly in the ER, is
heavy chain binding protein, BiP. BiP is one of the heat shock family of
proteins and is thought to have a role in protein folding, retention, and
assembly. It is a 78 kd protein resident in the ER (Haas and Wabl, 1983; Bole et
al., 1986; Munro and Pelham, 1986).
Nascent, unfolded, or unassembled proteins, including
immunoglobulin heavy chains, are transiently complexed with BiP (Bole et
al., 1986; Gething et al., 1986). Various workers have shown that it is
associated with misfolded proteins, for example VSV G protein (Gething et al.,
1986; de Silva et al., 1990). Hendershot (1990) has shown that BiP associates in
vivo with immunoglobulin heavy chains when light chains are absent (in a
cell line not synthesizing light chain); when light chains are introduced, the
BiP-heavy chain complex is disrupted and assembled Ig molecules are
secreted. BiP may thus complex with heavy chains found in pre-B cells.
Scharff and Laskov (1970) also review data that show that the heavy chain is
never secreted in the absence of light chain synthesis; production of heavy
chains is toxic to cells, probably because they can't be properly folded and
secreted in the absence of light chains. Only heavy chains with deletions are
found secreted in the absence of light chains (reviewed in Scharff and Laskov
(1970)).
The formation of disulfide bonds is catalyzed by protein disulfide
isomerase (PDI), a 60 kd resident protein of the ER (Roth and Koshland, 1981).
The levels of protein disulfide isomerase are elevated in immunoglobulin-
secreting cells; PDI represents approximately 0.03-0.11% of total protein in
non-immunoglobulin-secreting cells, but 0.35-0.79% of total protein in
myeloma cells secreting immunoglobulin, a 8-10 fold increase.
After their assembly and glycosylation in the ER, immunoglobulins
move through the Golgi compartments, where the glycolytic side chain(s) are
trimmed and modified, and are then secreted. Protein transport and sorting
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in the Golgi have been reviewed by Pfeffer and Rothman (1987) and Burgess
and Kelly (1987). The time required for immunoglobulins to move through
the Golgi and be secreted is the slowest step in immunoglobulin synthesis
and processing. The rate of secretion of immunoglobulins varies; the time it
takes for immunoglobulins to appear in the medium varies from 15-90
minutes, and the half-time for secretion from 45 minutes to three hours.
Typical half-times for secretion of IgG are 45-60 minutes. Rates of
immunoglobulin secretion measured in different cells are shown in Table 1-3.
Table 1-3.
Rates of Secretion of Immunoglobulins
Ig (cell line) Time Reference
Ig appears half-time 90%
in medium complete
IgA n.a. 40 min >180 min 100 min* Bargellesi et al. (1972)
IgG2a n.a. 60-90 min n.a. n.a. Liberti & Baglioni (1973)
IgG2b (MPC 11) 20 min 180 min 60 min Baumal & Scharff (1973a)
IgG2b (MPC 11) 20-30 min 240 min n.a. Scharff et al. (1970)
IgG (normal) 15 min 110 min 45 min Baumal & Scharff (1973a)
IgG (mur. hyb) n.a. 540 min 180 min Al-Rubeai & Emery (1990)
IgD - 40 min n.a. 120 min Argon & Milstein (1984)
n.a. Data not reported.
* estimated from data in paper.
C. Stability of Antibody Production
1. Long-term Loss of Antibody Production
The loss or decline of antibody secretion during culture of monoclonal
antibody producing cells is a serious problem. One method for retaining
productivity is by pursuing a rigourous program of subcloning; however, this
cannot be done during production runs. Some of the mechanisms
responsible for loss of mAb production during continuous culturing of
hybridomas have been reviewed by James and Bell (1987). A very common
L
per cell per generation, similar to the rate observed in C1 myelomas, 2 x 10-3
per cell-generation, and P3, an MPC 11 clone, 1 x 10-3 per cell-generation. The
loss of both H and L chain synthesis was 0.4 x 10-3 per cell-generation in an
MPC 11 clone. However, the rates of mutation to resistance to 6-thioguanine
and a number of other drugs were less than 10-6 per cell-generation. Wabl et
al. (1985) have suggested that a normal rate is 10-10 to
10-12 mutations per base pair per cell generation in mammals. This suggests
that the rates of mutation in immunoglobulin genes are at least five orders of
magnitude higher than the rate of background mutation.
The overgrowth of secreting cells by nonsecretors in culture is very
common, and can be a problem in production. Irreversible loss of
productivity in hybridoma cells has been seen by a number of workers (Galfre
et al., 1980, Gardner et al., 1985, Lee and Palsson, 1990; Tharakan and Chau,
1986a; Heath et al., 1990; Zurawski et al., 1978; Frame and Hu, 1990; Hiller et al.,
1991). The irreversibility, although not always characterized, suggests that
loss of production is due to gene loss and/or random mutations. Even if the
genes for mAb production are not lost, the loss of mAb secretion by some
other mechanism leads to an accumulation of non-antibody producing cells
in cultures over time.
reason for the loss of antibody production is chromosomal loss (Teng et al.,
1985; Uchiyama et al., 1987). This problem is especially acute in fusions of
mouse myelomas to human lymphocytes (Teng et al., 1985; Croce et al., 1980;
Uchiyama et al., 1987). Other reasons for the loss of antibody production are
the absence of receptors for growth and differentiation factors (Melamed et al.,
1985), defects in the synthetic machinery (Kozbor and Croce, 1985; Teng et al.,
1985), defects in the secretory machinery of the cell (Kozbor and Croce, 1985),
or the failure or loss of regulatory genes or another regulatory defect (Kozbor
and Croce, 1985; Teng et al., 1985) such as lack of nuclear factor KcB in a
myeloma (Atchison and Perry, 1987).
The rate of loss of monoclonal antibody production has been reported
at 10-2-10 -5 per cell-generation (Galfr6 et al., 1980; Gardner et al., 1985; JAck and
Wabl, 1987).
Baumal et al. (1973) measured the rate of loss of H and L chain synthesis
in a MPC 11 myeloma line and clonal derivatives. In MPC 11 cells, they
found the rate of loss of H chain production, from H+L+ to L+ to be 1.1 x 10-3
2. Selection Methods for Higher-Producing Cells
No one has yet devised a scheme to select for the expression of
immunoglobulin genes during growth in culture. This is because conditions
in culture such that the expression of mAbs confers a selective advantage on
the cell have not been available. It is possible to maintain selective pressure
on transfectomas via the antibiotic-selectable genes on the plasmids used to
transfect the cell line (Shaw et al., 1987); however, the antibiotic are very
expensive and products used clinically must be free of any traces of such
antibiotics (Schauf, 1987).
Although subcloning can't be used to select for high producers during
growth in culture, it can be used to select higher-producing variants of a
particular hybridoma. One group (Kitano et al., 1988) used an IgM producing
mouse-human-human heterohybridoma which was cloned at limiting
dilution several times. Clones were screened for productivity, and the
highest producing clone obtained was selected and recloned. In three rounds,
a high-producing clone was selected which produced almost 20 times as much
mAb as the parental line (150-200 jtg/ml vs 7-10 pg/ml). They considered five
factors as possible explanations for the improved production: 1. gene
amplification; 2. improved efficiency of transcription; 3. stabilization of
mRNA; 4. improved efficiency of translation; and 5. improved efficiency of
mAb secretion. They did not discover any gross chromosomal alterations in
the high producing clone. However, electron microscopy showed a much
higher intracellular IgM content, as well as increased numbers of microvilli
on the cell surface. This perhaps is due to or allows a higher rate of secretion
of antibody, as cells secreting high levels of proteins, such as chymotrypsin,
have many microvilli on their surface (Alberts et al., 1983a).
Another group (McKinney et al., 1991) selected subpopulations of cells
by flow cytometric sorting. They selected a subpopulation consisting of the
4% of the sorted cells with the highest amounts of surface IgG and showed
that the initial specific productivity of these cells was about 25% higher than
that of the unsorted population, although the total amount of antibody
produced in batch culture was similar to that of the unsorted population. In
this case, however, secretion was subject to feedback inhibition by antibody in
the supernatant, which limited the total amount of mAb secreted. With cell
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lines not subject to feedback inhibition, it may be possible to select for higher
producers by several rounds of flow cytometry, even though surface antibody
in some cell lines only weakly correlates with specific productivity (Meilhoc et
al., 1989).
Recently, Powell and Weaver (1990) demonstrated that individual
antibody secreting cells can be selected via flow cytometry. Cells are
immobilized in agarose droplets containing a capture antibody, incubated in
medium, and then incubated with a fluorescent antibody. This method could
be used to select for higher producing hybridomas, as the secreted product
itself is measured.
D. Antibody Production Kinetics in Cell Culture
1. Growth versus Antibody Production
A fundamental question that must be answered for the production of
any biological is how its production is related to the growth rate of the
producing cells. Many such studies of monoclonal antibody production have,
unfortunately, been done in batch culture. When cells are inoculated into
fresh medium, there is a short lag, then a period of exponential growth,
followed by a stationary phase during which the total cell density is constant.
Finally, the viable cell density declines and the culture dies.
Analysis of specific antibody productivity in batch cultures should not
be used to determine whether antibody production is growth or non-growth
related, as a true steady-state is never achieved. Changes in the growth rate
observed in batch culture can not be decoupled from changes in the levels of
nutrients and waste metabolites. The growth rate decreases either due to
exhaustion of nutrients or due to accumulation of toxic metabolites, such as
lactate or ammonia. Another problem is that in batch cultures, the
environment is constantly changing; nutrients are depleted, waste products
are accumulated, and the pH decreases. In many cases, it is not known what
the limiting nutrient is and not even whether the culture ceases growth due
to a nutrient limitation or accumulation of a toxic metabolite(s). It may be
that the accumulation of a waste metabolite, or a decrease in pH affect both
the growth rate and the specific rate of antibody production; concluding that
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the slower growth rate increases specific productivity is erroneous. The
constantly changing environment makes analyses difficult. Nevertheless,
many workers have used batch growth systems to analyze antibody
productivity.
In batch studies, some workers find that much of the antibody secretion
is after cells have reached stationary phase. Most hybridomas secrete antibody
during the period of exponential growth as well as during the period of time
when the cell density is no longer increasing. Often, a further increase in
product titer is even seen when the viable cell density is rapidly decreasing.
Many groups have reported that during batch culture of hybridomas a
significant amount of the antibody produced, on the order of 50%, is produced
when the cells are no longer viable (Reuveny et al., 1985, Merten et al., 1985,
Boraston et al., 1984). Possible reasons for this phenomenom are that the cells
release surface bound antibody as they are dying or that intracellular antibody
from lysed cells is released into the supernatant.
In general, however, there is agreement that mAb production in batch
cultures is roughly related to the number of viable cells (de St. Groth, 1983;
Boraston et al., 1984;., Velez et al., 1986; Birch et al., 1985; Luan et al., 1987), and
that prolonging the viability of cell increases antibody titers.
Another important point is that there is a wide variability in both
growth rates and specific rate of antibody production between different
hybridoma lines. For example, experiments with 10 different hybridoma
lines (de St. Groth, 1983) indicated that specific productivity, even between
cell lines which have the same myeloma fusion partner, the specific
productivity of the resulting hybridomas varies by a factor of 15-20 fold.
Analysis of his data shows a weak correlation between the maximum growth
rate and specific productivity; the hybridomas with faster doubling times, (11
to 18 hours) tended to produce at a faster rate than those with slower doubling
times (> 20 hours). However, the productivity within the faster-growing
group of hybridomas still varied 7-fold. Merten et al. (1985) have suggested
that the specific production rate of any hybridoma is actually primarily
dependent on factors such as the state of differentiation of the B cell prior to
fusion, the genetic makeup of the hybridoma (ie, which chromosomes of the
two parental cells were retained), and the medium composition, rather than
the growth rate.
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2. Antibody Secretion versus Cell Cycle
Related to the question of how antibody secretion is affected by the
growth rate is if and how antibody synthesis and secretion vary as a function
position within the cell cycle. The cell cycle is divided into four phases: gap 1
phase (Gl), the DNA synthesizing phase (S), the gap 2 phase (G2), and mitosis
(M) (Alberts et al., 1983b). A cell will stop progression through the cell cycle at
a point late in the G1 phase, the restriction point, unless signaled to continue
through another whole cell cycle. The time required for a cell to complete the
S, G2, and M phases remains approximately constant independent of the
growth rate, with the length of the G1 phase increasing with a decrease in the
growth rate (Alberts et al,, 1983b).
Immunoglobulin synthesis as a function of position in the cell cycle
can be studied by synchronizing cells. A number of investigators have
reported that the maximum rate of immunoglobulin synthesis occures in late
G1 or early S phase, while others found that immunoglobulin synthesis does
not vary with the cell cycle.
Most studies on immunoglobulin synthesis as a function of position in
the cell cycle have relied on synchronizing cells by two successive (about 12
hours) incubations with thymidine with removal for 6-7 hours between
incubations (double thymidine block). Even though exposure to thymidine
perturbs growth, leading to a decrease in the duration of the cell cycle, since
protein and RNA synthesis continue, it is useful method to obtain
synchronized cells (Cowan and Milstein, 1972).
Byars and Kidson (1970) used a double thymidine block to synchronize
an IgG2a-secreting myeloma cell line at the G1/S boundary. They found that
total synthesis of antibody was maximal at late S through G2, falling to one
third of this level in G1. However, the rate of secretion was maximal during
G1 phase. While total protein synthesis was nearly constant until mitosis, the
rate of immunogluobulin synthesis was maximal during S, and the rate of
secretion maximal in G2.
Takahashi et al. (1969) also synchronized cells at the G1/S boundary
using double thymidine block and analyzed their intracellular IgG content.
They found that the peak intracellular immunoglobulin concentration was in
early S/G1, three to four times the level during mitosis. They also found that
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at all times during the cell cycle, that there was a wide variation of
immunoglobulin content per cell in the population.
Buell and Fahey (1969) synchronized two human immunoglobulin
synthesizing cell lines in mitosis via exposure to thymidine followed by
treatment with colcemid. Both lines had 3-6% of cells containing
intracellular immunoglobulin (detected via fluorescein-conjugated antisera)
at mitosis. The percentage of Ig-positive cells increased to about 40% at late
G1/early S. Synchronization in early S, done by double thymidine block, gave
80% Ig-positive cells, rising to 91%, and then falling to 20% in mitosis.
Labelling of synchronized cells indicated that secretion was maximal in S
phase and lowest during mitosis and the early G1 phase.
Al-Rubeai and Emery (1990) used a murine hybridoma secreting IgG
and synchronized cells via a double thymidine block. They also found that
IgG synthesis and secretion were cell cycle dependent, with IgG secretion
lowest at mitosis and twice that at Gl; synthesis was also lowest, one third of
maximal, at mitosis.
Abraham et al. (1976) synchronized MPC-11 cells in G1 phase by
isoleucine starvation, and found that light chain synthesis is maximal at the
end of G1 and early S phase and minimum at G2 and mitosis, with a 3-fold
variation; in contrast, amino acid incorporation into total protein did not
fluctuate much during the cell cycle.
Cowan and Milstein (1972) used P3K (MOPC 21) cells, synchronized by
double thymidine block and found less than 10% variation of intracellular
immunoglobulin during the cell cycle.
Liberti and Baglioni (1973) synchronized C1 mouse myeloma cells
which secrete an IgG2a and have a doubling time of 14-16 hours by a double
thymidine block which synchronizes cells at the G1/S boundary. They found
that the rate of synthesis of IgG was relatively constant during the cell cycle
except for a drop during mitosis.
Damiani et al. (1979) studied IgG synthesis and secretion in a mutant
MPC-11 cell line which adheres to glass but produces IgG2a at the same rate as
its parent. They obtained synchronized mitotic cells by treatment with
colcemid and detachment of mitotic cells, and found that the ratio of newly
synthesized Ig to total cell protein was constant throughout the cell cycle.
Secretion of immunoglobulin was found not vary during the cell cycle.
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Garatun-Tjeldsto et al. (1976) also used MPC-11 synchronized cells in G1
by isoleucine starvation and found that synthesis and secretion of light chain
was maximal in late G1/early S phase, with a 3-fold variation in synthesis
rates and a 6-fold variation in secretion. They suggest that the results of
Liberti and Baglioni (1973), who found no cell-cycle-dependent changes in
immunoglobulin synthesis are due to light chain losses incurred during
freezing of their samples prior to analysis, and show data that light chain
precipitates and that these complexes are lost upon freezing.
Suzuki and Ollis (1989) proposed a cell cycle model for antibody
production. This model is based on findings that maximum IgG synthesis is
during late G1 and early S, and assumes that decreased growth rates in
continuous culture are due to the arrest of a fraction of cells in late G1 (also
termed Go), with the rest of the cells still cycling. The model assumes that the
cell cycle time increases as the growth rate decreases, and that the cell cycle
time attains a "constant maximum value". The model assumes that there is
a fraction of arrested cells (in late Gl) which is zero at maximal growth rates
and increases at low growth rates. They used the experimental data of Miller
et al. (1988) to obtain values for the maximum cell cycle time and to calculate a
fraction of arrested cells at each growth rate. The model predicts that the
specific productivity of arrested cells is about seven-fold that of the specific
productivity of all cycling cells when the fraction of arrested cells is zero.
Based on their findings, they suggest that methods to arrest cells while
maintaining high viability and cell density will increase specific productivity.
Methods to arrest viable cells include serum deprivation, inhibition by drugs
(such as excess thymidine or cAMP), or oxygen supply limitation.
In summary, these results suggest that in some myelomas and
hybridomas, immunoglobulin synthesis and secretion may fluctuate as a
function of the cell cycle. Certainly, processing would be expected to decline
during mitosis, when the ER and Golgi is fragmented (Alberts et al., 1983c).
These results may also partly explain why for many hybridomas, specific
immunoglobulin secretion increases when cells are dividing slowly or not at
all.
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3. Inhibition of Antibody Production
Antibody production in cell culture bioreactors have been measured as
a function of inhibitory waste metabolites such as lactate and ammonia
(Glacken et al., 1988; Reuveny et al., 1986a), as well as in relation to pH
(Glacken et al., 1986), and oxygen supply (Miller et al., 1987; Boraston et al.,
1984; Reuveny et al., 1986a). Several groups have also compared the
productivity of different hybridomas in serum-containing and serum-free
media (Tharakan and Chau, 1986b; Glassy et al., 1987; Schneider, 1989). A brief
survey of some of these results is presented here.
3.1 Lactate
Cells in culture produce lactate by glycolysis of glucose. Accumulation
of lactate has been shown to inhibit cell growth rates and specific productivity,
either as a pH effect or as lactate itself (Glacken et al., 1986) but the tolerance of
different hybridomas to lactate varies.
Glacken et al. (1988) measured the initial growth rate and specific
productivity at low cell densities during exponential phase in batch culture.
The effect of lactate was investigated by addition of sodium lactate to cultures.
They found that addition of lactate up to 40 mM did not change the growth
rate, but decreased specific productivity. Specific productivity in cultures to
which 40 mM lactate was added decreased 50% relative to control cultures.
Dodge et al. (1987) measured the effect of lactate on initial growth of
MB8178 hybridomas. Addition of 33 mM lactate decreased the growth rate
only by about 9%; addition of 67 mM lactate decreased the growth rate by 55%
in the presence of 0 or 3 mM ammonia. The effects of lactate and ammonia
on antibody production were not reported.
Reuveny et al. (1986a) tested the effect of lactate on cell growth and
antibody production using the hybridoma line VII H-8 and found that the
addition of modest amounts of lactate stimulated growth and antibody
production. The addition of lactate at levels ranging from 5 to 28 mM
increased the cell concentration and antibody titers over those of the control
culture; antibody levels after 6 days were increased by about 33%.
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3.2 Ammonia
Ammonia, another toxic metabolite, accumulates in culture via the
spontaneous deamination of glutamine and by the catabolism of glutamate
(Glacken, 1988). Although the tolerance of cell lines varies, the addition of
ammonia to 2-3 mM, a level seen at the end of batch culture, has been shown
by a number of researchers to decrease the growth rate of hybridomas but not
to affect specific productivity. The protonated form, ammonium (NH4),
rather than ammonia (NH3), is thought to be the more toxic species (Glacken,
1988; Doyle and Butler, 1990).
Glacken et al. (1988) added ammonia (as ammonium chloride) to
cultures and found that levels in excess of 2.3 mM decreased the growth rate
but had no effect on specific productivity. Additon of 5 mM ammonia
decreased the growth rate by about 50%, but again did not affect the specific
productivity. McQueen and Bailey (1990) tested the effect of ammonia on the
specific productivity of hybridoma cells in batch culture. They found that the
specific productivity was the same at either 0 or 3 mM NH4C1, about 0.125
pg/c-hr. However, the total number of cells and the growth rates were less at
3 mM ammonia.
Reuveny et al. (1986a) tested the effect of ammonia on cell growth and
antibody production using the murine hybridoma line VII H-8. Both the
antibody titer and the cell density decreased with increasing amounts of
ammonia added. The specific productivity was not affected at less than 5 mM,
but decreased when the level of ammonia in the supernatant was greater
than 5 mM.
Dodge et al. (1987) measured the effect of lactate and ammonia on
initial growth of MB8178 hybridomas (see also below). The addition of 3 mM
ammonia caused the growth rate to decrease by 60%; at 6 mM ammonia, the
growth rate was close to zero. Addition of both 3 mM ammonia and 33 mM
lactate (similar to the amounts present at the end of a batch culture), on the
other hand, decreased the growth rate by only 30%.
Doyle and Butler (1990) measured the effect of pH on the toxicity of
ammonia on a murine hybridoma. In the absence of ammonia, the optimal
pH for growth was 7.4, with a broad optimum pH from 7.2-7.6. Ammonium
chloride was added to cultures where the pH was varied from 6.8 to 7.8. The
toxicity varied with the pH, with greater toxicity for a given level of
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ammonium chloride added as the pH increased. At a pH of 7.8, 4 mM
ammonium chloride gave a 50% reduction in growth, while at a pH of 6.8, 7.6
mM ammonium chloride was required to give the same reduction in growth.
They were able to correlate the reduction in growth to the level of
ammonium ion (NH4 ). The effect of pH and ammonia on antibody
production was not reported.
Truskey et al. (1990) found that addition of 2 mM ammonia reduced the
growth rate of a murine hybridoma (20-8-4S) by about 50%. The effect of
ammonia on antibody production was not reported. Ozturk and Palsson
(1990) found that even 1 mM ammonia decreased the growth rate of a murine
hybridoma (167.4G5.3) by circa 30%.
3.3 pH
The optimum pH for cells in culture varies somewhat, but is typically
in the range of 7.0 - 7.4. McQueen and Bailey (1990) tested the effects of pH on
the specific productivity of hybridoma cells in batch culture. They found that
the specific productivity was the same at pH values ranging from 6.8 - 7.6.
However, the total number of cells and the growth rates were less at pH 6.8
than at the other pH tested.
Miller et al. (1988) investigated the effect of pH on growth and antibody
production in continuous culture. The optimum pH for growth was 7.1-7.4,
with continually decreased growth and viability at pH 6.8, where no steady-
state was obtained. Cells placed at pH 7.7 showed a decrease in viable cell
number, but then adapted and showed behavior similar to that at pH 7.1-7.4.
The specific rate of antibody production at pH 6.8 was about 3 times that at pH
7.1-7.4, probably due to the decreased growth rate observed at pH 6.8. At pH
7.7, specific productivity was initially 1.5-fold higher than at pH 7.1-7.4, but
then decreased after cells had'adapted to the higher pH.
3.4 Dissolved Oxygen
Several investigators have studied growth and antibody production as
a function of dissolved oxygen. The optimum dissolved oxygen
concentration varies with the cell type, but typically shows a broad range of
10-60% of air saturation.
Reuveny et al. (1986a) studied the effect of dissolved oxygen on growth
and antibody production in batch cultures. Dissolved oxygen at 25% (where
100% equals equilibrium with air) prolonged cell viablility and increased total
antibody production by about 50%; while 50-60% dissolved oxygen gave
maximum growth. However, from data shown by Reuveny et al., it is
obvious that the higher dissolved oxygen (50-60%) caused early depletion of
glucose from the medium, so if more glucose had been supplied, it is possible
that the same amount of antibody would have been made as at 25% dissolved
oxygen.
Boraston et al. (1984) found that growth rates were constant at dissolved
oxygen tensions from 8-100% of atmospheric (mAb production as a function
of dissolved oxygen was not reported). Mizrahi et al. (1972) found that the
optimum dissolved oxygen for a lymphoid cell line was 100% air.
Miller et al. (1987) tested the effect of dissolved oxygen from 0.8-100% of
air on a Sp2/0-derived hybridoma in continuous culture at a constant
dilution rate of 0.0225 hr-1 . They found that the optimum dissolved oxygen
for antibody production was 50%, while the optimum for cell growth was
about 0.5%. The specific productivity increased from about 0.09 pg/c-hr at
dissolved oxygen levels of 1-10% to 0.16 at 50% and decreased slightly to 0.135
pg/c-hr at 100% dissolved oxygen.
3.5 Serum
Some workers have found that the specific productivity of hybridomas
is increased when the serum normally added to cultures is replaced with a
serum-free supplement, and have suggested that this is due to inhibitory
factor(s) present in serum (Glassy et al., 1987; Glassy et al., 1988; Tharakan and
Chau, 1986b).
Tharakan and Chau (1986b) showed that specific antibody productivity
of an IgG-producing murine hybridoma (455) was higher in serum-free
medium (0.025 vs 0.015 pg/c-hr) although total cell counts and final titers
were higher in serum-containing medium. Glassy et al. (1987) found that
specific productivity of three human-human hybridomas producing IgG and
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IgM was enhanced by 3-4 fold when cultivated in serum free medium as
compared to medium supplemented with 10% FBS. Glassy et al. (1988)
tabulated data on the growth and specific productivity of 12 hybridomas in
serum-free and serum-supplemented media. The specific productivity was
higher for 9 of 12 hybridomas grown in serum-free medium, and was the
same in serum-free or serum-supplemented medium for the other three.
Again, this suggests, but does not prove, that serum may contain factor(s)
which inhibit antibody production in some hybridomas.
3.6 Feedback Inhibition
There is some data in the literature suggesting that some hybridomas
may be subject to product feedback inhibition in cell culture. Antibody
secretion has shown to be inhibited by the accumulation of antibody in
supernatants (McKinney et al., 1991). Antibody synthesis has also been shown
to be inhibited by accumulation of a growth factor (Kidwell, 1989) secreted by
some hybridomas.
Results from one group suggested that some hybridomas which secrete
antibody to levels of less than 1 gg/ml are subject to feedback inhibition by an
unspecified component of the supernatant (Merten et al., 1985). Two "low
producer" lines tested by Merten et al. (1985) produced less than 1 gg/ml
antibody in batch culture; initial secretion rates were 0.45-0.9 pg/cell-hr which
rapidly dropped to almost zero. In an experiment with the low producing
hybridomas, where the medium was changed every 20 minutes, the antibody
secretion rates remained at the initial levels. They found that secretion in
these hybridomas was not inhibited by the addition of a different mouse IgG
to the same level found in the supernatant, nor by the addition of
supernatant from a different hybridoma line, suggesting, but not proving that
inhibition of antibody synthesis is due to feedback inhibition by antibody
accumulated in the supernatant.
Recently, however, McKinney et al. (1991) demonstrated that a murine
hybridoma line (ATCC HB124) secreting IgG2a is subject to product feedback
inhibition. Antibody was purified from culture supernatants and added back
to cultures inoculated in fresh medium. The specific rate of antibody
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secretion decreased linearly with the antibody concentration initally present
in the medium, and dropped to zero when 27-36 gg/ml antibody was added.
Interestingly, this was quite similar to the maximum amount synthesized in
batch culture, about 26 gg/ml.
Lee et al. (1991) also observed that antibody production in fed-batch
cultures of an immobilized murine hybridoma ceased when the antibody
concentration in the medium reached 25-30 gg/ml. Serum, glucose, and
amino acids were not limiting. However, experiments to distinguish
between feedback inhibition due to accumulation of antibody or inhibition
due to accumulation of an unknown inhibitor of antibody synthesis produced
by the cells were not done.
Growth factors may also inhibit antibody production in culture.
Kidwell (1989) grew mouse hybridoma 109 cells, which produce IgM, in
hollow fiber reactors with low (4000 mwt) and high (0.5 micron) cutoffs. He
found that antibody production in reactors with high molecular weight cutoff
hollow fibers was more than twice that in low molecular weight cutoff
reactors. The inhibition of antibody production was found to be due to the
accumulation of TGFpl, a 25 kd protein produced by this hybridoma, in the
reactors with the low molecular weight cutoff membranes. TGF31, when
added at the levels found in the hollow fiber reactor, was found to inhibit
both growth and antibody production when added to low density batch
cultures in T-flasks. 0.05 ng TGFpl was found to inhibit growth by 50% and
IgG production by 90% in Col 12 cells grown in T-flasks. and also inhibited
growth and productivity of the 109 cells secreting IgM.
4. Continuous Culture
In continuous culture, medium is added and medium containing cells
is withdrawn at the same rate, allowing achievment of a steady state, where
the growth rate is equal to the dilution rate. This type of culture is termed
chemostat. Varying the medium feed allows control of the specific growth
rate, and the cell density may be controlled by designing the medium so that a
single nutrient or metabolite is limiting. In a turbidostat, the medium feed is
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adjusted to maintain a constant cell density so that the growth rate of the cells
is near or at the maximum.
A number or workers (Reuveny er al., 986OD; Miller er al., 1 8; Iverten
et al., 1985; Ramirez and Mutharasan, 1990; Ray et al., 1989) have reported that
in continuous culture antibody production is negatively associated with the
growth rate, with higher specific rates of antibody secretion at slower growth
rates.
Miller et al. (1988) found that the specific productivity in continuous
culture increased 2-fold as the doubling time increased from 12.4 to 31.5
hours. Ramirez and Mutharasan (1990) also observed a 2-fold increase in
specific productivity as the doubling time increased from 19.8 to 34.7 hours.
Glacken et al. (1988) measured initial growth and antibody production
rates at low density in batch cultures. They found that the specfic productivity
per total cell remained constant at about 2.3 pg/c-hr at growth rates greater
than 0.023 hr-1. Slower growth rates were associated with decreased viability
and a decrease in specific productivity per total cell. However, they did not
measure cell viability, so the specific productivity per viable cell may have
remained nearly constant even at very low growth rates.
Ray et al. (1989) grew a murine hybridoma at dilution rates from 0.01 to
0.04 hr-1. Specific productivity was 1.5 pg/c-hr at a dilution rate of 0.01
(doubling time 31.5 hours), increased to 2.5 pg/c-hr at a dilution rate of 0.02
(doubling time 27.7 hours), and then decreased to 1.2 pg/c-hr at dilution rates
of 0.025-0.04 hr- 1 (doubling times between 22.4 and 17.3 hours). It appears that
above a critical growth rate, antibody productivity decreased with increasing
growth rate, again similar to results of Miller et al. (1988).
Antibody production may, however, also be influenced be the
particular nutrient that was growth limiting in a particular system, and on
whether growth was substrate or waste product limited (Birch et al., 1985). For
example, Birch et al. (1985) found that the specific rate of antibody production
increased with increasing growth rate when glutamine was the limiting
nutrient, but decreased with increasing growth rate when either glucose or
oxygen were the limiting nutrients.
Recently, workers using a recombinant Sp2/0 myeloma producing
chimeric human-mouse IgG found clear growth-associated antibody
production (Robinson and Memmert, 1991). At a growth rate of 0.0158 hr-1
(doubling time of 43.8 hrs), specific productivity was 0.58 pg/c-hr, while at a
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growth rate of 0.0425 hr-i (doubling time of 16.3 hours) the specific
productivity was 3.17 pg/c-hr, a 5.4-fold increase in specific productivity.
5. Antibody Production in High Cell Density Culture Systems
5 1 NoTrni .-hormo e~neous('p Cultre S sPtems
Perfusion culture systems for suspension cells may be classified as
homogenous or nonhomogeneous. Nonhomogeneous systems that have
been used for monoclonal antibody production include hollow fiber units
(Van Brunt, 1986; Sch6nherr et al., 1987; Hopkinson, 1985; Klerx et al., 1988;
Mancuso et al., 1990) and stirred tank or expanded bed systems in which cells
are grown immobilized in encapsulated beads (Himmler et al., 1985; Nillson et
al., 1983; Posillico, 1986; Shirai et al., 1987; Sinacore et al., 1989).
Generally, the concentration of antibody recovered from a non-
homogenous system such as a hollow fiber unit are much higher than
obtainable in batch or continuous culture (mg/ml vs. gg/ml). However,
most results are given in units of milligrams of antibody collected per unit
time, or total antibody collected over the run, without concurrent
measurements of cell numbers or growth rate. Unfortunately, this makes it
impossible to determine how the specific productivity varied with the growth
rate or cell density.
Sch6nherr et al. (1987) used a hollow fiber to produce monoclonal
antibodies. Cells grew to a density of about 2 x 108 c/ml in the extracapillary
space. No data on specific productivity was given; however, the yield per ml
of medium supplied was the same as obtained in static culture.
Mancuso et al. (1990) grew a murine hybridoma in a hollow fiber
system and estimated the cell density at 108 c/ml using NMR data and oxygen
consumption data, and estimate a specific productivity of 0.9 pg/c-hr during
stationary phase, similar to the productivity of this line at a dilution rate of
0.017 hr-1 (apparent doubling time of 41 hours) in continuous culture. This
indicates that the specific productivity in the hollow fiber reactor is about the
same as in continuous culture at a low growth rate.
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Yoshioka et al. (1990) encapsulated hybridomas (ATCC HB-8852) in
chitosan-carboxymethl cellulose and obtained densities of 107 c/ml as
compared to about 106 c/ml in suspension culture. The total amount of mAb
produced by encapsulated cells was 1.5 that produced by the batch culture,
indicating that the specific productivity decreased, perhaps due to a nutrient
limitation or accumulation of metabolic wastes.
Sinacore et al. (1989) grew a murine hybridoma in suspension culture
in immobilized in calcium alginate beads to a cell density of 2 x 107 viable
cells/ml medium, or about 108 c/ml beads. The specific productivity of
immobilized cells was slightly lower than in suspension culture (qp = 0.53
pg/c-hr in suspension and 0.425 pg/c-hr when encapsulated). The growth rate
in the immobilized cells was 0.038 hr-1 (doubling time of 18.2 hrs) as
compared to 0.046 hr-1 (doubling time of 15.1 hrs) during exponential growth
in suspension culture, suggesting that the specific productivity decreased with
decreasing growth rate.
Shirai et al. (1987) describe the production of human IgA using
hybridomas (line 4H11) immobilized in calcium alginate in an expanded bed
fermentor. They found that the specific productivity in suspension culture
during exponential growth and in cells immobilized in the beads was the
same.
To summarize, it appears that for many hybridomas, specific
productivity can be maintained at low growth rates and high cell densities as
long as nutrients are supplied, and wastes removed, at a rate adequate to
maintain cell viability.
5.2 Stirred Fermentors and Recycle Systems
Systems employing a spin filter to retain cells in the stirred tank, first
described by Himmelfarb et al. (1969), have been used successfully for
production of monoclonal antibodies (Reuveny et al., 1986b; van der Velden-
de Groot et al., 1990).
Reuveny et al. (1986b) compared the production of antibody in a
murine hybriodoma in batch, fed-batch, semicontinuous culture, and
perfusion culture. The specific productivities in batch, fed-batch, and semi-
continuous culture were similar; productivity in batch ranged from 0.38-0.58
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pg/c-hr, while 
specfic productivity 
in semi-continuous 
culture ranged 
from
044-067 /c-hr 
In erfusion culture 
the spec 
e
proportional to the viable cell density.
Takazawa et al. (1988) describe the production of IgA by a mouse-
human hybridoma in a stirred tank equipped with in situ hollow fiber
modules for medium exchange. In a culture containing 10% FBS, the specific
productivity increased from 0.83 pg/c-hr at day 3 (1.5 x 106 viable c/ml) to 2.1
pg/c-hr at days 8-10 (7 x 106 viable c/ml). In contrast, in serum-free culture,
the specific productivity remained at 0.83 pg/c-hr even though cell densities
increased the same as for the culture containing 10% FBS; indicating that the
serum-free culture lacked some essential factor. The increase in specific
productivity may have been due to either a change in the growth rate, or due
to the accumulation of metabolites produced by the cells which stimulated
antibody production.
5.3 Cell Settlers
Some of the design problems associated with spin filters and external
tangential filters include fouling and clogging of the filter and loss of cell
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as in batch culture during exponential growth up to 1-2 x 107 viable c/ml, but
then increased to 0.71-1.25 pg/c-hr during the time of approximately constant
cell density. Thus, the combination of slow growth and high cell density
appeared to increase specfic productivity by a factor of 2-3. In related work
Velez et al. (1987), also using a spin filter and the same cell line achieved a cell
density of 5 x 107 viable c/ml. The specific productivity was about 1 pg/c-hr
(ie no increase over 2 x 107 viable c/ml). The authors suggest that the
decrease in cell metabolism under low-growth conditions and/or the
secretion of a factor stimulatory to antibody production which can accumulate
to stimulatory levels at high cell density may be the cause of the increase in
specific productivity.
van der Velden-de Groot et al. (1990) also grew a murine hybridoma in
a fermentor equipped with a spin filter, and obtained a maximum viable cell
density of 9.2 x 106 c/ml at a dilution rate of 0.5 v/day. Here, the specific
productivity remained constant during both the time of increasing cell
density and constant cell density, at about 1.4 pg/viable c-hr, remaining
viability due to mechanical damaging of the cells due to shear. Newer
systems incorporating either a cell settling tube (Batt et al., 1990) or conical cell
separator (Kitano et al., 1986; Tokashiki et al., 1988; Tyo and Thilly, 1989) in the
outlet flow have been developed to address these problems. Cell settlers have
the advantage of requiring no moving parts or pumps which damage cells. In
addition, since cells are differentially lost from the tank based on a
combination of size and density, they are self-cleaning, as dead cells, which
are both smaller and lighter than live cells, are preferentially removed.
Some results with external cell settlers are described below.
Takazawa and Tokashiki (1989) grew human-mouse hybridomas in serum-
free medium in a stirred tank with an inner tube and an outer vessel. Cells
precipitate in the settling zone between the inner tube and outer vessel by
gravity. The maximum viable cell density with one line was 107 c/ml, with
specific productivity independent of cell density at about 0.83 pg/c-hr. With
another cell line the maximum cell density was 4-5 x 106 c/ml and the specific
productivity was also independent of the growth rate at about 1.7 pg/c-hr.
Sato et al. (1983) used a conical cell sedimentation column to grow
Namalwa cells to high cell density for the production of interferon. Kitano et
al. (1986) used the same cell sedimentation column designed by Sato et al. to
produce human antibody. The specific productivity of the hybridomas
declined from 0.31 pg/c-hr during increasing cell density to about 0.17 pg/c-hr
at cell densities greater than 107 c/ml, indicating that specific productivity was
growth-linked.
Batt et al. (1990) used a stirred fermentor with an external settling tube
for cell recycle, using an Sp2/0-derived mouse hybridoma (AB2-143.2)
producing an IgG2a. They achieved a cell density of 107 viable c/ml at a
perfusion rate of 1.7 volumes/day. The specific productivity increased from
0.083 to 0.21 pg/c-hr as the cell density increased; however the viability was
only about 45%. The increase in specific productivity was probably due to
decrease in the growth rate observed at higher cell densitites, which had
previously been seen for this cell line (Miller et al., 1988).
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E. Summary
While much work has focused on analysis of nutrient uptake and
production of metabolic wastes, many fundamental question concerning
changes in cell physiology remain unanswered. One question which has not
been satisfactorily answered is how the growth rate and specific rate of
antibody production are related to each other, and what factor(s) determine
whether the specific productivity increases or decreases as a function of viable
cell density. As discussed, this seems to vary among different hybridomas,
and no general conclusion can be formed.
A related topic is how one should understand the great variability in
specific antibody production rates, which vary by almost three orders of
magnitude (Merten et al., 1985; de St. Groth, 1983), even among hybridomas
with the same fusion partner. An additional point to consider is the decline
of specific productivity of cells sometimes seen in long-term culture, which
can be caused by outgrowth of low and/or nonproducing cells, or by poorly
characterized environmental changes associated with high density culture.
To give an indication of the wide variety of specific secretion rates
among different hybridomas and for the same hybridomas at different growth
rates, I have summarized some of the literature data in Table 1-4. This table
includes the measured rates of secretion in batch as well as in continuous and
perfusion culture. In Table 1-4, the first column describes the cell line, where
m refers to mouse, hu to human, and ch = chimeric. In fusions of cells from
different sources, the underlined source (for example, Mh_) indicates the type
of immunoglobulin produced.
Maximum rates of secretion, seen for mouse myeloma cell lines and
tumors, and for a few murine hybridomas, are 2000-3500 molecules mAb/cell-
sec. Two murine hybridomas grown by de St. Groth (1983) exceded this rate of
production 2-fold. While most of the reported rates of secretion for mouse-
human and chimeric hybridomas are 5-10 fold lower, a few mouse-human
hybridomas and one transfectoma show rates of secretion comparable to those
for murine cell lines.
Table 1-4.
Survey of Rates of Monoclonal Antibody Production
Cell Line Ig Doubling qP Reference
(type) Time (molecules
(hours) mAb / cell-sec)
Batch Culture
m myeloma MPC-11 cells IgG2b Laskov & Scharff, 1974
clone I 22.1 2300a  "
clone II 20.3 3300a
m myeloma tumor in vivo n.r. n.r. 1400-2300 Humphrey & Fahey, 1961
m-m AB2-143.2 IgG2a 13.3 1630 Miller et al., 1988
m-m MRC Ox-19 IgGi 21 650-790 Dalili & Ollis, 1989
m-m VIII H-8 IgG 24 420-650 Reuveny et al., 1986b
m-m CRL-1606 IgG 17.3 2680 Glacken et al.,1988
34.7 2680 "
m-m ATCC HB124 IgG 35 1900 McKinney et al., 1991
m-hu-hu (3 clones)b
N12-16.63 IgM 32 130 Kitano et al., 1988
N12-16.63.49.19 IgM 28 1200 "
N12-16.63.49.19.69 IgM 27 2300
m-m L20 IgGi 21 890 Fell et al., 1989
m-m 7E6-10 (L20 deriv.,
chimeric hu-m H chain) ch IgGi 14 450
Sp2/0 transfectoma
CLC LT14 w/ hu-m IgG ch IgGi 16-20 220 Buser, 1989
(continued on next page)
L  --
Continuous Culture
m-m AB2-143.2
m-m VIII H-8
m-m N-146
m-m N-226
m-m N-527
m-m S-6
m-m S-84
rat-NS1 R33-18-12
rat-NS1 R33-24-12
rat-NS1 R33-60
rat-Sp2/0 IM/41
rat-Sp2/0 C2-23
Sp2/0 transfectoma ATCC
CLR 1581w/ ch hu-m IgG
IgG2a 12.4
31.5
IgG
IgG1,,K
IgG2a,1c
IgG2a,,c
IgG2bK
IgM,ic
330
670
24 490-750
11.4
23.6
17.3
17.12
31.2
n.r. 14.1
n.r. 51.9
n.r. 29.8
n.r. 17.2
n.r. 18.1
ch IgG
16.3
43.8
5800
615
7640
1208
380
2460
108
675
3400
2330
3540
650
Miller et al., 1988
Reuveny et al., 1986b
de St. Groth, 19 83c
Robinson & Memmert, 1991
Sp2/0 transfectoma
C46 w/ ch hu-m IgG
ch IgGi 14.6
19.5
High Density (Perfusion)
m-m VIII H-8
m-m AB2-143.2
m-hu H2
m-hu H3
m-hu V1
m-hu V2
m-hu V6
m-hu 4H11
IgG
IgG2a
IgG
IgG
IgG
IgG
IgG
IgA
Sp2/0 transfectoma
CLC LT14 w/ hu-m IgG ch IgGi
n.r. 790-1390
n.r. 93-230
48
120
38
1630
930
1630
Reuveny et al., 1986b
Batt et al., 1990
Takazawa &
Tokashiki, 1989
to
56 2040
70
67
17-21d
15-45e
330
1300
10-220
Shirai et al., 1987
Buser & Morrill, 1990
n.r. not reported. a secreted as IgG.
b higher-producing clones were selected from the same cell line.
c cells were grown in a cytostat at their maximum growth rate.
d growth rate calculated from cell cycle data.
e growth rate calculated from cell concentrations in bioreactor & cell separator.
Buser, 198860
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II. Experimental Methods
A. Cells and Cell Culture Methods
Cells
Sp2/0 cells are a non-antibody producing murine myeloma cell line
(Shulman et al., 1978). These cells were originally obtained by cloning and
selection of non-immunoglobulin producing cells from a hybrid of a murine
BALB/c spleen cell and the myeloma line X63-Ag8 by Shulman et al. (1978).
Sp2/0 cells were obtained from Centocor, Inc.
The C46 cell line is a recombinant Sp2/0-derived transfectoma which
secretes a chimeric mouse-human IgG1 antibody specific for a cancer-
associated glycoprotein antigen found on colorectal carcinomas (Shaw et al.,
1988b), and was obtained from Centocor, Inc. Sp2/0 cells were transfected
with chimeric mouse-human antibody genes as described by Shaw et al.
(1988b). Initially, a murine hybridoma line secreting the monoclonal
antibody 17-1A was raised against SW1083 human colorectal carcinoma cells.
Then, chimeric immunoglobulin genes were constructed in which the DNA
segments encoding the variable regions of the heavy and light chains of the
17-1A antibody were joined to the portion of an immunoglobulin gene
encoding the human yl and K constant regions. The chimeric heavy chain
gene was then cloned into a plasmid carrying the neo gene, and the chimeric
light chain into a plasmid carrying the gpt gene. The transfectoma was
produced by protoplast fusion of Sp2/0 cells with E. coli cotransformed with
both plasmids. Transformants were initially selected for neomycin resistance
with the antibiotic G418, and stable transformants expressing the recombinant
monoclonal antibody were then grown in medium supplemented with G418
and mycophenolic acid (Sun et al., 1987). A transformant was subcloned to
produce the C46 cell line, which secretes 10-20 gJg/ml IgG in batch culture.
The parental cell line, 17-1A, has been in Phase I and II clinical trials,
where it has had some success in reducing tumor size (Sears et al., 1982; Sears
et al., 1984; Sears et al., 1985). However, most patients developed an antibody
response to the murine antibody (Sears et al., 1984; Sears et al., 1985). In
contrast, phase I trials with the recombinant monoclonal antibody produced
by C46 cells indicated that an antibody response against the chimeric antibody
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was seen in only one of ten patients, demonstrating its improved therapeutic
potential (LoBuglio et al., 1989).
Initial experiments were done using C46 cells. However, these cells
lose their antibody-producing capability with time, and production declined
to less than 1 pgg/ml in batch culture after 6 months. Therefore, a subclone of
this cell line, designated CLC LT14, isolated at MIT (Tsuruda, 1989) was used
for all high density bioreactor experiments. This line secretes 12-15 jgg/ml
antibody in batch spinner culture, with a specific productivity of 0.2-0.3
pg/cell-hr during exponential growth, and has a doubling time of 16-20 hours
during exponential growth. A new vial of cells was thawed every month in
order to ensure that the productivity of the cells remained constant.
Medium
Cells were grown in DMEM (obtained either from Gibco, Grand Island,
NY or from JRH Biosciences, Lenexa, KS) supplemented to a final
concentration of 6 mM glutamine, 2 mM pyruvate, and 50 gLM 3-
mercaptoethanol. A 50X stock solution of supplements was dissolved in
dH20 and filter-sterilized, and all supplements were of cell culture grade
quality. This supplemented DMEM was designated DMEM*. Medium was
supplemented with fetal bovine serum (Hyclone, Logan, UT) which was heat
treated at 560 C for 30 minutes.
Stock Cultures
Stock cultures of cells were maintained in exponential growth in T-
flasks (Costar, Cambridge, MA) by passaging three times per week. Stock
cultures were grown in DMEM* supplemented with 5% fetal bovine serum
(FBS) in a 370 C humidified incubator with an 8% CO2 atmosphere.
Batch Spinner Cultures
Batch spinner cultures were used to assess the productivity and growth
rate of cells and to compare different media formulations. Batch cultures,
unless noted otherwise, were inoculated from exponentially growing cells in
T-flasks at an initial density of 5 x 104 c/ml into 100 ml of DMEM*
supplemented with 5% FBS. Spinners (Wilber Scientific, Boston, MA) were
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stirred at 40-50 rpm in a 370 C incubator with an 8% CO2 atmosphere, and
were sampled daily.
Semi-continuous Cultures at Constant Oxygen Tension
Cultures were grown in spinner flasks and diluted daily or as needed to
maintain the cell density between 3 and 1.2 x 105 c/ml in exponential growth.
Spinners were equipped with silicon tubing coiled inside for oxygen transfer,
with a KLa of about 10 hr-1 . Gas mixtures containing 5% CO 2 and either 10%,
20%, 40%, or 60% oxygen, with the balance nitrogen, were passed through a
column of water, then through the tubing, and vented to the headspace.
Control spinners (no oxygen control) were oxygenated by surface aeration via
the atmosphere of the incubator.
Enumeration of Cells
An aliquot of cells was diluted into 19 ml of saline solution in a
prefilled vial such that the cell density was between 104 and 105 cells/ml. The
diluted suspension was counted in a Coulter Counter (model ZF, Coulter
Electronics, Hialeah, FL) and the concentration of cells in the aliquot
calculated using the formula cells/ml = corrected count x dilution factor x 2.
Determination of Cell Viability
Cell viability was determined using the trypan blue exclusion method.
An aliquot of cells was diluted with PBS and 5X trypan blue solution (0.4%
trypan blue in saline solution, 8 g/l NaC1) and counted using a
hemocytometer. Percent viability was estimated by dividing the number of
cells excluding trypan blue by the total number of cells counted.
mmý I _
Bioreactors incorporating a nested conical cell separator were used for
these studies, constructed by modifying a 250 ml spinner flask. A schematic of
the bioreactor and cell separator is shown in Figure II-1. The working
volume was 265 ml. Oxygenation was provided via gas passed through one
meter of expanded PTFE tubing (W.L. Gore and Associates, Inc., Elkton, MD)
coiled against the inside wall of the spinner and vented to the headspace.
Gas, initially air with 5% CO2 and then 40% oxygen with 1% CO2, balance
nitrogen, was bubbled through a column of water prior to entering the tubing
in the bioreactor.
One sidearm was fitted with a silicone cork with two stainless steel
tubes to allow for medium inflow and sampling. Fresh medium was
pumped in through the sidearm tube and spent medium withdrawn through
the top of the cell separator. A constant volume was maintained by setting
the outlet pump slightly faster than the inlet pump. Sterile connections were
made using C-flex splicable tubing (Cole-Parmer, Chicago, IL) spliced with a
sterile connection device (SCD, Dupont, Wilmington, DE).
Cell recycle was via a lamellar conical cell settler, constructed from five
pyrex funnels as shown in Figure II-1. The design and operating parameters
of the conical cell settler are described in detail by Tyo and Thilly (1989). The
stem of the bottommost funnel was fitted into a teflon adaptor which had
holes at the bottom and held the stir paddle. A second bioreactor was
constructed with a modification of the conical cell separator, which was
_1_1_
Cloning
Cells were plated into 96 well round bottom plates (Costar, Cambridge,
MA) at limiting dilution in a volume of 200 pl/well in DMEM*
supplemented with 10% FBS. Plates were kept in a 370 C humidified
incubator with an 8% CO2 atmosphere. Plates were scored for the presence of
clones after 14 days. In some cases, supernatants were removed and frozen at
-200 C for later determination of antibody titers. Plating efficiency (P.E.) was
calculted using the following formula:
P. E. = -In(empty wells/total wells) / (cell/well plated) x 100.
B. Perfusion Culture System
aerated via thin walled silicon tubing (Dow Corning, Midland, MI) coiled
around the outer surfaces of the two innermost funnels.
Bioreactors were inoculated from exponentially growing spinner
cultures at approximately 5 x 105 c/ml. The medium used was DMEM*
supplemented with 4% FBS. The bioreactors were sampled daily, and the cell
density, viability, and flow rate were measured. The cell density and viability
downstream of the cell separation device were also measured daily.
Supernatants were clarified by centrifugation and frozen at -200 C for later
analysis of antibody titers. Viable cells and washed cell pellets were frozen at
-700 C for later analyses.
___
Figure II-1.
Schematic of Perfusion Bioreactor with Conical Cell Separator
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C. Analytical Techniques
1. Measurement of Antibody Titers
Antibody titers in supernatants and cell lysates were measured via a
sandwich Elisa. Polystyrene plates (Flow Laboratories, McLean, VA) were
coated with 100 Jtl/well of the first antibody (goat antihuman F(ab')2, Jackson
Immunoresearch Laboratories, Inc., 872 W. Baltimore Pk., PA, catalog # 109-
005-097) in 0.05 M sodium carbonate buffer, pH 9.8 at a concentration of 10
gg/ml. Plates were sealed and incubated for two hours at room temperature.
The coating solution was removed, and the plates were blocked with 200
pl/well of blocking buffer (3% BSA (Sigma, St. Louis, MO) and 1% normal
goat serum (Sigma, St. Louis, MO) in phosphate buffered saline). Phosphate
buffered saline (PBS) consisted of 8 g/l NaC1, 0.2 g/l KC1, 0.2 g/1 KH 2PO4, and
1.15 g/l Na2HPO4, pH 7.1. Plates were sealed and incubated for one hour at
room temperature. The blocking buffer was removed and the plates were
washed four times with PBS containing 0.05% Tween 20. Plates were sealed
and stored at 40 C. The coated plates were stable for at least four months at
40 C.
To perform an assay, 100 jtl of DMEM* supplemented with 5% FBS was
pipetted into rows B-H of the plate, and 20 pl of samples and standards were
pipetted into wells in row A containing 180 Cl of DMEM* 5%FBS. Eight-fold
serial dilutions of standard and samples were made going down the plate,
leaving 100 pl/well. When necessary, the amount of sample was increased to
place it into the linear range of the assay. The standard was human IgG
(Jackson Immunoresearch Laboratories, , 872 W. Baltimore Pk., PA, catalog #
009-000-003) prepared at 8 gg/ml in DMEM* 5%FBS, aliquotted, and frozen at
-200 C. Duplicate standards were run on each plate, and column 1 was used as
a blank. Plates were then sealed and incubated for one hour at 370 C. The
medium was removed and the plates were washed four times with PBS
containing 0.05% Tween 20. Plates were incubated with 100 pl/well of the
second antibody (alkaline phosphatase-conjugated goat antihuman IgG (Tago,
Inc., Burlingame, CA, catalog # 2490) at a dilution of 1/5000 in 1% BSA
(Sigma, St. Louis MO) in PBS. The appropriate dilution was determined for
each lot of second antibody. Plates were then sealed and incubated for one
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hour at 370 C. The second antibody was removed and the plates were washed
four times with PBS containing 0.05% Tween 20. Substrate was freshly
prepared by adding Sigma 104 phosphate substrate tablets (5 mg/tablet) to
substrate buffer to a final concentration of 1 mg/ml. Substrate buffer was
prepared by the addition of 48 ml of diethanolamine and 24.5 mg MgCl2 to 400
ml dH20, adjusted to pH 9.8, and kept in the dark at room temperature. 100
pl/well of substrate was added to plates, and the reaction was quenched after
20 minutes at room temperature by addition of 100 pl/well of 2N NaOH.
Plates were read at 410 nm in an Elisa plate reader (EAR400, SLT
Labinstruments, Austria) programmed to subtract the value of the blank from
each sample dilution.
The concentration of antibody in the sample was calculated using a
BASIC program, shown in Appendix 1. A best fit line to the linear portion of
a plot of absorbance versus log of the dilution was calculated for the standard
and samples. The concentration of antibody in the samples was estimated by
comparing the sample dilution to the standard dilution at an absorbance of
0.8 absorbance units.
In order to obtain reliable results, duplicate standards were run on each
plate, and all samples were assayed at least in duplicate on separate plates.
The limit of detection of this method was 0.3 ng/ml.
For analysis of antibody titers in supernatants of clones (data shown in
Figure III-58 and Table 111-9), the Elisa assay was performed as described above,
but the concentration of antibody in the samples was calculated using a
commercial software program (AssayZap, Biosoft, Cambridge, UK). This
program computes a standard curve based on the equation y = [(a -d)/(1 +
(x/c)b] + d, where x is the concentration, y is the absorption, and a, b, c, and d
are fitted parameters.
2. Preparation of Cell Lysates for Measurement of Antibody
Content
Cells were lysed using the method of Meilhoc et al. (1989). An aliquot
containing 5 x 105 cells was pelleted by centrifugation for 5 minutes at 3000
rpm and washed once with PBS. The cell pellet was suspended in 200 •l
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KH 2PO4 (5 mM, pH 7.4) and incubated for eight minutes at room
temperature. 200 Jl of 15 mM KH2PO4 /270 mM NaC1, pH 7.4, 50 Jl 1%
Triton X-100, and 12 •l 0.2M CHAPS were then added. Cells were vortexed
and centrifuged at 40 C at 10,000 rpm for ten minutes. The supernatant was
removed and assayed for immunoglobulin content via the Elisa assay
described above.
3. Isolation and Labelling of DNA Probes
Probes for the human constant regions of the immunoglobulin heavy
and light chains were obtained as pBR322 inserts in E. coli from Dr. John
Ghrayeb at Centocor, Inc. The heavy chain probe is a 7.5 kb fragment
encompassing the human IgGi constant region, and the light chain probe
consists of a 2.5 kb fragment encompassing the human light chain (kappa)
constant region. A probe for rat a-tubulin was obtained as a 1.4 kb cDNA
insert in pBR322 in E.coli from Dr. Frank Solomon's lab at MIT.
Large-scale plasmid preparations were done as described in Maniatis
(1982a). Cultures of E. coli containing the plasmids described were grown in
LB medium containing 25 mg/ml ampicillin and amplified by the addition of
chloramphenicol. Cells were harvested and the plasmids isolated using the
alkaline lysis method (Maniatis, 1982b). Isolated plasmids were each cut with
the appropriate restriction enzyme(s); the light chain plasmid was cut with
Eco R1, the heavy chain plasmid with Bam H1 and Sal 1, and the a-tubulin
plasmid with Pst 1. The restricted plasmids were run on 1% agarose-TBE gels,
and the correctly sized fragment excised. Excised fragments were minced and
the DNA was electroeluted on a DEAE cellulose D-gel (Epigene, Baltimore,
MD) column, following the manufacturer's protocol. The concentration of
purified DNA probes was estimated in ethidium bromide stained agarose gels
by comparison of the intensity with molecular weight markers of known
concentration. Probes were stored at -200 C.
Prior to hybridizations, 50-100 ng of probe was random prime labelled
with 32P-dCTP (3000 Ci/mmol, New England Nuclear NEG-013H) using a
commercial kit obtained from Amersham (1601Y), following the
manufacturer's instructions. Unincorporated nucleotides were removed
using a Sephadex spun column (Maniatis, 1982c). The specific activity was
measured by scintillation counting and was typically 5 x 108 cpm/ng.
4. Isolation of Genomic DNA and Southern Blotting
DNA was isolated by differential elution from anion exchange resin
columns (Quiagen Inc., Chatsworth, CA) using the manufacturer's protocol.
Genomic DNA was quantified by measuring the absorption at 260 nm and
using the conversion 1 A260 = 50 gg/ml double-stranded DNA. 0.7% agarose-
1X TBE (0.089 M Tris-borate, 0.089 M boric acid, 0.002 M EDTA, pH 8) gels were
prepared according to standard methods (Maniatis, 1982d) and loaded with
ten gg of DNA cut with the appropriate restriction enzyme per lane. DNA
molecular weight markers (BRL, Bethesda, MD) were run in one lane to
allow determination of the sizes of hybridized DNA. Gels were run for 16-20
hours at 1.5 volts/cm. Gels were photographed and then transferred to Gene
Screen Plus (DuPont) nylon membranes, using the manufacturer's protocol
for capillary transfer (Dupont, 1985a). Southern blots were probed with
random-primed probes for the immunoglobulin heavy and light chains.
Hybridization buffer consisted of 1% SDS, 1 M sodium chloride, 10% dextran
sulfate, and 100 gg/ml denatured salmon sperm DNA with 4 x 105 cpm
probe/ml, and blots were hybridized overnight at 650 C following the Gene
Screen Plus (Dupont, 1985b) protocol. Blots were exposed to Kodak X-ray
films (Kodak X-Omat AR) with an intensifying screen (DuPont Cronex
Lightning Plus) to visualize bands.
5. Isolation of RNA and Northern Blotting
All solutions and glassware which were not disposable were treated
with 0.1% diethlypyrocarbonate to inhibit RNAses (Ausubel et al., 1987). Total
cellular RNA was isolated by adapting the method of Chomczynski and
Sacchi (1987). Cells were lysed directly into a solution of 4 M guanidinium
thiocyanate, 25 mM sodium citrate, pH 7.0, 0.5% sarcosyl, and 0.1 M D3-
mercaptoethanol (GITC solution) and stored at -700 C until RNA was isolated.
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One ml of GITC solution was used per 107 cells. To isolate RNA, samples
were first extracted with 0.1 ml 2N NaAcetate, pH 4, 1 ml water-saturated
phenol, and 0.2 ml of CHCl3:isoamyl alcohol 24:1 per ml of GITC solution.
Samples were vortexed and centrifuged for 10 minutes at 4000 rpm at 40 C.
The aqueous phase was reextracted with 0.5 ml phenol/0.5 ml of
CHC13:isoamyl alcohol 24:1 per ml of GITC solution. Samples were vortexed
and centrifuged for 10 minutes at 4000 rpm at 40 C, and the aqueous phase was
removed. RNA was precipitated by addition of 150 p.l 2N NaAcetate, pH 4,
per ml of aqueous solution and addition of an equal volume of isopropanol.
Samples were precipitated at -200 C for at least 2 hours and then centrifuged
for 30 minutes at 10,000 rpm and 40 C. The pellet was washed with 80%
ethanol, vacuum dried, and dissolved in 0.5% SDS. RNA was quantified by
measurment of the absorption at 260 nm, using the conversion of 1 A260 = 40
gtg/ml RNA.
Denaturing formamide/formaldehyde 1% agarose gels were prepared
according to standard methods (Ausubel et al., 1987) and loaded with 15 gg
total RNA per lane. RNA molecular weight markers (BRL, Bethesda, MD)
were run in one lane to allow determination of the sizes of hybridized RNA.
Gels were run for three hours at 100 volts. Gels were photographed and then
transferred to Gene Screen Plus (DuPont) nylon membranes, using the
manufacturer's protocol for capillary transfer (DuPont, 1985c). Blots were
baked for 2 hours at 800 C in a vacuum oven to reverse the formaldehyce
reaction, and irradiated for seven minutes at a distance of 1.5 inches over a
ultraviolet light table.
Northern blots were probed with three different random-primed
probes. Hybridization buffer consisted of 1% SDS, 1 M sodium chloride, 10%
dextran sulfate, and 100 gg/ml denatured salmon sperm DNA with 4 x 105
cpm probe/ml, and blots were hybridized overnight at 600 C following the
Gene Screen Plus (DuPont, 1985d) protocol. Quantification of the signal
intensity was done using a Phosphor Imager (Molecular Dynamics,
Sunnyvale, CA).
6. Preparation of Samples for Polysome Gradients
Cell lysates were isolated from bioreactors using the method of Bennett
and Adams (1987) and frozen at -700 C until processed. An aliquot of 3 x 107
cells was collected by centrifugation at 2000 rpm at 40 C for five minutes. Cell
pellets were lysed into 1 ml of ice-cold lysis buffer consisting of 0.25 M sucrose,
10 mM Hepes, pH 7.5, 10 mM KC1, 3 mM MgC12, 1 mM dithiothreitol, 0.2%
Triton X-100, 0.05% sodium deoxycholate, and 0.2 mg/ml heparin as a
ribonuclease inhibitor. The lysate was centrifuged 10 minutes at 10,000 rpm at
40 C in an eppendorf centrifuge to pellet nuclei and mitochondria. The
supernatant containing the polysomes was was removed and stored at -700 C.
Sucrose gradient solutions contained 10 mM Hepes, pH 7.5, 10 mM KC1, 3
mM MgC12, 1 mM dithiothreitol, 0.2 mg/ml heparin and either 15% or 50%
sucrose. Sucrose gradients were prepared by combining 7 ml of 15% sucrose
gradient solution and 8 ml of 50% sucrose gradient solution in a gradient
maker. Eight A260 absorbance units of lysate was then layered atop 14.5 ml of
a 15-50% sucrose gradient in 15 ml tubes, and centrifuged for 2 hours at 27,000
rpm. 0.5 ml fractions were collected and an aliquot of each fraction was taken
to measure the absorbance at 254 nm. The fractions were extracted with 0.5
ml of a 1:1 mixture of phenol/chloroform, and precipitated, washed, and
dried as described in Section II.C.5. for isolation of RNA and Northern
blotting, and dissolved in 5 •l dH20 and then run on a 1.2% denaturing
agarose formamide/formaldehyde gels, also as described in Section II.C.5.
Gels were photographed, transferred to GeneScreen Plus, and hybridized as
for Northern blots. Band intensities were quantified via phosphorimaging.
7. Flow Cytometry Methods
For measurement of intracellular antibody content, cells were prepared
as follows: Aliquots of 2 x 106 cells were collected by centrifugation, washed
with ice-cold PBS, permeabilized with 70% ethanol in PBS for 30 minutes on
ice, washed with PBS, and then incubated with 150 •l of a 1/15 dilution of one
of three Fab2' fragments of goat antihuman antibodies conjugated to
fluorescein (FITC) for 30 minutes at room temarature. Cells were then
~
Awashed with PBS, resuspended in 1 ml PBS, and kept on ice until analyzed.
Previous titrations ensured that the FITC-conjugated antibody was in excess at
a 1/15 dilution. The three FITC-conjugated antibodies used (obtained from
Jackson Laboratories, Inc. W. Baltimore Pike, PA) and their specificities are
listed in Table II-1.
Table II-1.
FITC-conjugated Reagents used to Stain Cells for Intracellular Antibody
Catalog # Description Specificity
109-096-088 FITC-conjugated goat anti-human (H+L) Fab 2' anti(H+L)
109-096-098 FITC-conjugated goat anti-human Fc Fab2' anti-H
109-096-097 FITC-conjugated goat anti-human (Fab-2) Fab 2' anti-L
In a second protocol, cells were first stained with ethidium monoazide
and then permeabilized with paraformaldehyde. Aliquots of 2 x 106 cells were
collected, washed with PBS, and the cell pellets were then incubated with
ethidium monoazide (EMA) for twelve minutes on ice. Treatment of cells
with EMA was done by adapting a protocol obtained from Stuart Connor of
the Flow Cytometry Lab at MIT. A stock solution of EMA at 0.1 mg/ml was
aliquotted and stored at -200 C, and 20 gl was added to cell pellets to a final
concentration of 1 gg/2 x 106 cells. The EMA was crosslinked by exposing
samples to 10 minutes of white fluorescent light and 2 minutes of ultraviolet
light, at a distance of 10 cm. Cells were then washed with PBS, permeabilized
with 1% paraformaldehyde in PBS for 30 minutes on ice, washed with PBS,
and then incubated with a 1/15 dilution of one of three Fab2' fragments of
goat antihuman antibodies conjugated to FITC for 30 minutes at room
temarature. Cells were then washed with PBS, suspended in 1 ml PBS, and
kept on ice until analyzed.
Samples were run on a Coulter Epics C (Coulter, Hialeah, FL) flow
cytometer. Green fluorescence (FITC) was measured with excitation at 488
nm and bandpass emission measured at 530 nm. Sp2/0 cells were used to
assess non-specific binding of the FITC-conjugated antibody reagents. Flow
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cytometer voltages were adjusted so that both the positive and negative
sample peaks were on scale. Red fluorescence (EMA) was measured with
excitation at 488 nm and bandpass emission measured at 610 nm.
One of two methods was used to convert the logarithmic mean of
green fluorescent intensity to a linear mean. Some data was converted using
a computer program (EPICS Cytologic Software V2.0, Coulter Corp., Hialeah,
FL) which sums the number of cells in each channel times the channel
number and computes a linear mean. The other method uses a theoretical
equation developed by Schmid et al. (1988). The logarithmic mean
fluorescence for a three decade log amplifier such as the Coulter Epics C flow
cytometer is related to the linear mean by:
linear mean = (theoretical base)(logarithmic mean) (1)
For a three decade log amplifier, the theoretical base = 1000(1/256) = 1.0273508,
so:
linear mean = 1.0273508(logarith m ic mean) (2)
The mean logarithmic fluorescent intensities of antibody-positive cells was
converted to linear intensities using equation 2.
D. Mathematical Analyses
1. Growth and Antibody Production in Batch Cultures
Growth in batch culture is described by:
dXv = gXv - aXv = iLappXv
dt (3)
where Xv = the viable cell density (cell/ml)
t = the growth rate (hr-1)
a = the death rate (hr-1)
iapp = p~- a (hr-1)
and t = time (hours).
During exponential growth, the viable cell density is in excess of 97%,
cell death is negligible, and . = P-app. Equation 3 then reduces to:
dt (4)
where X = total c/ml. Integration of equation 4 gives:
In _
At (5)
where X0 and Xt are the cell densities at the begining and end of a time
interval, and At = the time interval. The doubling time was calculated using:
In (2)TD = 9(6)
where TD = doubling time in hours. The growth rate during exponential
growth of batch cultures during exponential growth was calculated from the
slope of the linear regression of the log of the cell concentrations versus time.
The specific rate of antibody production in batch culture is proportional
to the viable cell density and is given by:
d[mAb] = qpXv - kdeg[mAb]
d t (7)
where [mAb] = concentration of monoclonal antibody in units of gg/ml, qP =
specific rate of antibody production in units of pg/c-hr, and kdeg = a first order
degradation constant for monoclonal antibody in units of hr-1. At high
viability, and in the absence of product degradation, equation 7 reduces to:
___
d[mAb] = qpX
dt (8)
Substituting gives:
d[mAb] = qpXoeht
dt (9)
Integration of equation 9 results in:
mAbt - mAbo - qp (Xt- Xo)9(10)
where mAbO and mAbt are the concentration of monoclonal antibody at the
beginning and end of a time interval. Substituting again, and rearranging,
results in:
(mAbt - mAbo) In(Xt/Xo)
qp - At Xt - Xo (11)
The specific productivity in batch spinners was calculated during exponential
growth using equation 11. The log mean cell density, XLM, is equal to the
reciprocal of the second term in equation 11, as shown below:
XLM = Xt- XO
In(Xt/Xo) (12)
Use of the logmean cell density is justified over a short interval when the
growth rate is constant or nearly so.
2. Growth and Death Rates in Perfusion Bioreactors
Growth of cells in perfusion bioreactors utilizing the conical cell
separator to effect cell recycle was modeled as:
~I_
dXv = PXv - aXv - (ev Xv D)
dt (13)
where Xv = viable cell density (c/ml)
t = time (hours)
L. = growth rate (hr-1)
a = death rate (hr-1)
ev = separation ratio for viable cells (Xv removed/Xv in
bioreactor
and D = the bioreactor dilution rate (hr-1) which is equal to F/V,
where F = flow rate (ml/hour) and V = volume of the
bioreactor (ml).
For the case of the perfusion bioreactors, the viable cell density cannot
be approximated by total cell density, and the death rate is significant.
Integration of equation 13 results in the following non-steady state solution:
Xvt = Xvo e ((I - a - evD)At) (14)
where Xvo and Xvt are the viable cell densities at the beginning and end of a
time interval, and At = time interval (hours). Rearranging gives an
expression for the growth rate, g.:
In( Xvt)
CI = a + evD + NXvO]
At (15)
Equation 15 contains two unknowns, g. and a. However, pgapp can be
obtained from rearrangement of equation 15:
In Xvtl
11app = g - a = EvD + o
At (16)
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Equation 17 gives the change in nonviable cell density as a function of
time.
dXD aXv 
- (ED XD D)
d t (17)
where XD = nonviable cell density (c/ml)
ED = separation ratio for viable cells (Xv removed/Xv in
bioreactor.
Making the following substitution:
dXD = aXvo e((uapp 
- EvD)At) 
- (ED XD D)
dt (18)
where Pgapp = gJ - a, and integrating, results in the non-steady state expression
for the death rate, a:
B ( XDt -XDoe'EDDAt)
Xvo e-DDAt ( eBAt - 1 ) (19)
where XDO and XDt = nonviable cell density at the beginning and end
of a time interval, and
B = gapp + DED - DEv.
Equation 19 was used to obtain the death rate, a, which was then
substituted into equation 15 to obtain the growth rate, g. Equations 15 and 19,
the non-steady state solutions to equations 13 and 17, were used to calculate
growth and death rates in the perfusion bioreactors because the cell density
changed with time.
3. Antibody Production in Perfusion Bioreactors
The rate of product formation in the perfusion bioreactors, assuming
no degradation of product, is given by:
c{mAb] b
dt
qp Xv - D[mAb] (20)
(20)
where mAb = concentration of IgG in the supernatant (•ig/ml)
qP = specific rate of antibody produciton (pg/c-hr)
D = bioreactor dilution rate (hr-1)
The following substitution for qP was made:
qp = QP
Xv,LM
Qp In(Xvt/Xv o)
XVt - XVo (21)
where Qp = volumetric productivity in Jgg/ml-hr, and Xv,LM = log mean of
the viable cell density, as defined in equation 12. Substituting equation 21
into 20 yields:
(mAb]
mAb] = Qp -
dt
D[mAb] (22)
Integration of equation 22 gives the following expression for the
volumetric productivity:
Qp =D[mAbt - mAbo e - D &t]
1 -e - DAt
where mAbo and mAbt = concentration of IgG in the supernatant (•tg/ml) at
the beginning and end of a time interval.
Equation 23 was used to solve for the volumetric productivity in the
perfusion bioreactors. The specific productivity was then calculated using
equation 21.
(23)
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4. mRNA Synthesis and Degradation Rates
The change in any mRNA species under quasi-steady state conditions,
when cells are in balanced growth, is described by the following equation:
The assumptions are that mRNA synthesis is independent of the mRNA
concentration, and that the decay of mRNA is first order with respect to the
concentration of RNA.
d[mRNA]i ksi - kdi [mRNA]i 
- p [mRNA]i
dt (24)
where ksi = rate of synthesis of the ith species (hr-1)
kdi = rate of decay of the ith species (hr-1)
gt = growth rate (hr-1)
i = the ith species
t = time (hours).
At steady-state, this equation reduces to:
[mRNA]i = ksi
kdi + t. (25)
where the rate of mRNA synthesis of any species is balanced by its rate of
decay and dilution by growth.
For the special case of treatment with actinomycin D, an inhibitor of
RNA synthesis, ks = 0, and equation 23 reduces to:
d[mRNA]id[mNA - kdi [mRNA]i - p. [mRNA]i
dt (26)
Integrating equation 25 gives:
[mRNA]i,t = [mRNA]i,to e-(kdi + g)At (27)
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where [mRNA]i,tO and [mRNA]i,t are the amounts of mRNA at the
beginning and end of a time interval. Rearrangement of equation 27 gives:
k[mRNA]i,to 
- kdi
- = kdiAt (28)
which is used to calculate the rate of decay, kdi.
In practice, the half-life of immunoglobulin mRNA species were
estimated from a log-linear plot of the amount of mRNA remaining as a
function of time after initiating actinomycin D treatment. The half-life
(hours) was equal to the time at which 1/2 of the amount of mRNA present
at initiation of actinomycin D treatment (time zero) remained.
III. Experimental Results
A. Low Cell Density Experiments
1. Growth and Antibody Production in Batch Spinners
Cell growth and antibody production were first characterized in batch
spinners. After inoculation of cells into a spinner, there is a short (12-24
hours) lag period, and then a period of exponential growth until day 3-4,
depending on the inoculum density, during which viability is in excess of
97%. After this time, cell growth slows, and the cells enter stationary phase
and finally cell death occurs.
Antibody titer increases with cell density and reaches a maximum
during stationary phase at 12-20 gg/ml. The apparent growth rate during
exponential phase is 0.035-0.043 hr-1 (doubling times of 16-20 hours), and the
average specific rate of antibody production during exponential growth is
approximately 0.2 pg/c-hr. As the viability was in excess of 97%, the apparent
growth rate was approximately equal to the true growth rate. In batch
spinners, antibody production is growth-associated; the specific rate of
antibody production is highest during exponential growth.
Figure III-1 shows growth curves in batch spinners for CLC LT14 cells
maintained for one (1-A and 1-B) and three (3-A and 3-B) weeks at low cell
density, and Figure 111-2 the antibody titers for the same spinners. The growth
rate, doubling time, and specific productivity, were calculated for days 0-3 and
are shown in Table III-1. It may be seen that the specific productivity
decreased by about 25% over the two week interval. The specific productivity
(qP) of CLC LT14 cells declines by about 70% over a period of one month in
culture.
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Figure III-1.
Growth of CLC LT14 Cells in Batch Spinners after
One and Three Weeks in Culture
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Cultures were inoculated into batch spinners from exponentially
growing cells in T-flasks on the same day at 5 x 104 cells/ml and were
sampled daily. The medium used was DMEM* supplemented with 5%
FBS. One vial of CLC LT14 cells had been thawed and maintained in T-
flasks for three weeks, and was used to inoculate spinners 3-A and 3-B.
A second vial had been thawed and maintained in T-flasks for one
week, and was used to inoculate spinners 1-A and 1-B.
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Figure III-2.
Immunoglobulin Production of CLC LT14 Cells in Batch Spinners after
One and Three Weeks in Culture
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Samples of supernatants from the same spinners shown in Figure III-1
were removed daily and frozen at -200 C. Immunoglobulin titers in
supernatants were measured using an Elisa assay, as described in
section II.C.1, Materials and Methods. Values represent the average of
duplicate determinations.
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Table III-1.
Growth Rate, Doubling Time, and Specific Productivity of CLC LT14 Cells
After One and Three Weeks in Culture
After 1 Week After 3 Weeks
A B A B
growth rate (hr -1) 0.040 0.040 0.037 0.040
doubling time (hrs) 17.5 17.5 18.9 17.5
Specific Productivity 0.19 0.20 0.13 0.16
(pg mAb/cell-hr)
Values for the growth rate, doubling time, and specific productivity
were determined for the cultures shown in Figures III-1 and III-2 over
days 0-3. The growth rate was determined from the slope of the linear
regression of the log of the cell concentrations versus time. The
doubling time was calculated using equation 6. Specific productivity
was calculated using equation 11.
2. Growth and Antibody Production in Semi-continuous
Culture at Different Levels of Dissolved Oxygen
Initially, the growth and antibody production rates were studied as a
function of dissolved oxygen (DO). Duplicate cultures of C46 cells were grown
in spinner flasks and diluted daily or as needed to maintain the cell density
between 3 and 1.2 x 106 c/ml in exponential growth; oxygenation was as
described in Section II.A. The dissolved oxygen was maintained by using gas
mixtures containing 5% CO2 and either 10%, 20%, 40%, or 60% oxygen (where
100% is equal to pure oxygen). Control spinners (no oxygen control) were
oxygenated by surface aeration via the atmosphere of the incubator. Figure
III-3 shows cumulative growth as a function of dissolved oxygen; each curve
is the average of two replicate cultures. The apparent growth rates were
calculated by linear regression of the cumulative growth data over days 1-5.
Figure 11-4 shows the apparent growth rate and doubling times as a
function of dissolved oxygen, with the corresponding percentage of oxygen in
-`--
the gas phase shown on the upper y axis. Growth slowed as the dissolved
oxygen concentration increased; the doubling time at 90 jIM (10% oxygen) and
for the control cultures without oxygen control was almost identical (14.6 and
14.5 hours); at 180 p.M (20% oxygen) the doubling time was 16.0 hours, at 360
p.M (40% oxygen) it was 19.4 hours, and at 540 p.M (60% oxygen) it was 30.8
hours. The horizontal arrows on the control culture serve to indicate that the
dissolved oxygen tension varied from 180 pM (right after dilution) to
approximately 30 pgM.
Figure III-5 shows the specific rate of antibody production as a function
of the doubling time. The specific rate of antibody production increased with
increasing doubling time, reached a maximum of of 0.11 pg/c-hr at a doubling
time of 19.5 hours (growth rate of 0.036 hr-1) and declined to 0.093 pg/c-hr at a
doubling time of 30.8 hours. While the doubling time of control cultures and
those at 90 pM oxygen was almost identical, the specific productivity of the
control cultures was 25% higher (0.058 pg/c-hr) than that of the cultures at 90
pM (0.046 pg/c-hr). At a doubling time of 30.8 hours, the specific rate of
antibody production per total cell was 0.093 pg/c-hr. However, the specific
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oxygen probably decreased cell viability, as shown to be the case for another B
cell line, TK6 (Oller et al., 1989).
Figure 111-6 shows the specific rate of antibody production regraphed as
a function of dissolved oxygen. The specific rate of antibody production
increased as a function of dissolved oxygen, reaching a maximum value at
360 p.M dissolved oxygen. Increasing the dissolved oxygen level in the
cultures, up to 360 p.M, appeared to enhance the specific productivity while
slightly decreasing the growth rate; however, we cannot tell whether the
primary cause of the change in productivity is due to the effect of oxygen on
cell metabolism or due to a decrease in the growth rate.
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Figure 111-3.
Cumulative Growth of C46 Cells at Different Levels of Dissolved Oxygen
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Cultures of C46 cells were grown in spinner flasks using DMEM*
supplemented with 2.5% horse serum and 2.5% FBS and were diluted daily or
as needed to maintain the cell density between 3 and 1.2 x 106 c/ml in
exponential growth; oxygenation was as described in Section II.A. Constant
dissolved oxygen tension was maintained by using gas mixtures containing
5% CO2 and either 10%, 20%, 40%, or 60% oxygen (where 100% is equal to
pure oxygen). Control spinners (no oxygen control) were oxygenated by
surface aeration via the atmosphere of the incubator. Each growth curve is
the average of two replicate cultures.
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Figure III-4.
Growth Rate of C46 Cells as a Function of Dissolved Oxygen
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Apparent growth rates for the cultures depicted in Figure 1I-3 were calculated
by linear regression of the cumulative growth data over days 1-5. The
apparent growth rate was calculated for each of two replicate cultures by linear
regression of the cumulative growth data over days 1-5, and the average
apparent growth rate of the two replicates is shown. The doubling time at
each condition was then calculated using equation 6.
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Figure III-5.
Specific Rate of Antibody Production of C46 Cells as a Function of
Doubling Time
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Specific rates of antibody production for the cultures depicted in Figure III-3
were calculated for days 1-5 using equation 11. Spinners were sampled daily,
and immunoglobulin titers in samples of culture supernatants were
measured at Centocor, Inc. The specific productivity per total cell was
calculated for each of two replicate cultures over daily intervals and the
average specific productivity at each condition is shown.
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Figure III-6.
Specific Rate of Antibody Production of C46 Cells
as a Function of the Dissolved Oxygen Concentration
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The data shown in Figure I1-5 was regraphed as a
function of the dissolved oxygen concentration.
The effects of dissolved oxygen on growth and antibody production of
hybridomas have been studied at oxygen tensions up to 180 gIM by other
workers. Miller et al. (1987) tested the effect of dissolved oxygen from 1-180
JiM dissolved oxygen on a Sp2/0-derived hybridoma producing an IgG2a
(143.2 cells) in continuous culture at a constant dilution rate of 0.0225 hr-1 and
found that the optimum dissolved oxygen for antibody production was about
90 gM, while the optimum for cell viability was about 1 gM. The specific
productivity varied from about 0.09 pg/c-hr at dissolved oxygen levels of 1-18
jiM to 0.16 at 90 gIM and declined to 0.135 at 180 JIM dissolved oxygen.
Boraston et al. (1984) found that growth rates were constant at dissolved
oxygen tensions from 14-180 JIM dissolved oxygen (antibody production as a
function of dissolved oxygen was not reported).
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B. High Cell Density Perfusion Culture
1. Cell Growth and Cell Separator Performance
The central aim of my thesis was to study the dynamics of antibody
production at high cell density. In order to obtain high cell densities, cells
were grown in a perfusion bioreactor with cell recycle, utilizing a novel
conical cell settler designed in this laboratory. A number of bioreactor runs
were done to test different designs of the conical cell settler, and provided
initial data on the performance characteristics of the cell settler, and growth
and antibody productivity of the cells, and six of these bioreactor runs were
analyzed in detail.
In the first experiment, three bioreactors, designated #1, #2, and #3, were
run in parallel for up to 42 days. After analysis of the data obtained from
these runs, another set of three reactors was designed and run in order to
collect additional on-line data. The second set of bioreactors were designated
#4, #5, and #6. CLC LT14 cells were used in all six perfusion bioreactors.
In both sets of experiments, cells were inoculated at approximately 5 x
105 c/ml into the perfusion bioreactors. The medium initially consisted of
DMEM* supplemented with 4% FBS. Perfusion was initiated on day two, and
flow rates were ramped to approximately three volumes/day until a steady-
state cell density was obtained. The strategy employed was first to ramp the
perfusion rate to 3 reactor volumes/day and hold it there until a steady-state
was attained.
Figure 111-7 shows the viable cell densities and viability in perfusion
reactors #1-#3 as a function of time. The flow rates for these reactors were
ramped to three volumes/day and remained there from days 6 to 19, when
they were increased to six volumes/day. At day 33, the inlet medium to #2
was changed to a 2:1 mix of DMEM* 4%FBS: balanced salt solution (Butler et
al., 1983), and at day 36 to a 1:1 mix of DMEM* 4%FBS: balanced salt solution.
At a flow rate of three volumes per day, viable cell densities of 107 c/ml
were obtained; at a flow rate of six volumes per day, the viable cell density in
reactors #1 and #2 increased to approximately 2 x 107 c/ml. At a flow rate of 6
vol/day, the cell density in #3 initially increased but then began to decrease by
day 28, due to decreased efficiency of retention of viable cells by the cell
separator. Substitution of the mix of DMEM* 4%FBS: balanced salt solution
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for complete medium to #2 caused a decrease in both the viable cell density
and viability, shown to be due to glucose limitation (Tyo, 1991).
A second set of bioreactor runs was performed in order to analyze cells
on-line, test the effect of nutrient supplements, and test the effect that
oxygenation of the cell separator would have on cell growth and antibody
production. These reactors were run for 14 days. The experimental design
was similar to the first set of bioreactors, with the following changes. The
design of reactor #4 was identical to that of #1-3. The conical cell separator for
the two other reactors (designated #5 and #6) was modified to contain 2 meters
of thin-walled silicon tubing to allow aeration. The conical cell separator to
#5 was aerated; while #6 was not aerated and served as the design control for
#5. The medium to all three reactors was identical until day 8. On day 8, the
inlet medium to #4 was modified to contain 8% FBS, and on day 10, the inlet
medium to #6 was modified to contain twice the amounts of 3-
mercaptoethanol, cysteine, and methionine found in DMEM*.
Figure III-8 shows the viable cell densities and viabilities in perfusion
reactors #4-6 as a function of time. A steady-state density of 107 viable c/ml
was obtained in all three reactors at a perfusion rate of 3 volumes/day, with a
viability of about 75%. Modifying the inlet medium to #4 to contain 8% FBS
did not increase the viable cell density. Similarly, modifying the inlet
medium to #6 to contain twice the amounts of P-mercaptoethanol, cysteine,
and methionine found in DMEM* also had no effect on the viable cell
density. Oxygenation of the cell separator to #5 also did not affect the viable
cell density. The medium modifications and oxygenation of the cell separator
are discussed in more detail in sections mI.B.4.2 and III.B.4.3.
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Figure III-7.
Viable Cell Density and Viability in Reactors #1-3
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Three reactors were inoculated in parallel from exponentially growing CLC
LT14 cells at 5 x 105 cells/ml. These reactors were designated #1, #2, and #3 in
this and ensuing figures. The medium was DMEM* supplemented with 4%
FBS. Reactors were sampled once or twice daily. Total cell numbers were
measured using a Coulter counter, and viability was measured via trypan
blue exclusion. Perfusion was initiated on day 2, ramped to 3 volumes/day,
and remained at 3 volumes/day from day 6 to day 19, when it was increased
to 6 volumes/day. On day 32, the inlet medium to reactor #2 was diluted with
a salt solution (Butler et al., 1983) as indicated in the figure.
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Figure III-8.
Viable Cell Density and Viability in Reactors #4-6
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Three reactors were inoculated in parallel from exponentially growing CLC
LT14 cells at 5 x 105 cells/ml. These reactors were designated #4, #5, and #6 in
this and ensuing figures. The medium was DMEM* supplemented with 4%
FBS. Reactors were sampled once or twice daily. Total cell numbers were
measured using a Coulter counter, and viability was measured via trypan
blue exclusion. Perfusion was initiated on day 2, ramped to 3 volumes/day,
and remained at 3 volumes/day for the duration of the experiment. Media
and cell separator modifications are described in the text.
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2. Cell Growth and Death Rates
The viable cell density in the reactors is a function of the separation
ratio, that is, the efficiency with which cells are returned from the cell
separator to the bioreactor, the growth rate, and the death rate (see Section II.D
for the mathematical analysis). The separation ratio, E, was calculated for
both viable (ev) and dead (ED) cells as:
Ev = Xoutlet,v/Xbioreactor,v (29)
and ED = Xoutlet,D/Xbioreactor,D (30)
where Xoutlet,v and Xoutlet,D = viable and dead cell concentrations (cells/ml)
in the outlet stream, and Xbioreactor,v and Xbioreactor,D = viable and dead cell
concentrations (cells/ml) in the bioreactor.
The separation ratios for viable and dead cells, and the perfusion rates
for bioreactor #1 are shown in Figure 1I-9. The separation ratio for viable
cells and the perfusion rate for reactors #4-6 is shown in Figure rI-10. The
average separation ratio for viable cells at a flow rate of approximately three
volumes per day was 0.023 in bioreactor #1, 0.060 for reactors #2, and 0.044 in
reactor #3. The average separation ratios for viable cells in the second
experiment were 0.020 for #4, 0.015 for #5, and 0.041 for #6. The separation
ratios for dead cells were higher than those for viable cells and ranged from
0.12-0.3 at a flow rate of 3 volumes/day. Dead cells were preferentially
removed due to their smaller size.
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Figure III-9.
Perfusion Rate and Separation Ratios in Reactor #1
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The perfusion rate was calculated from measurements of the volume
of medium removed, divided by product of the time interval over
which it was collected and reactor volume. Separation ratios for viable
and dead cells were calculated from cell counts and viability
measurements of the cells in the bioreactor and effluent stream, using
equations 29 and 30. This data is obtained from measurements in
reactor #1; its growth curve is shown in Figure III-7.
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Figure III-10.
Separation Ratios and Perfusion Rates in Reactors #4-6
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Experimental protocols were as described for Figure M-9. This
data is obtained from reactors #4-6; their growth curves are
shown in Figure III-8.
The differences in the observed separation ratios for the different
bioreactors are most likely due to slight differences in the ratio of the flow rate
of the outlet pump as compared to the inlet pump for each reactor. When the
outlet pump is set faster than the inlet pump, as was done to set the level of
medium in the reactors, then as the level of the medium decreases to below
the inlet to the cell separator, an occasional air bubble is pulled up through
the separator, disturbing the laminar flow necessary for cell separation and
causing removal of a higher percentage of the cells inside the reactor. The
performance of the cell separator in this system is very strongly affected by
how closely the inlet and outlet pump rates are matched, as this will
determine how often a bubble is pulled through the separator. In addition,
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the cell densities measured in the outlet stream varied, depending on
whether a bubble had recently been pulled through the separator or not.
At a flow rate of approximately six volumes per day, the average
separation ratios for viable cells increased over those at three volumes/day.
The average separation ratio was 0.029 for #1, 0.077 for #2, and 0.1485 for
reactor #3. The cell removal rate in #3 was so high that the viable cell density
actually decreased on days 31-36 (see Figure 111-7).
By sampling the exit stream as well as the reactors, it is possible to
estimate the growth and death rates in the bioreactors. In order to eliminate
experimental "noise", the raw data for total cell number, percent viability,
flow rate, and separation ratios was smoothed using a three point running
average. The apparent growth rate was calculated using equation 16.
in Xvt
Ilapp = g - a = EvD + Xv
At (16)
where gapp = apparrent growth rate (hr-1 )
gt = growth rate (hr-1)
a = death rate (hr-1)
Xvt = viable cell density (c/ml) at the end of a time interval
Xvo = viable cell density (c/ml) at the beginning of a time interval
At = time (hours)
Ev = separation ratio for viable cells (Xv removed/Xv in
bioreactor)
D = the bioreactor dilution rate (hr-1) which is equal to F/V,
where F = flow rate (ml/hour) and V = volume of the
bioreactor (ml).
The death rate was calculated using equation 19:
-XDoe'DDAt )
DAt( eBAt 1) (19)
where B = -Lapp + DED - DF-
XDt = dead cell density (c/ml) at the end of a time interval
XDO = dead cell density (c/ml) at the beginning of a time interval
Ev = separation ratio for dead cells (XD removed/XD in
bioreactor).
The growth rate was then calculated using:
I. = gapp+a (31)
and the doubling time using:
TD = In(2)
9t (6)
Death rates, growth rates and doubling times were calculated for
reactors #1-6, and the average rates (numerical averages of the growth and
death rates over each time interval) are summarized in Table 111-2. The
growth and death rates were calculated for the time (days 1-14 for reactors #1-3
and days 1-9 for reactors #4-6) during which the cell density was increasing,
the time during which the viable cell density was constant, and at perfusion
rates of 3 and 6 volumes/day. These intervals were chosen to see if the
growth rate decreased once the cells had reached a dynamic steady-state cell
density. During the time interval when the cell density was increasing, the
calculated doubling times for all the reactors except #4 and #5 are similar to
those seen during exponential growth in batch culture (16-20 hours).
It can be seen that the doubling times, except for reactors #2 and #3, increased
when the cell density was at steady-state. It may also be seen that the
calculated growth rates appeared to be slower in bioreactors #4-6 as compared
to bioreactors #1-3 both when cell density increased and when it was constant.
The death rate showed a slight increase at constant vs. increasing cell density
in most of the reactors (#2 and #4-6).
To summarize, it appears that 1) the doubling time during the time
interval when cell density is increasing is similar to that in batch spinners
during exponential growth, 2) the doubling time either remained the same
(#2 and #3), or increased slightly (#1) or significantly (#4-6) during the time
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interval when the cell density was constant, anc a) cells continuec to grow
even at high cell density.
However, the calculations of growth and death rates are subject to
significant errors. Both the growth and death rates are first-order derivatives,
so any fluctuation in the measurements of the viable and dead cell densities
are magnified. The values for the separation ratios are very sensitive to
variations in the cell concentration in the exit stream, and the equation used
to calculate the death rate utilizes the exponential values of the separation
ratios for both viable and dead cells. Therefore, the values shown in Table III-
2 should be considered estimates rather than absolute values. In addition,
these experiments were not designed to obtain growth and death rates. In
order to obtain more accurate estimates of the growth and death rates, it
would be necessary to collect larger and more frequent samples of the exit
stream to accurately determine the total and viable cell concentrations.
Another method to estimate cell doubling times is via determination
of the distribution of cells in different phases of the cell cycle. This is done by
analyzing the relative DNA content of a population of cells via flow
cytometry. For example, hybridomas in exponential and stationary phase can
be distinguished (Ramirez and Mutharasan, 1990) by the decrease in the
percentage of cells in S phase.
Morrill (1991) measured the relative DNA content of cells from
bioreactors #4-6 via flow cytometry and calculated their doubling times. A
comparison cell cycle distributions of cells from the bioreactors to those of
exponentially growing control cells showed that the doubling times of cells in
the bioreactors at day 3 were 16-17 hours as compared to 18 hours for the
control culture. On day 10, cells in bioreactors #4 and #5 had doubling times
of 20-21 hours, while cells in bioreactor #6 had a doubling time of 17 hours;
control cells had a doubling time of 18 hours.
These data indicate that the growth rate in the bioreactors at both low
and high cell density is similar, if not identical, to that of cells in exponential
phase, with the growth rate slowed slightly on day 10 in bioreactors #4 and #5.
Thus, experimental error is most likely the cause of the varying estimates of
the growth rates calculated using the separation ratios.
van der Velden-de Groot et al. (1990) monitored the percentage of cells
in different phases of the cell cycle during growth of hybridomas to 9 x 106
viable c/ml in a perfusion culture utilizing a spin filter. They, like Morrill
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(1991), found that the percentage of cells in each phase of the cell cycle
remained fairly constant during the course of the experiment. The doubling
time, estimated from a plot of viable cell density as a function of time, also
remained constant.
Calculated
Table III-2.
Growth and Death Rates in Perfusion Bioreactors
n.d. not done
The reactor numbers, #1-6, refer to the same two sets of reactors for
which growth curves are shown in Figures 11-7 and III-8. The growth
and death rates were calculated for each sampling interval. Growth
rates were calculated using equation 31, and death rates using equation
19. Shown are the average (linear) values over each interval. The
doubling time was calculated from the average growth rate over each
interval, using equation 6.
98
Time interval Reactor
#1 #2 #3 #4 #5 #6
increasing cell #
growth rate (hr -1) 0.033 .039 0.040 0.027 0.021 0.036
death rate (hr-1)  0.019 .020 0.024 0.010 0.005 0.009
Doubling time (hrs) 20.8 17.8 17.5 25.6 32.6 19.5
constant cell #
growth rate (hr-1) 0.023 .045 0.040 0.016 0.016 0.014
death rate (hr-1) 0.016 .032 0.024 0.012 0.012 0.011
Doubling time (hrs) 29.6 15.5 17.2 43.6 42.8 48.4
3 v/day perfusion
growth rate (hr-1) .029 .038 0.038 0.019 0.017 0.020
death rate (hr-1) .019 .022 0.024 0.013 0.012 0.011
Doubling time (hrs) 23.7 18.1 18.2 37.2 41.4 34.1
6 v/day perfusion
growth rate (hr-1) .032 .048 0.046 n.d. n.d. n.d.
death rate (hr-1) .019 .035 0.026
Doubling time (hrs) 22.0 15.5 15.0
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3. Immunoglobulin Production
3.1 Volumetric Rate of Immunoglobulin Production
Immunoglobulin production may be calculated on a volumetric
(system output) or specific (outpur per cell) basis. The volumetric
productivity (Qp), in units of gg/ml-hr, measures the productivity of the
system, while the specific rate of immunoglobulin production (qP), in units of
pg/c-hr, measures the output of the cell. Calculations and and results for
both volumetric and specific productivity in the perfusion bioreactors are
shown below.
The volumetric rate of immunoglobulin production was calculated
from immunoglobulin titers in the supernatant using equation 23:
Qp = D[mAbt - mAbo e - D t]
1 -e -DAt (23)
where mAbo and mAbt = concentration of IgG in the supernatant (Jig/ml) at
the beginning and end of a time interval; other terms have been previously
defined.
The immunoglobulin titers in reactors #1-3 are shown in Figure III-11,
and those in reactors #4-6 are shown in Figure III-12. Titers were highest at
day 2, when perfusion had just been started, and then again at days 5-10 in
reactors #1-3 and days 7-11 in reactors #4-6. The second peak in
immunoglobulin titers corresponds to an increase in the volumetric
productivities, shown in Figure III-13 for reactors #1-#3, and in Figure ]1-14
for reactors #4-6. The volumetric productivity in reactors #1-#3 was about 0.4
ptg/ml-hr from days 4 to 14, during which time the cell density was
increasing, and then it declined from 0.15 gig/ml-hr to 0.05 gJg/ml-hr until day
32. The volumetric productivity in reactor #3 at day 32 then increased to
about 0.2 pgg/ml-hr, due to a decrease in the cell density (see Figure m-7).
In reactors #4 and #5, the volumetric productivity increased to about
0.35 gg/ml-hr over days 7 to 12, and then declined; in reactor #6, similar
kinetics were observed except that the volumetric productivity was about 50%
higher than in reactors #4 and #5.
Figure III-11.
Antibody Titers in Reactors #1-3
IgG
igg/mi
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Samples of supernatants from the same reactors shown in Figure 111-7 were
removed daily and frozen at -200 C. Immunoglobulin titers in supernatants
were measured using an Elisa assay, as described in section II.C.1, Materials
and Methods. Values represent the average of duplicate determinations.
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Figure III-12.
Antibody Titers in Reactors #4-6
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Samples of supernatants from the same reactors shown in Figure I1-8 were
removed daily and frozen at -200 C. Immunoglobulin titers in supernatants
were measured using an Elisa assay, as described in section II.C.1, Materials
and Methods. Values represent the average of duplicate determinations.
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Figure III-13.
Volumetric Productivity in Reactors #1-3
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The volumetric productivity over each sampling interval was calculated
using equation 23. Reactor numbers #1-3 refer to the same reactors for which
growth curves are shown in Figure III-7.
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Figure III-14.
Volumetric Productivity in Reactors #4-6
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; are shown in Figure III-8.
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If the specific productivity per cell were constant, then the volumetric
productivity would have increased linearly as a function of the viable cell
density.
3.2 Specific Rates of Immunoglobulin Production
The specific rate of antibody production was calculated as follows:
Qp In(Xvt/Xvo)
qp
Xvt- XVo (31)
where Xvo and Xvt are the viable cell densities at the beginning and end of a
time interval (c/ml).
Figures III-15 and I-16 show the specific rate of antibody production
(qP) in reactors #1-3, and reactors #4-6, respectively. It may be seen that the
specific rate of antibody production in both experiments declined quite
precipitously. In reactors #1-3 the specific productivity decreased from 0.25
pg/c-hr to 0.01 pg/c-hr by day 15, remained at this value until day 22, and then
decreased further to 0.003 pg/c-hr, where it remained until day 33. At that
time, the cell density in reactor #3 declined; this decline in cell density was
accompanied by an increase in the specific productivity to 0.04 pg/c-hr.
In reactors #4-6, the specific productivity decreased from 0.15 pg/cell-hr
to 0.04 pg/c-hr by day 4 and remained at this value until day 9, when it
decreased to about 0.01 pg/c-hr. The specific productivity in reactor #6
remained at the higher initial value of 0.15 pg/c-hr for a longer period of
time, probably due to a slight dip in the cell density at days 3-5 (see Figure II-
6). The specific productivity of #6 also remained about 50% higher than that
of #4 and #5 during the whole run; the reason for this is not clear but may be
due to the slightly higher separation ratio, and ensuing higher growth rate
which was observed in this reactor, as compared to reactors #4 and #5.
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Figure III-15.
Specific Rates of Antibody Production in Reactors #1-3
Specific
Productivity
pg mAb/cell-hr
0.40
0.35
0.30
0.25
0.20
0.15
0.10
0.05
0.00
The specific rate of
calculated using equ
for which growth ct
0 5 10 15 20 25 30 35 40 45
Time - Days
antibody production over each sampling interval was
iation 31. Reactor numbers #1-3 refer to the same reactors
irves are shown in Figure II-7.
105
Figure III-16.
Specific Rates of Antibody Production in Reactors #4-6
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The specific rate of antibody production over each sampling interval was
calculated using equation 31. Reactor numbers #4-6 refer to the same reactors
for which growth curves are shown in Figure 111-8.
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Others have also studied growth and antibody production at high cell
density in suspension culture, and have found that the specific rate of
immunoglobulin production remained constant, or even increased with
increasing cell density. van der Velden-de Groot et al. (1990) grew a murine
hybridoma in a fermentor equipped with a spin filter, and obtained a
maximum viable cell density of 9.2 x 106 c/ml at a dilution rate of 0.5 v/day.
The specific productivity and growth rates remained constant during both the
time of increasing cell density and constant cell density.
Reuveny et al. (1986b) compared the production of antibody in batch,
fed-batch, semicontinuous culture, and perfusion culture. The specific
productivities in batch, fed-batch, and semi-continuous culture were similar;
productivity in batch ranged from 0.38-0.58 pg/c-hr, while specfic productivity
in semi-continuous culture ranged from 0.44-0.67 pg/c-hr.
In perfusion culture, utilizing a spin filter for cell retention, the specific
productivity was the same as in batch culture during exponential growth up
to 1-2 x 107 viable c/ml, but then increased to 0.71-1.25 pg/c-hr during the time
of approximately constant cell density. Thus, the combination of slow growth
and high cell density appeared to increase specfic productivity by a factor of 2-
3. The authors suggest that the decrease in cell metabolism under low-growth
conditions and/or the secretion of a factor stimulatory to antibody production
which can accumulate to stimulatory levels at high cell density might have
been the cause of the increase in specific productivity.
The specific rate of immunoglobulin production declined from an
initial average specific productivity of 0.2 pg/c-hr to less than 0.02 pg/c-hr in
all bioreactors, during a period of time when the cell density was increasing
and had not yet reached a dynamic steady-state. This downregulation of
immunoglobulin production provided two conditions, one of high antibody
productivity, and one of low antibody productivity for the molecular cascade
analysis of antibody production, the results of which are presented in Section
m.C.
To aid in understanding the phenomenom of downregulation of
antibody production in the bioreactors, a number of hypothesis were
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developed. These hypothesis, and the results of experiments and data
analyses to test these hypotheses are presented below.
1. Immunoglobulin is secreted at a normal rate, but may be degraded by
proteases (from lysed cells). Degradation of immunoglobulin would lead to
lower product titers and hence lower calculated values for specific
productivity. Results, shown in section III.B.4.1, indicate that there is no
degradation of immunoglobulin.
2. A decrease in the growth rate at high cell density may cause
downregulation of antibody production. The doubling time of cells at high
appeared to be only slightly lower than that at low cell density, and this
change cannot account for the decrease in specific productivity. Results of
calculations of growth rates are shown in Section mI.B.2. Cell growth rates, in
the bioreactors, as calculated using the separation ratios, varied from 0.045-
0.014 hr-1 (doubling times 15.5 to 48.4 hours) and were not correlated with
specific productivity. Doubling times calculated from cell cycle distributions
(Morrill, 1991) indicate that the doubling time increased slightly from 17-18
hours (day 3, qP = 0.1-0.04) to 21 hours (day 10, qP = 0.02 pg/c-hr). These
doubling times are similar to those observed in batch spinners in exponential
growth when the specific productivity is high (0.2 pg/c-hr). Experiments in
semicontinuous culture show that the specific productivity increased with
increasing doubling time (Section III.A.2).
3. Conditions in the bioreactor may cause inhibition of antibody
secretion. This may be caused by nutrient limitation(s) or accumulation of
toxic waste products. Results, shown in Section III.B.4.2, indicate that a
nutrient limitation does not appear to be the cause of the downregulation of
specific productivity. Experiments by Morrill (1990) indicated that neither
accumulation of lactate or ammonia is the cause of the downregulation of
antibody production.
4. Anoxic or low pH conditions in the cell settler may cause inhibition
of antibody secretion. Results, shown in section MI.B.4.3, indicate that
oxygenation of the cell settler to provide oxygen and pH control did not affect
the specific productivity.
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5. The downregulation of antibody production may be cell-density
dependent. Results, shown in section III.B.5.2, indicate that the
downregulation of antibody production is proportional to the log of the
viable cell density.
6. Conditions in the bioreactor may favor rapid genetic drift of cells;
spontaneously arising non-producing mutants may overgrow producing
cells. Results, shown in section I.D, indicate that the downregulation of
antibody production observed in the bioreactors is reversible; cells removed
from bioreactors exhibit the same antibody productivity as cells maintained at
low cell density for an equivalent number of generations.
4. Tests of Bioreactor Conditions on Immunoglobulin
Production
4.1 Stability of Secreted Immunoglobulin
It is possible that antibody was secreted at a normal level but degraded
by proteases and that therefore the measured level of mAb in the supernatant
would be less than what is secreted by the cells. A decrease in productivity
due to proteolytic degradation of immunoglobulin has been observed by
Schlaeger et al. (1987) and van Erp et al. (1991) for hybridomas grown in
hollow fiber bioreactors.
Two experiments were done to test for possible antibody degradation in
the bioreactors, which could be mediated by the presence of proteases liberated
from dead and/or lysed cells. The cell viability in the bioreactors #1-#3 at high
cell density (1-2 x 107 c/ml) was generally about 80%. This resulted in the
presence of a significant number, on the order of 2 x 106 c/ml, of nonviable
cells. Since measurements of antibody titers in the supernatant are used to
calculate specific productivity, degradation would give a much lower estimate
for the specific productivity.
To test for antibody degradation, duplicate aliquots of bioreactor
supernatants, Sp2/0 supernatants, supplemented medium (DMEM* with 5%
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FBS), and PBS were spiked with human IgG (Jackson Immunoresearch Labs,
cat. # 009-000-003) to give a final IgG concentration of 9.9 gg/ml. This
antibody is the one used as a standard in the Elisa assay. In addition, trypsin
(Flow Labs, cell culture grade) was added to a final concentration of 0.1% to
samples of medium and PBS spiked with IgG. The bioreactor supernatants
were from days 14 (Bioreactor #1) and 16 (Bioreactor #3), days on which the
measured specific productivity was < 0.01 pg/cell-hr. The actual levels of
immunoglobulin in these samples prior to the addition of IgG were,
respectively, 0.05 and 0.3 gg/ml.
The spiked samples were incubated at 370 C and sampled at 0, 3, 6, 9.5,
and 24 hours. The experiment was terminated at 24 hours since 24 hours is
equivalent to 3 reactor volumes at a flow rate of 3 volumes/day. At a flow
rate of three volumes/day, 95% of the medium is removed in one day.
Samples were immediately frozen and then analyzed for antibody
concentration via an Elisa assay.
Results are shown in Figure 11-17. Although there is some scatter in
the data, it can be seen that there was no significant degradation in any of the
samples. Curiously, no apparent degradation of antibody was observed in the
samples spiked with 0.1% trypsin. This may be due to the fact that antibodies
have a high degree of secondary structure, as well as a number of inter- and
intrachain disulfide bonds, which may serve to hold the molecule together
even if the polypeptide chains are nicked by trypsin, and allow the antibody to
retain its native configuration and be recognized by the antibodies to IgG used
in the Elisa assay.
Supernatant and media samples were also tested directly for the
presence of proteases using a kit obtained from Boeringer Mannheim which
tests for the presence of endoproteinases (# 582433). Following the
manufacturer's instructions, fibrinogen and thrombin were mixed, and
allowed to clot in a petri dish. Samples were spotted onto the plate and
incubated at 370 C. The presence of proteases is detected by a cleared area, or
plaque, due to the lysis of fibrin, where the sample is applied. Aliquots of
bioreactor supernatants, stock cell supernatants (from T-flasks), stock cells,
and trypsin were tested. Samples with volumes up to 30 gl were applied
directly to the fibrin, and 100 p1 samples were applied to a 5 mm Whatman
filter paper disc placed on the fibrin. The results obtained are shown in Table
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111-3. As can be seen in Table 111-3, there is no detectable protease activity in
either the supplemented medium or any of the supernatants. There may be a
minute amount of protease activity in the stock cell sample, as there was a
minute amount (1-2 mm) of clearing around those samples. However, a
similar amount of clearing was also seen in the supplemented medium,
which is not expected to contain any proteases and does not cause degradation
of antibody. For most of the 100 p.l samples, a small zone was cleared after 18
hours. This may simply reflect a dilution of the test solution by the sample
due to the relatively large volume of sample applied. Furthermore, it can be
seen that the trypsin activity was easily measured. In fact, lysis around the
samples containing trypsin was already detectable after only 5 minutes of
incubation (data not shown). The results indicate that antibody is not
degraded in the bioreactor, and that the calculated specific productivity, based
on measurements of antibody in the supernatant, is equal to the rate of
carrfminn f nfihnodv
Figure III-17.
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Table 111-3.
Results of Testing for Proteolytic Activity
4.2 Addition of Nutrients
One possible cause of the downregulation in antibody production is
that one or more of the nutrients in the medium may have been depleted.
However, extensive analyses by Tyo (1991) of reactor #1-3 supernatants
indicated that at perfusion rates of three volumes/day, neither glucose,
pyruvate, glutamine, or any amino acid supplied in the medium was
limiting. However, the levels of methionine and cysteine could not be
accurately measured. Other nutrients which could limit antibody production
are 1-mercaptoethanol, an essential nutrient for these cells, and growth
factor(s) supplied in the serum. While the role of P3-mercaptoethanol is
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Sample Vol added Diameter of Cleared Area (mm)
(9l) after 1 hr. after 18 hrs.
DMEM* 5% FBS 15 1 1
100 1 2
Bioreactor supernatant 15 - 1
Day 14 100 1 2
Bioreactor supernatant 15 - 1
Day 15 100 1 2
Stock supernatant 30 - -
100 - -
Stock w/ cells 15 - -
30 - -
100 1 2
0.1% trypsin 5 2 7
in PBS 15 5 11
30 10 18
100 15 >30
2.5% trypsin 15 12 25
in PBS 100 25 >30
- m
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unclear, it has been shown to act as a mitogen, to stimulate the uptake of
cysteine, and to prevent peroxide damage to cells (Ohmori and Yamamoto,
1983).
To test whether cysteine, methionine, P-mercaptoethanol or serum
factors were limiting immunoglobulin production, the inlet media to reactors
#4 and #6 were modified on days 8 and 10 (see Figure 111-8). The inlet medium
to reactor #4 was modified to contain 8% FBS, while the inlet medium to
reactor #6 was modified to contain twice the amounts of P-mercaptoethanol,
cysteine, and methionine of DMEM*. These nutrient addition experiments
were done together with J. Morrill.
The rationale of these experiments was that if depletion of a growth
factor in the serum, or of j-mercaptoethanol or one of the sulfer-containing
amino acids was limiting immunoglobulin synthesis, then doubling the
concentration should double the specific productivity, unless the cell density
also increased. However, neither doubling the serum content nor doubling
the amounts of 3-mercaptoethanol, cysteine, and methionine had any
discernible effect on either the viable cell density, viability, or specific
productivity.
The work of Tyo (1991) and these experiments indicate fairly
conclusively that the downregulation of antibody production is not due to a
nutrient limitation; the only nutrients which have not been measured or
tested are the vitamins (such as choline, folic acid, riboflavin, and thiamine)
which are present in the basal DMEM* medium.
4.3 Oxygenation and pH Control
Oxygen was supplied to the bioreactors via a combination of gassing
through teflon tubing and headspace aeration, as described in Section II. By
knowing the KLa of the system, about 15 hr-1, and the oxygen uptake rate of
the cells (0.1 x 10-6 IM/cell-hr), we maintained the dissolved oxygen between
90 and 180 gM. This was experimentally verified by measuring the dissolved
oxygen in reactors #3-6 at the end of the experiment; it was about 120 gM in
all three reactors. The experiments described in Section III.A.2 indicated that
oxygen in excess of 90 gM, and below 360 pM, resulted in high rates of
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antibody secretion. The pH in the reactors was always between 7.0 and 7.4, the
same as for batch cultures.
However, in the cell separator neither the pH or the dissolved oxygen
were controlled at physiological levels. The pH in the cell separator was low,
about 6.7, judging from the color, at high cell density. Such a low pH value
has been shown to cause cell death or poor growth in many systems (for
example, Miller et al., 1988). In addition, cells were most likely exposed to an
anoxic condition in the cell separator. I estimated that the dissolved oxygen
was close to zero, since the cell separator was not oxygenated. A quick
calculation indicates that at a cell density of 5 x 106 c/ml, depletion of the
dissolved oxygen in the medium, if it is initially 180 gM, will occur in 20
minutes. The calculation of the average residence time of a cell in the cell
separator is beyond the scope of this thesis. However, at a flow rate of three
volumes/day, it takes about one hour for fluid to move to the widest point of
the separator, during which time any cells which will be returned to the
reactor have settled onto the inner surface of the cell separator, from where
they are recycled to the reactor.
In order to assess the effect of exposure of cells to the low pH and
anoxic conditions in the cell separator, I modified the cell separator to reactor
#5 as described in Section II.B, and oxygenated it with the same gas mixtures
used to supply oxygen to the reactors. Oxygenation of the separator controlled
the pH at a physiological level (between pH 7.0 and 7.4) but did not affect
either the viable cell density, cell viability or immunoglobulin production, as
can be seen from Figures 111-8 and 111-16 (compare growth and specific
productivity of reactors #4 and #5). Thus, transient exposure of cells to the
environment of the cell separator are not the cause of the downregulation of
immunoglobulin production.
The results of Batt et al. (1990) also suggest that transient exposure of
cells in cell settler to unfavorable conditions of pH and oxygen tension should
not affect productivity. In their system, utilizing an external cell settling tube,
the settler retained 100% of the viable cells. This resulted in continuously
decreasing viability until the experiment was terminated; however, specific
productivity did not decrease with decreasing viability.
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5. Comparison of Two Sets of Perfusion Experiments
5.1 Kinetics of Growth and Antibody Production
While the two sets of experiments were of similar design, some
differences in the results should be noted. In particular, the flow rate was
ramped more quickly in the second set of experiments (#4-6), and as a result,
the cell density increased to a steady-state concentration of 107 viable c/ml by
day 9, as opposed to day 16 in the first set of runs (#1-3). Figures mI-18a and b
compare growth and specific antibody production obtained in reactor #1
(panel 18a) as compared to results from reactor #4 (panel 18b). Data for the
other runs are not shown here because the kinetics for runs #1-3 were almost
identical over the first 16 days; kinetics for runs #4-5 were also almost
identical. The kinetics for run #6 are slightly different and have been
discussed in section III.B.
The observed trends in both sets of experiments were similar, except
that the kinetics of decline in specific antibody production in the first reactor
runs (#1-3) was slower than that observed in the second set of runs (#4-6).
This slower decline was accompanied by a slower increase in cell density, and
slower ramping of the flow rate. Nonetheless, the phenomenon of the
decrease in specific productivity with increasing cell density is quite
consistent.
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Figure III-18.
Comparison of Growth and Antibody Production in Reactors #1 and #4
a. Data for days 1-16, shown for reactor #1 in Figures 111-7, 1I-13, and rI-15 was
regraphed.
b. Data shown for reactor #4 in Figures 111-8, 111-14, and 111-16 was regraphed.
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5.2 Effects of Cell Density on the Specific Rate of Antibody
Production
Examination of the data suggested that the specific rate of antibody
production is a strong function of the viable cell density. In order to analyze
this, the specific rate of antibody production was plotted as a function of
viable cell density in the perfusion reactors. From a plot of the log of the
specific productivity vs. cell density, shown in Figure 111-19, it can be seen that
the log of specific productivity is a linear function of cell density. It can also
be seen that specific productivity declined exponentially as a function of cell
density at different rates in the two sets of bioreactor runs, with a greater
Figure III-19.
c Productivity as a Function of Viable Cell Density in Bioreactors
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Data shown for reactors #1-3 in Figures M1-7 and M-15 was
combined and regraphed. Data shown for reactors #4-6 in
Figures III-8 and 111-16 was also combined and regraphed.
118
hr
1 1
¥2
13
14
1 5
16
decline in specific productivity in the first set of bioreactor runs, and that the
rate of decay was similar within each experiment (comparing #1-3 and #4-6).
Equations of the form y = A*e(-Bx), where y = qP, x = viable c/ml, and A
and B are coefficients, were fit to the data from each reactor, and the
regression coefficients (r) ranged from 0.84-0.92 for #1-3, and 0.73-0.87 for #4-6.
The reason for the different rates of decline in specific productivity in the two
sets of bioreactors is most likely due to the fact that the first set of bioreactors
was run for six weeks. During a period of six weeks of growth at low cell
density, these cells would be expected to exhibit a significant irreversible
decline in specific productivity of 3-5 fold of the initial specific productivity (a
3-fold decline is seen in one month), so the faster rate of decline the first set of
reactors (#1-3) is probably due to superimposition of bioreactor
downregulation onto the irreversible decline in specific productivity.
This cell line appears to show a cell density-dependent decline in
specific productivity. This could be due to cell-cell interactions. Stallcup et al.
(1984) found that membranes isolated from normal spleen or lymphoid
tumor cells could inhibit the growth of several murine tumor lines,
including a B cell hybridoma. Experiments to determine whether
membranes isolated from CLC LT14 cells can inhibit cell growth or antibody
production are in progress in our laboratory (Morrill, 1992).
Alternately, cells could be producing a growth factor inhibitory ot
antibody production. If the rate of production of such a factor remained
constant, then it would accumulate in proportion to the viable cell density
when the flow rate remained constant.
For example, Kidwell (1989) found that a hybridoma line produced
TGFf1, which inhibited antibody production. He grew mouse hybridomas
which produce IgM in hollow fiber reactors with low (4000 mwt) and high (0.5
micron) cutoffs, and found that antibody production in reactors with high
molecular weight cutoff hollow fibers was more than twice that in low
molecular weight cutoff reactors. The inhibition of antibody production was
found to be due to the accumulation of TGFP1, produced by this hybridoma,
in the reactors with the low molecular weight cutoff membranes. TGFp1,
when added at the levels found in the hollow fiber reactor, was found to
inhibit both growth and antibody production when added to batch cultures in
T-flasks.
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5.3 Effects of Immunoglobulin Titers on the Specific Rate of
Antibody Production
Some workers have observed feedback inhibition, where the specific
productivity decreases, due accumulation of antibody (or an unidentified
inhibitory metabolite) in the supernatant. McKinney et al. (1991)
demonstrated that a murine hybridoma line (ATCC HB124) secreting IgG2a is
subject to product feedback inhibition. Antibody was purified from culture
supernatants and added back to cultures inoculated in fresh medium. The
specific rate of antibody secretion decreased linearly with the antibody
concentration initally present in the medium, and dropped to zero when 27-
36 jgg/ml antibody was added. Interestingly, this was quite similar to the
maximum amount synthesized in batch culture, about 26 jg/ml.
Lee et al. (1991) also observed that antibody production in fed-batch
cultures of an immobilized murine hybridoma ceased when the antibody
concentration in the medium reached 25-30 gg/ml. Serum, glucose, and
amino acids were not limiting. However, experiments to distinguish
between feedback inhibition due to accumulation of antibody or inhibition
due to accumulation of an unknown inhibitor of antibody synthesis produced
by the cells were not done.
I considered feedback inhibition due to the accumulation of antibody
unlikely, as the titers observed in the bioreactors (maximum 6-8 jgg/ml) were
always less than those seen at the end of a batch culture (12-20 jgg/ml). Figure
111-20 shows a plot of specific productivity as a function of antibody in the
supernatant for bioreactors #1-6. It may be seen that there is no correlation
between the specific productivity and antibody titers in the supernatant. This
suggests that there is no product feedback inhibiton, but does not rule out the
possibility that these cells may produce a factor which may downregulate
antibody synthesis.
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Figure 111-20.
Specific Productivity as a Function of Immunoglobulin Titers in
Bioreactors
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Data shown for reactors #1-3 in Figures 11-7 and rn-u. was combined and
regraphed. Data shown for reactors #4-6 in Figures 11-8 and II-12 was also
combined and regraphed.
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C. Molecular Dynamics - Measurements of Components in the
Immunoglobulin Synthesis Cascade
Here, I investigated the molecular mechanisms regulating antibody
synthesis when cells were at two different physiological states, one
corresponding to high specific productivity, and one corresponding to low
specific productivity. Cells from the perfusion bioreactor experiments were
initially at a condition of high productivity and then exhibited a density-
dependendent decline of specific productivity at high cell density.
Measurements on cells from the perfusion bioreactors were compared to
those performed using cells in low density batch spinners during exponential
growth. Cells in exponential growth were at a condition of high specific
productivity and provided a reference, or "control".
Regulation of antibody synthesis may be affected at several levels,
including transcription of immunoglobulin genes, processing of the primary
heterogeneous RNA transcripts, mRNA stability in the cytoplasm, translation
of mRNA in polysomes, and processing and export of the assembled
immunoglobulin. As is shown in the following sections, I measured the
gene copy number, relative steady-state immunoglobulin mRNA levels,
distribution of immunoglobulin mRNAs on polysomes, and amounts of
intracellular and secreted immunoglobulin. This allowed determination of
the rate-limiting steps in monoclonal antibody synthesis at both high and low
productivity.
1. Immunoglobulin Genes
The first molecules of interest in the cascade are the genes for the
immunoglobulin heavy and light chain genes. I probed cells for the presence
of the immunoglobulin heavy and light chain genes by isolating DNA, and
probing, via Southern blotting, for the presence of these genes. An estimate
of the gene copy number was also made. The C46 cell line, a Sp2/0
transfectoma, contains chimeric human-mouse immunoglobulin genes
stably inserted into the Sp2/0 genome, and its construction is described in
Section II.A. The CLC LT14 cell line used in this work is a clonal derivative of
122
-ON= ,,,,
the C46 cell line. Figure III-21 shows the derivation of the CLC LT14 clone
used for the perfusion bioreactor experiments.
Figure III-21.
Derivation of CLC LT 14 Cells
Sp2/0 cells transfected with genes for
IgG heavy and light chain by Centocor
researchers to produce C46 line
Grow C46 cells at MIT
(obtained from Centocor, Inc.)
Cells maintained in culture
become "low-producing cells"
Sp2/0 cells
Grow in spinners,
test DNA,RNA
isolate 500 clones
Select CLC LT14 clone used and
maintained in T-flasks; "stock"
Fresh vial thawed each month
Control SpinnersInoculate Bioreactors
Remove cells; inoculateinto spinners
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The structure of the plasmids used to create the C46 cell line, and some
of the restriction sites, are shown in Figure 111-22. Also shown in Figure III-22
are the probes used to detect the immunoglobulin genes. Probes to the
human constant regions were used, as probes for the variable regions would
cross-hybridize with Sp2 /0 genomic immunoglobulin variable sequences.
The light chain probe, designated pK, is 2.5 kb in length, and the heavy chain
probe, designated pCo, is 7.5 kb in length, and both contain intron as well as
exon sequences.
In order to examine the structure of the integrated immunoglobulin
genes in the transfectoma, DNA was isolated from cell pellets of cells grown
from bioreactor #1 samples, CLC LT14 cells maintained at low cell density in
T-flasks, Sp2/0 cells, and low-producing C46 cells. The Sp2/0 cells do not
contain the transfected immunoglobulin sequences, and served as a negative
control. The DNA was then digested with appropriate restriction enzymes,
and 10 jgg of each sample was run on a 0.7% agarose gel. Gels were transferred
to Genescreen Plus, and hybridized as described in Section II.C. Sizes of bands
were estimated using molecular weight markers. Table III-4 shows the
expected sizes of bands for immunoglobulin heavy and light chain genes
when digested with different restriction enzymes.
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Figure III-22.
Structure of the Immunoglobulin Heavy and Light Chain Genes
and the cDNA Probes Used
A. Immunoglobulin heavy chain
pSV2 A H gpt 17-1A VH
E B H H EH B E
I I I I. I I i l I I I
LV 1 H 2 3
17-1A VH - Human C 1 -- pBR
murine gpt
human C 1 probe pCo
B. Immunoglobulin light chain
pSV184 A H neo 17-1AK
HE B H E E E B E H
I I I I I I I I I
4--17-1A VK Human C K neo pACYC
nee
murine _ nei
human CK probe pK
1kb
In thlus figure, redrawn from Sun et al. (1987), exons are represented by filled
boxes, immunoglobulin-derived intron sequences by thick lines, and other
plasmid sequences by thin lines. Abbreviations for restriction enzyme sites
shown are as follows: E: Eco R1; B: Bam H1; H: Hind UI.
Panel a: The schematic structure of the immunoglobulin heavy chain gene is
shown. The sequence labelled 17-1A VH was derived from a portion of the
genomic DNA of the 17-1A hybridoma cell line, and the sequence labelled
human Cyl from DNA of a hybridoma secreting IgG1. The hatched bar
labelled human Cyl probe pCo covers the 7.5 kb portion of the
immunoglobulin gene directly above it.
Panel b: The schematic structure of the immunoglobulin light chain gene is
shown. The sequence labelled 17-1A VK was derived from a portion of the
genomic DNA of the 17-1A hybridoma cell line, and the sequence labelled
human CK from DNA of a hybridoma secreting kappa-chain
immunoglobulin. The hatched bar labelled human CK probe pK covers the
2.5 kb portion of the immunoglobulin gene directly above it.
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Table 111-4.
Expected Sizes of IgG Heavy and Light Chain Bands Digested with
Restriction Enzymes
Restriction Enzyme Probed for presence of:
Light Chain Heavy Chain
Bam H1 7.8 14.6
Hind 1m 9.8 12.4
Eco R1 - 13.1
Bam H1 & Hind I1 5.1 8.0
DNA digested with Bam HI is shown in Figures m-23a-d. When DNA
isolated from C46 and CLC LT14 cells is probed for the presence of the
immunoglobulin light chain, a band of 7.8 kb is expected; when probed for the
presence of the heavy chain, a band of 14.6 kb is expected (see Table 111-4).
Bam HI was chosen because it allowed determination of the presence of the
largest possible regions of both the H and L gene.
Figures m-23a and MI-23b show DNA digested with Bam H1, and
probed with the light chain probe pK. Lane 1 on figure m-23a shows that
there is only 1 cross-hybridizing band at about 6.5 kb in the parental Sp2/0
cells; this band is also, as expected, present in the transfectomas (lanes 2-11
and 13-16). Bam H1 digestion of the C46 and CLC LT14 cells generates two
other bands; one at about 9.4 kb, and the other at about 7.8 kb, which is the
expected size for the correctly integrated gene (see Table -114). Lanes 2, 3, and
4 are samples of the stock CLC LT14 cells in use. Lanes 5-11 show DNA from
cells frozen from bioreactor #1 and then grown in spinner culture. Lanes 5
and 6 are samples from day 2, while lane 7 is from day 3 cells, lane 8 from day
7, lane 9 from day 10, and lanes 10 and 11 from day 20 cells. Lanes 13-16 are
samples of low-producing C46 cells which had declined in productivity and
produced less than 5% of the antibody of the stock cultures.
Three pg of the same light chain probe pK (unlabelled) used to detect
the light chain was loaded in lane 12; this amount is equivalent to the
number of copies expected in 10 glg genomic DNA if there is 1 gene copy/cell.
This probe was run as an internal standard and also to allow an estimate of
the gene copy number to be made. I estimated a copy number of 1-2
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copies/cell for the light chain. Although the intensity of these samples varied
due to either sample degradation and/or uneven loading, it can be seen that
the pattern of integration is unchanged as a function of time. It is particularly
striking that the low-producing cells have not lost the gene for IgG light
chain.
Figures IHI-23c and II-23d show the same blots reprobed with the
immunoglobulin heavy chain probe, pCo. Lane 1 in Figure III-23c is blank,
indicating that there are no cross-hybridizing parental Sp2/0 genomic
sequences. The sizes of the two bands seen in lanes 2, 4-6, 9-11, and 13-16 are
about 12-16 kb and 8.8 kb; thus the higher molecular weight band is the
correctly integrated plasmid, as the expected size is 14.6 kb. It can be seen that
this higher molecular weight band is missing in the samples in lanes 3, 7, and
8. This was due to sample degradation, as evidenced on the ethidium
bromide stained gel prior to transfer. In Figure III-23d, it can be seen that the
integration pattern of the heavy chain is the same in the low-producing C46
cells as in the stock CLC LT14 cells.
The same samples were also digested with Hind III and probed for
presence of the light chain, and digested with EcoR1 and probed for the
presence of the heavy chain gene (data not shown). In these digestions, also,
the integration patterns remained the same for all the samples. Hind III
digests probed with the light chain probe give 3 bands of approximate
molecular weights 10.9 kb, 9.8 kb (correct size), and 6.6 kb (Sp2/0
crosshybridizing genomic sequence).
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Figure III-23.
Southern Blot of Samples Digested with Bam HI and Probed for IgG Heavy
and Light Chain Genes
10 gg of genomic DNA was digested with Bam H1, loaded, run on an 0.8%
agarose-1X TBE gel at 1.5 volts/cm for 18 hours, transferred to Genescreen
Plus, and probed for the presence of the IgG light chain (A. and B.). Blots were
then stripwashed and reprobed for the presence of the IgG heavy chain (C.
and D.). The heavy and light chain probes used are shown in Figure III-22.
Probes were labelled as described in section II.C.3 of Materials and Methods,
and isolation of DNA and Southern blotting was as described in section II.C.4.
Blots were exposed to Kodak X-ray films (Kodak X-Omat AR) with an
intensifying screen (DuPont Cronex Lightning Plus) to visualize bands for
two days at room temperature. The location and size, in kb, of the molecular
weight markers for blot A are shown on the left side.
A. Lane 1: Sp2/0 cells, lanes 2-4: CLC LT14 cells maintained at low cell
density, lanes 5-11: cells removed from bioreactor #1. Lanes 5 and 6: day 3;
lane 7: day 4; lane 8: day 7; lane 9: day 10; lanes 10 and 11: day 20. Lane 12: 3 pg
of unlabelled light chain probe pK. The blot was probed using the probe pK
for the IgG light chain constant region.
B. Lanes 13-16: C46 cells after 6 months in culture, producing less than 1
jlg/ml. The blot was probed using the probe pK for the IgG light chain
constant region.
C. Blot A was reprobed using the probe pCo for the IgG heavy chain
constant region.
D. Blot B was reprobed using the probe pCo for the IgG heavy chain
constant region.
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These experiments demonstrate that the observed integration patterns
of the heavy and light chain genes are the same for CLC LT14 cells
maintained either at low density or grown in bioreactors at high cell density.
In addition, it can be seen that the mechanism of the long-term loss of
antibody production seen in C46 cells and CLC LT14 cells is not due to large
deletions and/or rearrangements of either the immunoglobulin heavy
and/or light chain gene. These results are consistent with the data shown in
section III.D.2, where I show that the longterm decline in productivity in the
CLC LT14 cells is due to a decrease in immunoglobulin synthesis of all the
cells in the population, and not due to the accumulation of nonproducing
cells.
2. Immunoglobulin mRNAs
2.1 Measurement of Steady-state mRNA in Bioreactors
The first event in the synthesis of antibody is transcription; full-length
hn (heterogeneous nuclear) immunoglobulin RNAs are transcribed,
polyadenylated, intron sequences are spliced out, and the mature mRNA is
then exported to the cytoplasm.
To begin the study of the molecular dynamics of antibody production,
the steady-state levels of heavy and light chain mRNA from CLC LT14 cells
under different conditions of antibody productivity were examined. Cells
were isolated from perfusion bioreactors at time points corresponding to high
(0.2 pg/c-hr, same as in low density batch spinners during exponential
growth) and low (less than 0.2 pg/c-hr) specific rates of antibody production.
The steady-state levels of mRNA in cells in perfusion bioreactors were
compared to those from cells isolated from control spinners in exponential
growth, at a cell density of 8-12 x 106 c/ml and specific productivity of 0.2 pg/c-
hr. Total RNA was isolated, run on denaturing formamide/formaldehyde
gels and transferred, probed, and quantified as described in Section II.C. 15 igg
total RNA per lane was used. Blots were hybridized with a rat a-tubulin
cDNA in parallel with one of the immunoglobulin probes in order to
normalize for the amount of RNA loaded.
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Figure III-24 shows the time points at which RNA was isolated from
cells from reactor #1, superimposed onto a plot of specific and volumetric
productivities in reactor #1 vs. time. The filled arrows indicate the time
points where RNA isolated from bioreactor #1 cells was analyzed. The results
of Northern blotting analysis of these samples from bioreactor #1 are shown
in Figures I1-25 and 11-26.
Figure III-24.
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The growth curve for reactor #1 is shown in Figure I-7;
volumetric and specific productivities of reactor #1 were
regraphed from Figures M-13 and rI-15.
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Figure 111-25 shows a Northern blot of samples hybridized with a probe
for the immunoglobulin heavy chain and a-tubulin, while Figure III-26
shows the same samples hybridized with IgG light chain and a-tubulin
probes. The samples labelled "Days in Bioreactor #1" were isolated directly
from the bioreactor on the day indicated. It can be seen that the amounts of
both IgG heavy and light chain decreased as a function of time in the
bioreactor.
In order to measure the decrease in mRNA, the bands from these blots
representing heavy and light chain mRNA were cut out and the counts in
each was measured in a scintillation counter. Samples were first normalized
for the amount of RNA loaded using the a-tubulin signal. Expression of
immunoglobulin mRNA was then normalized to expression in the control
spinner (Stock Control 14C). The normalized intensities of the
immunoglobulin heavy and light chains are shown in Figure 111-27, it can be
seen that the levels of both IgG heavy and light chain mRNAs declined 3-fold
to approximately 30% of their original value by day 12 in the bioreactor, and
then remained at approximately this level. However, the specific
productivity, also shown in Figure 111-27, declined continuously throughout
the bioreactor run. Thus, it appears that the decline in steady-state mRNA
can account for only some, but not all, of the drop in specific productivity
observed in the bioreactors. Steady-state immunoglobulin mRNAs declined
3-fold, while the specific productivity declined over 30-fold from day 7 to day
19.
Figures UI-25 and III-26 also show that there are no cross-hybridizing
immunoglobulin-like mRNAs present in the parental Sp2/0 cells, and also
that there are no immunoglobulin-like aberrant transcripts in the C46
subclone CLC LT14 used. Tsurushita et al. (1987) also showed that Sp2/0 cells
did not contain any immunoglobulin heavy chain RNA sequences.
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Figure III-25.
Northern Blot of RNA from Cells in Bioreactor #1 Probed for
Immunoglobulin Heavy Chain and a-Tubulin
The specific and volumetric productivity of reactor #1 is shown in Figure III-
24. Cells were removed from reactor #1 on days 7, 8, 12, 17, 19, and 26. Stock
Control 14C were CLC LT14 cells harvested from exponentially growing
spinner cultures at a specific productivity of 0.2 pg/cell-hr. Sp2/0 cells were
also isolated from exponentially growing cells in spinner culture. RNA from
all samples was isolated as described in section II.C.5, Materials and Methods.
15 Cgg RNA per lane was loaded, and gels were run, transferred and
simultaneously probed with the immunoglobulin heavy chain probe pCo
and the a-tubulin probe as described in section II.C.5, Materials and Methods.
The blot was exposed to Kodak X-ray films (Kodak X-Omat AR) with an
intensifying screen (DuPont Cronex Lightning Plus) to visualize bands for
one day at room temperature.
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Figure III-26.
Northern Blot of RNA from Cells in Bioreactor #1 Probed for
Immunoglobulin Light Chain and a-Tubulin
The specific and volumetric productivity of reactor #1 is shown in Figure III-
24. Cells were removed from reactor #1 on days 7, 8, 12, 17, 19, and 26. Stock
Control 14C were CLC LT14 cells harvested from exponentially growing
spinner cultures at a specific productivity of 0.2 pg/cell-hr. Sp2/0 cells were
also isolated from exponentially growing cells in spinner culture. RNA from
all samples was isolated as described in section II.C.5, Materials and Methods.
15 gg RNA per lane was loaded, and gels were run, transferred and
simultaneously probed with the immunoglobulin light chain probe pK and
the a-tubulin probe as described in section II.C.5, Materials and Methods. The
blot was exposed to Kodak X-ray films (Kodak X-Omat AR) with an
intensifying screen (DuPont Cronex Lightning Plus) to visualize bands for
one day at room temperature.
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Figure 111-27.
Relative Levels of IgG Light and Heavy Chain Message
in Cells Isolated from Reactor #1 on Days Indicated
U % Heavy Chain
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The northern blots used to generate this data are shown in Figures mII-25 and
mI-26. To quantify the immunoglobulin heavy chain signal, the bands of the
blot shown in Figure m-25 corresponding to the a-tubulin signal and the
immunoglobulin heavy chain signal were cut out, placed in vials with
scintillation fluid, and counted. The counts from the ca-tubulin signal were
used to normalize for the amount of RNA loaded; all samples were
normalized to the control sample (Control 14C). Then, the % heavy chain
signal of each bioreactor sample was expressed relative to the signal from the
control sample (Control 14C). To quantify the immunoglobulin light chain
signal, the bands of the blot shown in Figure III-26 corresponding to the a-
tubulin signal and the immunoglobulin light chain signal were cut out,
placed in vials with scintillation fluid, and counted. These were then
normalized and quantified as for the heavy chain signal.
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RNA was also isolated from cells grown in the second set of bioreactors
(reactors #4-6). Figure m-28 shows a typical ethidium bromide-stained gel of
RNA samples from bioreactor #4. Lane 1 shows the position of the RNA
molecular weight markers, and the 28S and 18S ribosomal RNA bands in the
samples are labelled.
Figure III-29a shows a blot of these samples from reactor #4 probed for
the presence of a-tubulin and light chain mRNA, and Figure mI-29b shows
the same blot after stripping and rehybridized with a probe for
immunoglobulin heavy chain. The extra higher molecular weight band in
Figure m-29b is due to cross-hybridization of the heavy chain probe, pCo with
the 28S ribosomal RNA.
The molecular weights of immunoglobulin mRNAs were estimated
from a log plot of molecular weight markers and ribosomal RNA versus the
distance migrated, shown in Figure 111-30 for molecular weight markers and
ribosomal RNAs shown in Figure m-28. The heavy chain mRNA was found
to be approximately 1.8-2.1 kb, and the light chain mRNA was 1.2 kb, as
expected (Schibler et al., 1978). The a-tubulin mRNA was found to be
approximately 2.1 kb.
Figures III-31a shows a blot of samples from reactor #5 probed for the
presence of a-tubulin and light chain mRNA and Figure EII-31b shows the
same blot rehybridized with a probe for IgG heavy chain. Figure 1I-32 shows
a blot of samples from reactor #6 probed for the presence of a-tubulin and
light chain mRNA.
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Figure III-28.
Ethidium Bromide Stained Gel of RNA Samples from Bioreactor #4
The growth curve for reactor #4 is shown in Figure III-8, and the numbers
above each lane indicate the day on which cells were removed. RNA was
isolated as described in section II.C.5. 15 gg RNA per lane was run.
Molecular weight markers were run in the lane labelled M, and the
molecular weight of each band, in kb, is indicated on the left hand side of the
figure. The numbers, 0 through 14, refer to the day on which the sample was
isolated. Duplicate samples were independently isolated on days 0 and 14.
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Figure III-29.
Northern Blot of RNA from Cells From Bioreactor #4
The ethidium bromide-stained gel, prior to blotting, of these samples is
shown in Figure III-28, and the growth curve for reactor #4 is shown in Figure
1-8. The numbers above each lane indicate the day on which cells were
removed from reactor #4. RNA was isolated, transferred and probed as
described in section II.C.5. 15 gg RNA per lane was run. The numbers, 0
through 14, refer to the day on which the sample was isolated. Duplicate
samples were independently isolated on days 0 and 14. Blots were exposed to
Kodak X-ray films (Kodak X-Omat AR) with an intensifying screen (DuPont
Cronex Lightning Plus) to visualize bands for one day at room temperature.
a. The blot was simultaneously probed for presence of immunoglobulin light
chain and a-tubulin using the immunoglobulin light chain probe pK and the
a-tubulin probe. The position of the molecular weight markers is shown on
the right, and the size is indicated in kb.
b. The blot was stripwashed and reprobed using the heavy chain gene probe
pCo. The position of the molecular weight markers is shown on the right,
and the size is indicated in kb.
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Figure III-30.
Molecular Weight of RNA Size Standards vs. Distance Migrated in Gel
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The distance which the molecular weight standards and ribosomal RNAs
migrated was measured for the ethidium bromide-stained gel shown in
Figure III-28. The sizes of the RNA molecular weight markers are shown in
Figure III-28. 28S ribosomal RNA = 4.712 kb, and 18S ribosomal RNA = 1.869
kb.
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Figure III-31.
Northern Blot of RNA from Cells From Bioreactor #5
The growth curve for reactor #5 is shown in Figure III-8. The numbers above
each lane indicate the day on which cells were removed from reactor #5.
RNA was isolated, transferred and probed as described in section II.C.5. 15 gg
RNA per lane was run. The numbers, 0 through 14, refer to the day on which
the sample was isolated. Duplicate samples were independently isolated on
days 0 and 14. Blots were exposed to Kodak X-ray films (Kodak X-Omat AR)
with an intensifying screen (DuPont Cronex Lightning Plus) to visualize
bands for one day at room temperature.
a. The blot was simultaneously probed for presence of immunoglobulin light
chain and a-tubulin and probed using the immunoglobulin light chain probe
pK and the (a-tubulin probe.
b. The blot was stripwashed and reprobed using the heavy chain gene probe
pCo.
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Figure III-32.
Northern Blot of RNA from Cells From Bioreactor #6 Probed for
Immunoglobulin Light Chain and ca-Tubulin
The growth curve for reactor #6 is shown in Figure III-8. The numbers above
each lane indicate the day on which cells were removed from reactor #6.
RNA was isolated, transferred and probed as described in section II.C.5. 15 igg
RNA per lane was run. The numbers, 0 through 14, refer to the day on which
the sample was isolated. Duplicate samples were independently isolated on
days 0 and 14. Blots were probed using the immunoglobulin light chain
probe pK and the a-tubulin probe. Blots were exposed to Kodak X-ray films
(Kodak X-Omat AR) with an intensifying screen (DuPont Cronex Lightning
Plus) to visualize bands for one day at room temperature. The blot was
simultaneously probed for the presence of immunoglobulin light chain and
a-tubulin using the immunoglobulin light chain probe pK and the a-tubulin
probe.
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Quantitation of the signal intensities of the heavy and light chain from
blots shown in Figures III-29a and b (reactor #4) is shown in Figure 111-33, with
the observed specific productivity on each day shown for reference. The a-
tubulin signal was used to normalize the immunoglobulin signals in each
sample, and the relative amount of heavy and light chain are normalized to
the average of the day 0 samples (qP = 0.15 pg/c-hr). Duplicate samples
isolated independently on days zero and 14 are shown and provide an
estimate of the error, about ± 10%. The levels of both heavy and light chain
mRNA decreased about 3-fold to about 30% of their original value by day 4,
and remained at this level throughout the run.
Quantitation of the intensities of IgG heavy and light chain for reactor
#5 is shown in Figures HI-34 and for the light chain for reactor #6 in Figure mI-
35 (heavy chain not done).
The results for all three reactors (#4-6) are quite similar. The level of
IgG heavy chain mRNA decreases slightly more, by a factor of 3 in reactor #4
and a factor of 4 in reactor #5, than light chain mRNA, which decreases by a
factor of 2.5 in both reactors. These results are quite similar to those for
reactor #1 (see Figure 111-27). As seen for samples from reactor #1, a 3-fold
decrease in both H and L chain mRNAs was observed concomitant with a 10-
fold decrease in secretion rates.
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Figure III-33.
Relative Amount of IgG Heavy and Light Chain mRNA as a
Function of Time in Bioreactor #4
0 0 3 5 6 7 8 9 10 11 12 13 14 14
Time - Day in Bloreactor
qP .15 .07.04 .03 .04 .05.03.025 .02 .02 .01 .01 pg/cell-hr
The northern blots used to generate this data are shown in Figures III-
29a and m-29b, and the specific productivity for reactor #4 is shown in
Figure 1-16. The signal intensity of bands on the blots shown in
Figure m-29 was quantified using a Phosphor Imager (Molecular
Dynamics, Sunnyvale, CA). The counts from the a-tubulin signal were
used to normalize for the amount of RNA loaded; all samples were
normalized to the average of the two day zero samples. The % light
chain signal of each bioreactor sample was then expressed relative to
average of the light chain signals from the two day 0 samples, and the
% heavy chain signal of each bioreactor sample was expressed relative
to the average of the heavy chain signals from the two day 0 samples.
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Figure III-34.
Relative Amount of IgG Heavy and Light Chain mRNA as a
Function of Time in Bioreactor #5
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The northern blots used to generate this data are shown in Figures III-
31a and I-31b, and the specific productivity for reactor #5 is shown in
Figure 1-16. The signal intensity of bands on the blots shown in
Figure HI-31 was quantified using a Phosphor Imager (Molecular
Dynamics, Sunnyvale, CA). The counts from the a-tubulin signal were
used to normalize for the amount of RNA loaded; all samples were
normalized to the average of the two day zero samples. The % light
chain signal of each bioreactor sample was then expressed relative to
the average of the light chain signals from the two day 0 samples, and
the % heavy chain signal of each bioreactor sample was expressed
relative to the average of the heavy chain signals from the two day 0
samples.
r-hJ
N
N
N
N
N
N
N
NNNNjNj
N;
Ni
N
N
NNN
Nj
150
ENNNýr"
-
L
T
U
V
U
V
V
V
\1
V
U
V
U l.i1
"%
I
9L
2
Z
Z
I
I
I
M
I1-
Figure 111-35.
Relative Amount of IgG Light Chain mRNA as a
Function of Time in Bioreactor #6
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The northern blot used to generate this data is shown in Figure III-32,
and the specific productivity for reactor #6 is shown in Figure I-16.
The signal intensity of bands on the blots shown in Figure I-31 was
quantified using a Phosphor Imager (Molecular Dynamics, Sunnyvale,
CA). The counts from the (a-tubulin signal were used to normalize for
the amount of RNA loaded; all samples were normalized to the
average of the two day zero samples. The % light chain signal of each
bioreactor sample was then expressed relative to the average of the
light chain signals from the two day 0 samples.
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2.2 Measurement of Steady-state mRNA in Cells in Batch
Spinners
The levels of steady-state immunoglobulin mRNAs were also
measured in cells maintained in culture for varying amounts of time. The
objective of these experiments was to see if the observed decline in specific
productivity with time in culture (discussed in Sections III.A.1 and m.D.1)
was due to a decrease in the steady-state levels of immunoglobulin mRNAs.
Cells frozen at days 3, 7, and 21 from reactor #1 were thawed and grown in
batch spinners, and total RNA was isolated during exponential growth, at a
cell density of < 106 cells/ml. Total RNA was probed for immunoglobulin
light and heavy chains, and the signals normalized to the intensity of the cz-
tubulin signal. Figure III-36 shows the percent of immunoglobulin light and
heavy chains relative to those of the control culture (14C). The specific
productivity of each culture is also shown in Figure 111-36.
The amount of heavy and light chain mRNAs are similar for the
control, day 3, and day 7 cultures, where the specific productivity was 0.1-0.2
pg/c-hr. However, the levels of light and heavy chain mRNAs in the day 21
samples are reduced 2-fold, corresponding to a 2-3 fold decline in specific
productivity relative to the other cultures.
This data shows that the 3 fold drop in specific productivity observed in
these cells over a period of about a month is due to decreased amounts of
steady-state immunoglobulin mRNAs available for translation, and that the
amount of immunoglobulin secreted during exponential growth at low cell
density is proportional to the amount of steady-state immunoglobulin
message per cell.
This observation further suggests that the "capacity" for
immunoglobulin synthesis, as estimated from the levels of immunoglobulin
steady-state message, of cells at high cell density in the bioreactors is at about
0.05 pg/c-hr, 2-4 times higher than the amount of synthesis seen in reactors
#4-6 after day 8, and 10-20 times higher than the amount of synthesis seen in
bioreactor #1 on day 26.
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Figure III-36.
Percent Heavy and Light Chain mRNA of Cells from Days 3, 7, and 21 of
Reactor #1 Grown in Batch Spinners
1
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To generate the data shown in this figure, cells frozen at days 3, 7, and
21 from reactor #1 were thawed and grown in batch spinners in parallel
with cells labelled Control 2. The two day 21 samples are from
duplicate spinners. Samples labelled Control 14C and Control 2 were
isolated from CLC LT14 cells maintained at low density and grown in
batch spinners. Total RNA was isolated during exponential growth as
described in section II.C.5, Materials and Methods. 15 gg RNA per lane
was loaded onto a gel, and the gel was run, blotted and probed as
described for Figure m-29 (data not shown). The signal intensity of
bands on the blots was quantified using a Phosphor Imager (Molecular
Dynamics, Sunnyvale, CA). The counts from the a-tubulin signal were
used to normalize for the amount of RNA loaded; all samples were
normalized to the sample labelled Control 14C. The % light chain
signal of each sample was then expressed relative to the light chain
signal of Control 14C, and the % heavy chain signal of each sample was
expressed relative to the light chain signal of Control 14C.
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2.3 Measurement of Stability of Immunoglobulin H and L
mRNAs
Since I found that the steady-state levels of both H and L chain mRNA
decreased with time in culture (Section m.C.2.2), I wanted to see if this was
due to a decrease in stability or in transcription rate. I chose to look at RNA
stability in the presence of actinomycin D, an inhibitor of RNA transcription.
Control stock cells maintained in T-flasks, and cells from days 2 and 20
from bioreactor #1 were treated with actinomycin D. Cells were grown to a
density of 8-12 x 105 c/ml in 100 ml spinners, and actinomycin D was added to
a final concentration of 0.5 gg/ml. Aliquots were withdrawn after 0, 1, 3, 5, 7,
and 9 hours from actinomycin D-treated spinners and a control spinner of
stock cells left untreated, and total RNA isolated and analyzed via Northern
blotting.
A representative blot, of time points from the day 2 spinners, is shown
in Figures m-37a and b. In Figure m-37a, it can be seen that levels of both IgG
light chain mRNA, as well as a-tubulin, dropped to undetectable levels
between 5 and 7 hours of treatment. The level of heavy chain mRNA, shown
in Figure 37b, also dropped to undetectable levels after 5 to 7 hours of
treatment with actinomycin D. The experiment was terminated after 9 hours
because cell viability was less than 35%. Similar blots were obtained for
treated control spinners and cells from day 20 (data not shown).
Band intensities in each lane were quantified via phosphor imaging,
and the data are summarized in Figures III-38a and m-38b, which show the
amounts of immunoglobulin light (Figure m-38a) and heavy (Figure III-38b)
chain mRNA remaining as a function of time of exposure to actinomycin D.
The data show some scatter, but indicate that: 1. the half-lives, when 50% of
the original amount of mRNA is left, of both light and heavy chain mRNAs
are about 3-4 hours, 2. the stability of mRNA from cells maintained in culture
for different times is similar, and 3. the reduction in the steady-state level of
immunoglobulin mRNAs with time in culture, leading to lower specific
productivity, is not due to a change in the stability of the mRNAs.
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Figure III-37.
Northern Blot Showing Decrease in mRNAs as a Function of Time of
Actinomycin D Treatment
Cells frozen at day 2 from reactor #1 were thawed and grown in batch
spinners. The sample labelled 14D Control was isolated from CLC LT14 cells
maintained at low density and grown in batch spinners. The day 2 cells were
treated with actinomycin D at 0.5 gg/ml and samples of cells were withdrawn
at time 0 and after 1, 3, 5, 7, and 9 hours of treatment. Total RNA was isolated
from all samples as described in section II.C.5, Materials and Methods. 15 gg
RNA npr lanP wa~ lnoaied nntn o two dC•plicafpe els anC the O1l w•r• rimn
blotted and probed as described for Figure mI-29. Blots were exposed to Kodak
X-ray films (Kodak X-Omat AR) with an intensifying screen (DuPont Cronex
Lightning Plus) to visualize bands for one day at room temperature.
The blot shown in the top panel was probed simultaneously for the presence
of immunuglobulin light chain and a-tubulin, using the light chain probe pK
and the a-tubulin probe.
rTh- bl -1-
e ot s own in t e bottom panel was pro
immunualobulin heavy chain. usine the heavy chain orobe oCo.
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Figure III-38.
Stability of Immunoglobulin Light and Heavy Chain mRNAs Measured
using Actinomycin D
Two of the northern blots used to generate this data are shown in Figure 1-
37. Spinners of CLC LT14 cells maintained at low density (Control) and of
cells frozen at day 20 from reactor #1 and thawed (day 20) were also treated
with actinomycin D at 0.5 gg/ml, in parallel with those of day 2 cells from
bioreactor #1. Samples of cells from these spinners were withdrawn at time 0
and after 1, 3, 5, 7, and 9 hours of treatment. A control spinner of CLC LT14
cells maintained at low density (Untreated Control) was run in parallel with
these spinners but not dosed with actinomycin D. Total RNA was isolated
from all samples as described in section II.C.5, Materials and Methods. 15 gg
RNA per lane was loaded onto two duplicate gels for each set of treated cells,
and the gels were run, blotted and probed as described for Figure 111I-29 (data
not shown).
The signal intensity of bands on the blots shown in Figure III-37 and the otherblots of untreated control, control, and day 20 cells (data not shown) was
quantified using a Phosphor Imager (Molecular Dynamics, Sunnyvale, CA).
To quantify the light chain signal, the counts in each blot probed for the light
chain were expressed as the % of the signal at time zero (when actinomycin D
treatment was initiated). The heavy chain signal was similarly quantified.
a. Stability of Immunoglobulin Light Chain
b. Stability of Immunoglobulin Heavy Chain
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These estimates for H and L mRNA stability agree with those of some
workers who also used actinomycin D treatment to estimate the stability of H
and L mRNAs in myeloma cell lines synthesizing immunoglobulin (Namba
and Hanaoka, 1969; Scharff and Laskov, 1970; Shutt and Krueger, 1972; Bibila
and Flickinger, 1991). However, my estimates are shorter than those obtained
by following the decay of uridine-labelled mRNAs (Cowan and Milstein, 1974;
Storb, 1973) or by inhibiting mRNA synthesis using a different inhibitor of
RNA transcription, DRB (Bibila and Flickinger, 1991); those workers
estimated that the stability of H and L mRNAs were 12-14 hours.
One possible reason for this discrepancy is that actinomycin D, which
prevents transcription by intercalating into DNA, has been shown to be toxic
to some cells (Sawiki and Godman, 1971; Singer and Penman, 1972).
Therefore, it is possible that this experiment may have underestimated
the stability of the immunoglobulin mRNAs, as treatment with actinomycin
D seriously degraded ribosomal RNA by 5 hours and was toxic to the cells, as
evidenced by a reduction in viability and the growth rate. Nevertheless, it
appears that the stability of the immunoglobulin H and L mRNAs is similar
in cells maintained in culture for varying times of up to one month.
3. Analysis of Polysome Distributions
The observed 3-fold decrease in steady-state mRNA cannot completely
account for the 10-15-fold decrease in IgG secretion observed in bioreactors #4-
6. One possibility is that there is reduced translation of immunoglobulin
mRNAs resulting in decreased synthesis of immunoglobulins. The
translational efficiency at high and low specific productivity was investigated
by running polysome gradients, which separate mRNAs based on the number
of ribosomes associated with each mRNA. If the observed downregulation of
IgG production were translational, condition(s) in the bioreactors at high cell
density may cause regulatory feedback/shutdown under which initiation of
synthesis from mRNAs nonessential for growth is less efficient. In this
case,the distribution of H and/or L mRNAs would shift towards fewer
ribosomes per polysome.
Cell lysates were isolated from bioreactors using the method of Bennett
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optical density profile for polysome gradients is shown in Figure 11-39, where
sedimentation was from right to left and the absorbance of the fractionated
sample was continuously monitored in a flow-through specrtophotometer
(redrawn from Bennett and Adams, 1987). The peaks for 40S ribosomal
subunits, 60S ribosomal subunits, monosomes, and polysomes are labelled.
Figure III-39.
Typical Absorbance Profile for a Sample Fractionated on a Sucrose
Gradient
E
0
C,
0o
0 00
0 5 10 15
Bottom Fraction ?
Redrawn from Bennett and Adams (1987).
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Figure III-40a shows the optical density profile at 254 nm for a sample
prepared from cells used to inoculate bioreactors #4-6 (day 0). Sedimentation
in this and all following figures is from right to left. The peaks expected for
40S ribosomal subunits, 60S ribosomal subunits, monosomes, and polysomes
for 2, 3, etc. ribosomes are smeared out because the absorbance was measured
from collected fractions, as opposed to flowing the gradient through a detector
as was done by Bennett and Adams (1987). Figures I-40b, m-40c, and 1I-40d
show the absorbance profiles for samples prepared from cells from bioreactor
#5, chosen for further analysis, on days 4, 11, and 12, respectively.
Figure III-41a shows an ethidium bromide stained blot of polysome
fractions isolated from the day 0 inoculum to reactors #4-6, and Figure IIE-41b
the results of blotting this gel and probing for the presence of a-tubulin and
immunoglobulin light chain. Figure III-41c shows the same blot after
stripping and reprobing for the presence of the immunoglobulin heavy chain.
Note that alternate fractions (for example, 1-15 in Figure 41) of the bottom of
the gradient were analyzed. This was done in order to analyze each polysome
gradient on one gel. Figure III-42 shows the relative intensity of the
immunoglobulin light chain and a-tubulin mRNA for samples from day 0 to
day 12. Panel I-42a represents cells from day 0, panel III-42b cells from day 4,
panel II-42c cells from day 11, and panel III-42d cells from day 12. Figure HI-
43a-d shows the same samples when blots were hybridized with a probe for
the IgG heavy chain.
There is a shift from larger to smaller polysomes over the course of
time in the bioreactors for both heavy and light chain. The light and heavy
chain profiles for day zero (inoculum) (Figures l-42a and III-43a) show that
most of the immunoglobulin mRNAs are in heavy polysomes and that the
heavy chain is associated with larger polysomes than the light chain. By day
4, the profiles begin to show a shift towards smaller polysomes, which is more
pronounced at days 11 and 12. The a-tubulin signal (Figure III-42) also shows
this shift towards lighter polysomes.
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Figure III-40.
Absorbance Profiles for Samples Fractionated on Sucrose Gradients
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Shown are absorbance profiles of samples of cell lysates fractionated through a
linear sucrose gradient, prepared as described in section II.C.6, Materials and
Methods. 0.5 ml fractions were collected. A 30 W1 aliquot of each fraction was
diluted 1/25 in dH20 and the absorbance at 254 nm recorded. Sedimentation
was from right to left. a: Inoculum refers to cells used to inoculate reactors
#4-6 (day 0); b: cells removed from reactor #5 on day 4; c: cells removed from
reactor #5 on day 11; d: cells removed from reactor #5 on day 12. The growth
curve for reactor #5 is shown in Figure 111-8.
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Figure III-41.
Gel and Northern Blots of Inoculum Fractionated on a Sucrose Gradient
Shown are the ethidium bromide-stained gel and northern blots of
fractionated polysome lysates of the cells used to inoculate reactors #4-6 (day
0). The absorbance of this fractionated sample at 254 nm is shown in Figure
m-40a. RNA from each fraction was isolated as described in section II.C.5, and
all the RNA isolated from each fraction was loaded onto the gel.
a. Ethidium bromide stained gel of fractionated samples from inoculum (day
0). Molecular weight markers were run in the lane labelled M, and the
molecular weight of each band, in kb, is indicated. The numbers refer to the
fraction number; alternate fractions were run at the bottom of the gradient.
b. The gel shown in a. was transferred and probed as desribed in section II.C.5.
The blot was simultaneously probed for presence of immunoglobulin light
chain and a-tubulin. The location and size of the molecular weight markers
is shown on the right side. The blot was exposed to Kodak X-ray films (Kodak
X-Omat AR) with an intensifying screen (DuPont Cronex Lightning Plus) to
visualize bands for two days at room temperature.
c. The blot shown in b. was stripwashed and reprobed for the presence of the
immunoglobulin heavy chain gene using the heavy chain probe pCo. The
location and size of the molecular weight markers is shown on the right side.
The blot was exposed to Kodak X-ray films (Kodak X-Omat AR) with an
intensifying screen (DuPont Cronex Lightning Plus) to visualize bands for
two days at room temperature.
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Figure III-42.
IgG Light Chain and a-Tubulin Signal in Polysome Gradients
The northern blot used to generate the data shown in Figure III-42a is shown
in Figure III-41b. To generate the data shown in Figures 42b-d, cells from
reactor #5 were removed on days 4, 11, and 12, and polysome lysates from
these samples were prepared and fractionated as described in section II.C.6,
Materials and Methods. RNA was isolated from each fraction, run on a gel,
and probed for the presence of the immunoglobulin light chain gene and a-
tubulin as described for Figure 111-41 (data not shown).
The signal intensity of bands on the blots shown in Figure III-41b and the
other blots of fractions from cells from reactor #5 on days 4, 11, and 12 (data
not srLowIn) was quanuinei using a rnosphor mager QivIolecuiar Dmynamlcs,
Sunnyvale, CA). The relative signal intensity of immunoglobulin light chain
and a-tubulin is shown on the y-axis as signal intensity (arbitrary units).
a: Inoculum refers to cells used to inoculate reactors #4-6 (day 0); b: cells
removed from reactor #5 on day 4; c: cells removed from reactor #5 on day 11;
d: cells removed from reactor #5 on day 12.
Figure III-43.
IgG Heavy Chain Signal in Polysome Gradients
The northern blot used to generate the data shown in Figure II-43a is shown
in Figure III-41c. The preparation of other samples shown in Figure III-43b-d
is described in Figure 111-42. Blots were stripwashed and reprobed for the
presence of the immunoglobulin heavy chain gene (data not shown).
The signal intensity of bands on the blot shown in Figure m-41c and the other
blots of fractions from cells from reactor #5 on days 4, 11, and 12 (data not
shown) was quantified using a Phosphor Imager (Molecular Dynamics,
Sunnyvale, CA). The relative signal intensity of immunoglobulin heavy
chain is shown on the y-axis as signal intensity (arbitrary units).
a: Inoculum refers to cells used to inoculate reactors #4-6 (day 0); b: cells
removed from reactor #5 on day 4; c: cells removed from reactor #5 on day 11;
d: cells removed from reactor #5 on day 12.
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Figure III-43.
IgG Heavy Chain Signal
in Polysome Gradients
a. 3.5 Cells from Day Zero Inocuium
10
10s
1 0 
s
10L
10'
100
1 3 5 7 0 11 13 15 1 17 18 1 20 212 23 24 s 26
Behm eam n NIumber Top
b. Cella from Bloretor 02 on Day 4
I I ý . .
ISI V_ .I10
III -- .1 11111
1 3 5 7 9 1011121314151t17181920I22123
saI Nr,. Lmber Top
1.0 106
8.0 10
4.0 10s
2.0 10'
a, ,0
CeaIs from Sloreactor #2 on Day 11
.U 1 2 4 46 9 1011121314161417119 20212223
seem Fen im Top
Cells from Bloreactor 2 on Day 12
4.0 10
2.5 10'
2.0 105
1.5 10i
5.O 10
01 3 9 1011121314151e17 1920212223
aeeltom prowbmoin Top
1.6 10"
1.4 10e
12 10'
1.0 106
&0 104
4.0 10'
2.0 10'
4
Alft 4 0
a from Bioreactor #2 1
S s 10
2 4 a 8 1 101112131418117181920212223
Bem m Fe a.mer Top
Cells from Bloreactor #2 on Day 12
2.0 1 05
1.6 10
s5
12 ii 0
8.010'
4.0 10
0.0 10
1 3 s67 1011121•1416s16171 1 20212223
Im Fmm Nui Top
166
Figure III-42.
IgG Light Chain and
a-Tubulin Signal in
Polysome Gradients
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In order to quantify the change in polysome distributions, I first
divided each gradient into 5 equal (a few sections contained 1 more or 1 less
fraction) sections. The signal intensities for immunoglobulin heavy and light
chain, and ca-tubulin in each section were summed, normalized to account
for the number of fractions analyzed in each section, and then expressed as
the percentage of the total signal. This data is shown in Table III-5.
Additonal samples not shown in Figures III-42 and III-43 from reactors
#4 and #6 are also shown. Fraction 1 represents mRNA associated with the
most ribosomes (bottom of gradient), while fraction 5 represents mRNA
associated with the fewest ribosomes (top of gradient). It can be seen that the
distributions of immunoglobulin signal in the 5 sections of the polysome
gradient are similar at day 0 and at day 4 in reactor #6, when the specific
productivity was 0.15 pg/c-hr. The distribution at days 4 (reactor #5) and 7
(reactor #4) are intermediate to those at days 11 and 12.
A comparison of the average signal intensities in each polysome
gradient section was made of the average of the day 0 and day 4 (reactor #6)
samples relative to the average of the samples at days 11 and 12. The
reduction in signal in section 1 was 8.8 fold for light chain, 7.2 fold for heavy
chain, and 11.6 fold for a-tubulin. Comparison of the sum of sections 1 and 2
gave a 2.6 fold reduction in light chain and a-tubulin, and a 2.4 fold reduction
in immunoglobulin heavy chain.
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Table 111-5.
Immunoglobulin and a-Tubulin Signals in Polysome
Sample Inoc. R# 6 R#5 R# 4 R# 5 R# 5 R# 6
Day 0 4 4 7 11 12 12
Fraction % Light Chain
1 Bottom 14 21 0 0 *2 2 2
2 41 47 41 4 24 14 26
3 22 13 **22 45 37 **40 **34
4 10 **5 **21 18 24 **13 **15
5 Top *14 13 15 33 *13 31 23
Fraction % Heavy Chain
1 Bottom 45 48 0 0 *5 8 n.d.
2 28 16 42 28 15 29
3 8 8 **5 26 8 **18
4 7 **14 **27 12 22 **13
5 Top *12 14 27 34 *49 32
Fraction % cz-Tubulin
1 Bottom 29 56 0 0 *6 7 2
2 28 18 29 15 22 22 16
3 13 8 **11 21 18 **15 **14
4 10 **6 **26 13 17 **15 **12
5 Top *20 12 34 51 *36 41 56
n.d. not done.
*One more fraction was included in the section than in the other sections of the sample.
**One less fraction was included in the section than in the other sections of the sample.
Data from inoculum and reactor #5 is shown in Figures m-42 and III-43.
Additional samples of cells from reactors were similarly processed (data
not shown). Each gradient was divided into 5 equal (a few sections
contained 1 more or 1 less fraction) sections. The signal intensities for
immunoglobulin heavy and light chain, and a-tubulin in each section
were summed, normalized to account for the number of fractions
analyzed in each section, and then expressed as the percentage of the
total signal. Growth curves for reactors #4-6 are shown in Figure III-8.
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These results suggests that there is a global decrease in protein
synthesis, since the average polysome size of immunoglobulin and tubulin
are both decreased in a coordinated fashion. This is most likely due to a
decrease in initiation. A general reduction in the rate of elongation would
not lead to a decrease in the average polysome size; rather, the polysome size
would increase, as translating ribosomes would pile up, as is seen in the
presence of emetine, an inhibitor of peptide elongation (Stevens, 1974). A
reduction in the rate of initiation, on the other hand, leads to a decrease in
the average polysome size (Stevens, 1974).
I also estimated the average number of ribosomes associated with the
immunoglobulin and a-tubulin mRNAs. This was done by using the data of
Stevens (1974), who found that the immunoglobulin heavy chain was
associated with an average of 14-18 ribosomes during exponential growth. I
assumed that the bottommost polysome fraction of each sample corresponded
to message associated with 20 ribosomes, that the topmost fraction
corresponded to message associated with one ribosome, and that polysomes
with increasing numbers of ribosomes were linearly sedimented (since
sedimentation was through a linear sucrose gradient). For the portions of
each gradient where alternate fractions were analyzed, I calculated the signal
intensity of the unanalyzed fractions by linear interpolation. The calculated
average number of ribosomes associated with the immunoglobulin and a-
tubulin mRNAs are shown in Table 11-6, for the same samples shown in
Table 111-5.
A comparison of the average number of ribosomes associated with
each mRNA on day 0 and day 4 in bioreactor #4 (condition of high
productivity) and on days 11 and 12 (condition of low specific productivity)
shows that there is a 1.4-fold reduction of the number of ribosomes associated
with the immunoglobulin light chain mRNA, a 2.3-fold reduction in the
number of ribosomes associated with the immunoglobulin heavy chain
mRNA, and a 2.6-fold reduction in the number of ribosomes associated with
the a-tubulin message. This, again, indicates that there was a reduction in
translation of message. Immunoglobulin heavy chain and a-tubulin
translation was reduced more than the immunoglobulin light chain.
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Table 111-6.
Average Number of Ribosomes Associated with Immunoglobulin
and a-Tubulin Signals
Average Number of Ribosomes per mRNA
IgG IgG
Sample Day Light Chain Heavy Chain ca-tubulin
Inoculum 0 13.5 16.6 14.3
Reactor #6 4 14.9 16.4 17.2
Reactor #5 4 10.9 8.3 6.6
Reactor #4 7 9.3 10.9 6.1
Reactor #5 11 10.1 4.0 7.5
Reactor #5 12 9.2 10.1 6.6
Reactor #6 12 10.1 n.d. 4.0
n.d. not done.
Data from inoculum and reactor #5 is shown in Figures m-42 and III-43.
Additional samples of cells from reactors were similarly processed (data
not shown). I assumed that the bottommost polysome fraction of each
sample corresponded to message associated with 20 ribosomes, that the
topmost fraction corresponded to message associated with one
ribosome, and that polysomes with increasing numbers of ribosomes
were linearly sedimented. For the portions of each gradient where
alternate fractions were analyzed, I calculated the signal intensity of the
unanalyzed fractions by linear interpolation. Shown are the calculated
average number of ribosomes associated with the immunoglobulin
and a-tubulin mRNAs.
170
mm r·~
4. Estimation of the Number of Heavy and Light Chain
mRNA Molecules in Cells
In the experiments described in the previous section (III.C.2), northern
blotting was used to estimate the relative levels of heavy and light chain
mRNAs in cells from control cultures in exponential phase, in cells from the
bioreactors at high and low specific productivity, and in cells removed from
bioreactors and grown in batch spinners. However, the absolute number of
mRNA molecules cannot be obtained from these experiments.
The use of a kinetic model, combined with my experimental data and
with literature values for rates of translation and transcription allows
estimations for 1) the theoretically maximum number of immunoglobulin
mRNAs per cell which could be synthesized and 2) the number of
immunoglobulin molecules synthesized by the CLC LT14 transfectoma.
Heavy and light chain mRNA synthesis may be modelled as:
d[mRNA]H = ksH - kdH[mRNA]H 
- g[mRNA]H
dt (32)
and
d[mRNA]L[mRNAL = ksL - kdL[mRNA]L - g[mRNA]L
dt (33)
where [mRNA]H,L = number of H or L mRNA molecules per cell
ksH,L = rate of synthesis of H or L mRNA (sec-1)
kdH,L = rate of degradation of H or L mRNA (sec-1)
and gt = growth rate (sec-1)
where the rate of change in each mRNA is equal to its rate of synthesis minus
degradation minus dilution by growth. During balanced growth, observed in
exponential phase in batch culture and also during days 9-14 in bioreactors #4-
6, the rates of synthesis of mRNAs are in quasi-steady state, and these
equations reduce to:
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mRNAH = ksH
kdH + I (34)
and
mRNAL = ksLkdL + L (35)
The rate of mRNA synthesis (Savinell et al., 1989) can be estimated as:
ksL = ksH = - (D)(E)Sc (36)
where vc = the velocity of polymerase II (nucleotides/gene-sec)
sc = the spacing of polymerase II (nucleotides)
D = the gene dosage = 1
and E = the efficiency of processing of heterogeneous nuclear RNA to
cytoplasmic mRNA.
This model assumes that neither polymerases nor any other
transcription factors are limiting, which is generally not the case. This model
also assumes that the mRNAs per cell will increase linearly with the gene
copy number for a transfected gene.
Since there are 1 to 2 copies of each immunoglobulin gene in CLC LT14
cells, I set D equal to 1. The efficiency of processing of hn RNA was estimated
at nearly 1 by Schibler et al. (1978), so I used a value of E of 0.95. Literature
values for the rate of polymerization by pol II are 83 nucleotides/sec, seen in
HeLa cells (Greenberg and Penman, 1966). The average spacing between two
polymerases is about 80 nucleotides (Miller et al., 1970). Using these values,
the rate of synthesis of H and L mRNAs = 1 molecule/second. The calculated
numbers of H and L mRNAs per cell at several different doubling times and
half-lives of immunoglobulin mRNAs, calculated using equation 34 are
shown in Table 111-7. The value for MPC-11 cells, assuming a half-life of 12
hours for the immunoglobulin mRNAs, is in the same range as values
measured by Schibler et al. (1978), and suggest that rates of transcription are
near their maximum in this cell line, which secretes about 2.5 pg/c-hr of
immunoglobulin, 10 times the level of our CLC LT14 cells. The difference in
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the levels of heavy and light chain mRNAs found by Schibler et al. (1978) is
probably due to differences in the efficiency of initiation of transcription.
The calculated numbers for CLC LT14 cells represent a theoretical
upper bound for the numbers of heavy and light chain immunoglobulin
molecules/cell.
Table 111-7.
Calculated Numbers of H and L mRNAs
mRNA # H or L
half-life (hrs, mRNAs/cell
35100
15000
36900
15200
38900
61400
30,000 H, 40,000 L
Condition
average values for hybridomas
CLC LT14 cells; measured tl/2
CLC LT14 cells if tl/2 were 12 hrs.
MPC-11 cells if tl/2 were 3.5 hrs.
MPC-11 cells if tl/2 were 12 hrs.
MPC-11 cells if tl/2 were 24 hrs.
measured by Schibler et al., 1978
in MPC-11 myeloma cells
To obtain an estimate for the absolute numbers of heavy and light
chain mRNAs in CLC LT14 cells, I used a kinetic model for immunoglobulin
peptide synthesis. The rate of change in immunoglobulin heavy and light
chains, neglecting degradation, is given by:
dH = TH mRNAH - gH - RHdt (37)
and
dL = TL mRNAL- L - RL
dt
where H and L = number of immunoglobulin H and L peptides per cell
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Doubling
time (hrs)
12
3.5
12
3.5
12
24
?
C
(38)
TH,L = rate of translation of H and L peptides (nucleotides/sec)
pt = growth rate (sec-1)
and RH,L = rate of consumption of H and L peptides (molecules/sec)
During balanced growth, these equations reduce to:
mRNAH = H + R
TH (39)
and
mRNAL - JL + RL
TL (40)
The rate of translation may be estimated as follows:
TH,L = (rib/mRNA) (nucleotides translated/rib-sec)
(# coding nucleotides/peptide) (41)
During exponential growth, the heavy chain mRNA is found in polysomes
containing 14-18 ribosomes, and the light chain mRNA in polysomes
containing 6-8 polysomes (Stevens, 1974). The rate of translation is about 20
nucleotides/sec (Hunt et al., 1969). The heavy chain mRNA contains about
1350 nucleotides of coding sequence, and the light chain mRNA, about 750
nucleotides (Auffray and Rougon, 1980).
I used equations 39 and 40 to estimate the amount of mRNA/cell
during exponential growth in batch spinners, using two different values for H
and L. Values for RH and RL, at a specific productivity of 0.2 pg/c-hr (223
molecules/c-sec) are 446 molecules/cell-sec, since 2 heavy and light chains are
assembled into each IgG. The amount of assembled IgG in cells during
exponential growth (measured by Elisa) is about 0.2 pg/cell, equivalent to 223
molecules of IgG per cell, giving minimum values for H and L of 446
molecules/cell. However, the Elisa method measures only assembled
immunoglobulin, which has been shown to represent about 40% of the total
amounts of cytoplasmic heavy and light chains (unassembled and assembled)
(Baumal et al., 1971). Using this value, H and L are equal to 1115 molecules
each.
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Upon examining equation 39 (same holds for equation 40), it becomes
obvious that the first term, giH, is quite small compared to the value for RH.
In fact, small variations in the growth rate do not affect the calculated number
of mRNAs per cell at all. Similarly, the two estimates used for H and L (446
or 1115 molecules H and L per cell) give the same number of mRNAs per cell.
The calculation of mRNA per cell is thus sensitive only to the value used for
the number of ribosomes per polysome, and the specific productivity.
Using a value of 0.2 pg/c-hr for the specific productivity, the light chain
mRNA/cell = 2800-2100 molecules/cell for values of 6 and 8
ribosomes/polysome. Heavy chain mRNA/cell = 2200-1700 molecules/cell
for values of 18 and 14 ribosomes/polysome. Schibler et al. (1978) measured
values of 30,000 heavy and 40,000 light chain mRNAs/cell in MPC-11
myelomas, which have a specific productivity of about 2.5 pg/c-hr. Assuming
similar polysome loading densities, the calculated values for light chain
mRNA are 35,000-42,000 and 21,000-27,000 for heavy chain mRNA, in line
with their measurements. This shows that this model is useful in calculating
the levels of heavy and light chain mRNAs per cell.
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5. Analysis of Intracellular IgG via Flow Cytometry
5.1 Intracellular IgG of Cells in Bioreactors
The intracellular IgG of this cell line decreases as the specific
productivity and growth rate, measured in batch culture, decrease. During
exponential growth at a doubling time of 16-20 hours, during which the
specific rate of antibody production is 0.2 pg/cell-hr, cells contain
approximately 0.2 pg IgG/cell as measured via Elisa. By late stationary phase,
the specific productivity is nearly zero, the growth rate is zero, and the
intracellular IgG is 0.03- 0.06 pg/cell.
The intracellular IgG content of cells can also be measured by
permeabilizing cells and incubating them with fluorescein-conjugated
antibodies to intracellular IgG and subsequent flow cytometry. This approach
gives information not only as to the average immunoglobulin per cell, but
shows the distribution of immunoglobulin content in a population of cells.
Flow cytometry was used to measure the amount of intracellular IgG in
cells removed from bioreactors during the course of the runs. Cells were
prepared for flow cytometry using two protocols, described in Section II.C. In
order to measure intracellular antibody, ethanol permeabilization, which
gives essentially 100% permeabilization, was used. Cells were permeabilized
with 70% ethanol in PBS and stained with one of three fluorescein (FITC)-
conjugated antibody reagents to either the human H+L chain, the human H
chain, or the human L chain. All FITC-conjugated antibody reagents were in
excess, so that green fluorescence was proportional to intracellular antibody
content.
Results of flow cytometry of Sp2/0 and control high-producing CLC
LT14 cells in exponential growth at low cell density are shown in Figures III-
44a-f. The x axis shows green fluorescence (log scale) and the y axis relative
cell number. The green fluorescence is proportional to FITC-reagent and
intracellular antibody content. Cells in panels 44a and 44b were stained with
the FITC-conjugated anti (H+L) antibody reagent. Sp2/0 cells, shown in panel
44a, do not have any intracellular IgG and were used to determine the
amount of nonspecific staining. The negative cutoff was set so that greater
than 99% of the Sp2/0 cells fell into the left region of figure mI-44a. Figure III-
44b shows control CLC LT14 cells. Using the same cutoff as for the Sp2/0 cells,
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>95% of the control cells are positive for intracellular antibody, with a day-to-
day variation of about 5%. Panels 44c and 44d in Figure m-44 show Sp2/0 and
control CLC LT14 cells stained with the FITC-conjugated reagent to the light
chain, and panels 44e and 44f show Sp2/0 and control CLC LT14 cells stained
with the FITC-conjugated reagent to the heavy chain. Here also, the negative
cutoff was set so that greater than 99% of the Sp2/0 cells fell into the left
regions of Figure m-44c and e, and again, greater than 95% of the control CLC
LT14 cells were postive for light and heavy immunoglobulin chains. In each
case, there is a very good separation of antibody-negative (Sp2/0) and antibody
positive (CLC LT14) cells.
Cells were removed from the bioreactors on days 3, 6, 10, 11, and 13,
and stained for intracellular antibody. On each day, high-antibody producing
control cells in exponential phase (grown in T-flasks), and Sp2/0 cells were
processed in parallel with cells removed from the bioreactors. Sp2/0 cells
were used as a negative control to assess non-specific binding of the FITC-
conjugated antibody reagents.
Results of flow cytometry of cells from bioreactor #4 are shown in
Figure 1-45. Cells in these samples were stained with the FITC-conjugated
anti (H+L) antibody reagent. Figure III-45a shows the fluorescent intensity of
Sp2/0 cells, and Figure m-45b shows fluorescent intensity of control CLC LT14
cells. Figure m-45c shows the fluorescent intensity observed in cells from the
bioreactor on day 3; it is nearly identical to that of the control cells. On day 6,
in Figure m-45d, 97% of the bioreactor cells are positive for intracellular
antibody, but the distribution is skewed towards lower fluorescence than the
distribution for control cells in m-45b. Figures 1I-45e and m-45f show cells
from days 10 and 13. It can be seen that there is quite a dramatic decline in
intracellular antibody content. On day 10, only 54% of the bioreactor cells
were positive for intracellular antibody, and by day 13, only 44% of the cells
were positive for intracellular antibody. From the distribution of
intracellular IgG in the samples from days 10 and 13, shown in Figures III-45e
and f, it can be seen that there are two subpopulations of cells; one
subpopulation is antibody-negative, and one subpopulation is antibody-
positive. Thus, most of the antibody secreted into the medium is produced by
only a fraction of the cells.
177
_ ___ __ __ I I_~_________q___li~_CX__I
Figure 11-44.
Intracellular Fluorescence of Sp2/0 and High-Producing CLC LT14 Cells
Aliquots of 2 x 106 cells were collected by centrifugation, washed with ice-cold
PBS, permeabilized with 70% ethanol in PBS for 30 minutes on ice, washed
with PBS, and then incubated with 150 pl1 of a 1/15 dilution of one of three
Fab 2' fragments of goat antihuman antibodies conjugated to fluorescein
(FITC) for 30 minutes at room temarature. Cells were then washed with PBS,
resuspended in 1 ml IBS, and kept on ice until analyzed. Previous titrations
ensured that the FITC-conjugated antibody reagent was in excess at a 1/15
dilution. The three FITC-conjugated antibodies used (obtained from Jackson
Laboratories, Inc. W. Baltimore Pike, PA) and their specificities are listed in
Table II-1 in section II.C.7, Materials and Methods.
Samples were run on a Coulter Epics C (Coulter, Hialeah, FL) flow cytometer.
Green fluorescence (FITC) was measured with excitation at 488 nm and
bandpass emission measured at 530 nm. The voltages were adjusted so that
Sp2/0 cells (negative control) and CLC LT14 cells maintained at low density(positive control) were both on scale. The negative cutoff cursor was set so
that >99% of the Sp2/0 cells' green fluorescence fell into the left hand region
of the histogram. Each histogram shows relative cell number versus the log
of green fluorescence.
a. Sp2/0 cells stained with anti (H+L) FITC reagent; b. CLC LT14 cells stained
with anti (H+L) FITC reagent; c. Sp2/0 cells stained with anti (L) FITC
reagent; d. CLC LT14 cells stained with anti (L) FITC reagent; e. Sp2/0 cells
stained with anti (H) FITC reagent; f. CLC LT14 cells stained with anti (H)
FITC reagent.
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a. Sp2/0 Cells Stained with
anti (H+L) Reagent
c. Sp2/0 Cells Stained with
anti (L) Reagent
b. CLC LT14 Cells Stained with
anti (H+L) Reagent
d. CLC LT14 Cells Stained with
anti (L) Reagent
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Figure III-45.
Cytoplasmic Antibody Content of Cells from Bioreactor #4 Stained with
anti-(H+L) FITC-conjugated Antibody Reagent
Sample preparation and flow cytometry settings were as described for Figure
1I-44. Samples of Sp2/0 cells and CLC LT14 cells maintained at low density
were prepared in parallel with samples removed from bioreactor #4 on each
day (only one set shown), and stained with the anti (H+L) FITC-conjugated
antibody reagent.
a. Sp2/0 cells (negative control); b. CLC LT14 cells maintained at low density
(positive control); c. cells removed from bioreactor #4 on day 3; d. cells
removed from bioreactor #4 on day 6; e. cells removed from bioreactor #4 on
day 10; f. cells removed from bioreactor #4 on day 13.
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d) Day 6
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Similar results were obtained using the two other FITC-conjugated
antibody reagents, one specific for the human IgG light chain and one for the
Fc fragment of the heavy chain. Results of staining with the anti-light chain
reagent are shown in Figures III-46a-e, and results of staining with the anti-
heavy chain reagent are shown in Figures III-47a-e. Results for samples from
bioreactors #5 and #6 were similar (data not shown).
Figures III-44 to mI-47 show the fluorescent intensities on a log scale. In
order to quantify the intracellular antibody content, this data was reanalyzed
in two ways. One method of quantifying the intracellular antibody content
was performed using a computer program (EPICS Cytologic Software V2.0,
Coulter Corp., Hialeah, FL) which sums the number of cells in each channel
times the channel number and computes a linear mean.
For the second method of quantifying intracellular antibody, I used the
equation developed by Schmid et al. (1988), shown below, to calculate the
mean fluorescence of the fraction of cells positive for intracellular antibody in
each sample.
linear mean = 1.0273508(logarithmic mean) (2)
I then calculated the value of the mean fluorescence multiplied by the
fraction of antibody-positive cells, for each sample, as shown in equation 42.
linear mean of all cells = (linear mean of aby+ cells)x (42)
(fraction of cells which are aby+)
The numbers obtained were expressed relative to the mean fluorescence of
the high-producing control cells maintained in T-flasks.
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Figure 111-46.
Cytoplasmic Antibody Content of Cells from Bioreactor #4 Stained with
anti-(L) FITC-conjugated Antibody Reagent
Sample preparation and flow cytometry settings were as described for Figure
mH-44. Samples of Sp2/0 cells and CLC LT14 cells maintained at low density
were prepared in parallel with samples removed from bioreactor #4 on each
day (only one set shown), and stained with the anti (L) FITC-conjugated
antibody reagent.
a. Sp2/0 cells (negative control); b. CLC LT14 cells maintained at low density
(positive control); c. cells removed from bioreactor #4 on day 6; d. cells
removed from bioreactor #4 on day 10; e. cells removed from bioreactor #4
on day 13.
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c. Bioreactor #4 Cells Day 6
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d. Bioreactor #4 Cells Day 10
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e. Bioreactor #4 Cells Day 13
Log Green Fluorescence Log Green Fluorescence
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Figure III-47.
Cytoplasmic Antibody Content of Cells from Bioreactor #4 Stained with
anti-(H) FITC-conjugated Antibody Reagent
Sample preparation and flow cytometry settings were as described for Figure
mI-44. Samples of Sp2/0 cells and CLC LT14 cells maintained at low density
were prepared in parallel with samples removed from bioreactor #4 on each
day (only one set shown), and stained with the anti (H) FITC-conjugated
antibody reagent.
a. Sp2/0 cells (negative control); b. CLC LT14 cells maintained at low dens
ity
(positive control); c. cells removed from bioreactor #4 on day 
6; d. cells
removed from bioreactor #4 on day 10; e. cells removed from bioreactor #4
on 
day 
13.
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Figure III-48 shows the mean fluorescence of cells in bioreactors stained
with the anti (H+L) reagent plotted as a function of time in the bioreactors.
The mean fluorescence of each sample was calculated using a software
program to convert log to linear means (described above), and then was
normalized to that of control cells for each day. #4, #5, and #6 in the legend
designate bioreactors #4, #5, and #6, respectively. Included in Figure m-48 are
data obtained with paraformaldehyde permeabilization, which gave identical
results to ethanol permeabilization. "ET" and "PF" designate
permeabilization with either ethanol or paraformaldehyde.
Results of this data transformation indicate that by day 6, the
fluorescent intensity of cells in bioreactors (a measurement of IgG content)
had declined 3 fold. On days 10 and 13, the fluorescent intensity of cells from
the bioreactor is only 0.15 of that of the controls. The mean fluorescence of
cells from reactor #6 on day 13 was about twice that of reactors #4 and #5,
reflecting the fact that the specific productivity in reactor #6 was also twice as
high.
Shown in Figure 111-49 is a plot of the mean fluorescence of cells
stained with the anti (H+L) reagent plotted as a function of time in the
bioreactors (same data as shown in Figure mI-48). However, here the mean
fluorescence was calculated using equations 2 and 42. It can be seen that the
two methods used to calculate the mean fluorescence of cells gave identical
results (compare Figures m1-48 and 111-49).
Figures 111-50 and 11-51 show plots of the mean fluorescence of cells
stained with the anti-L and anti-H reagents, respectively, plotted as a function
of time in the bioreactors. The mean fluorescence was calculated using
equations 2 and 42. The levels of intracellular light chain and heavy chain
decreased coordinately, indicating that synthesis of heavy and light chains
remained balanced. The level of light chain on day 13 was 10% of the control
value; the level of heavy chain was 10% of the control value; in reactors #4
and #5 and 20% of the control value in bioreactor #6.
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Figure III-48.
Mean Intracellular Antibody of Cells from Bioreactors #4-6 Measured Using
anti-(H+L) Reagent and Calculated Using EPICS Cytologics Software
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The mean green fluorescence of samples from reactors #4-6, Sp2/0 cells(negative control) and CLC LT14 cells (positive control) stained with
anti (H+L) FITC-conjugated antibody reagent was calculated using
EPICS Cytologics Software. The mean fluorescence of reactor samples
and Sp2/0 cells on each day were then expressed relative to that of CLC
LT14 cells processed that day (labelled "Control" in figure). Histograms
for the data set labelled "#4 (ET)" are shown in Figure 11145 (data for
other reactors not shown).
Samples labelled "PF" were permeabilized with paraformaldehyde as
described in section II.C.7, and samples were run on a Coulter Epics C(Coulter, Hialeah, FL) flow cytometer (data not shown). Green
fluorescence (FITC) was measured with excitation at 488 nm and
bandpass emission measured at 530 nm. The voltages were adjusted so
that Sp2/0 cells (negative control) and CLC LT14 cells maintained at
low density (positive control) were both on scale. The negative cutoff
cursor was set so that >99% of the Sp2/0 cells' green fluorescence fell
into the left hand region of the histogram. Samples labelled "ET" were
permeabilized and run as described for Figure HI-44.
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Figure III-49.
Mean Intracellular Antibody of Cells from Bioreactors #4-6 Measured Using
anti-(H+L) Reagent and Calculated Using Equation 2 and 42
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The mean green fluorescence of samples from reactors #4-6, Sp2/0 cells(negative control) and CLC LT14 cells (positive control) stained with
anti (H+L) FITC-conjugated antibody reagent was calculated using
equations 2 and 42. The mean fluorescence of reactor samples and
Sp2/0 cells on each day were then expressed relative to that of CLC
LT14 cells processed that day (labelled "Control" in figure). Histograms
for the data set labelled "#4 (ET)" are shown in Figure MI-45 (data for
other reactors not shown). Samples labelled "PF" were permeabilized
with paraformaldehyde as described in section II.C.7 and run as
described for Figure m-48 (data not shown); samples labelled "ET" were
permeabilized and run as described for Figure 111-44.
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Figure III-50.
Mean Intracellular Antibody of Cells from Bioreactors #4-6 Measured
Using anti-(L) Reagent
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The mean green fluorescence of samples from reactors #4-6, Sp2/0 cells(negative control) and CLC LT14 cells (positive control) stained with
anti (L) FITC-conjugated antibody reagent was calculated using
equations 2 and 42. The mean fluorescence of reactor samples and
Sp2/0 cells on each day were then expressed relative to that of CLC
LT14 cells processed that day (labelled "Control" in figure). Histograms
for the data set labelled "#4 (ET)" are shown in Figure m-46 (data for
other reactors not shown). Samples labelled "PF" were permeabilized
with paraformaldehyde as described in section II.C.7 and run as
described in Figure III-48 (data not shown); samples labelled "ET" were
permeabilized as described for Figure 11-44.
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Figure 111-51.
Mean Intracellular Antibody of Cells from Bioreactors #4-6 Measured
Using anti-(H) Reagent
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The mean green fluorescence of samples from reactors #4-6, Sp2/0 cells
(negative control) and CLC LT14 cells (positive control) stained with
anti (H) FITC-conjugated antibody reagent was calculated using
equations 2 and 42. The mean fluorescence of reactor samples and
Sp2 /0 cells on each day were then expressed relative to that of CLC
LT14 cells processed that day (labelled "Control" in figure). Histograms
for the data set labelled "#4 (ET)" are shown in Figure m-47 (data for
other reactors not shown). Samples labelled "PF" were permeabilized
with paraformaldehyde as described in section II.C.7 and run as
described in Figure III-48 (data not shown); samples labelled "ET" were
permeabilized as described for Figure 1I-44.
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The decrease in intracellular antibody correlates quite well to the
decrease in specific antibody production rate observed in the bioreactors.
Figure Mn-52 shows a plot of intracellular antibody as a function of specific
productivity. Also included in Figure III-52 are the relative intracellular
antibody content of cells maintained in culture for varying amounts of time
up to one month (Morrill, 1990) and labelled "cells grown by J. Morrill".
These cells had been removed from bioreactor #1 at different time points,
frozen, thawed, and grown in spinners at low cell density.
With the exception of the data points labelled "Bioreactor day 3
samples" there is a linear correlation between intracellular antibody content
and specific productivity. Linear regression of all data points except the day 3
bioreactor samples gave a correlation coefficient of 0.98.
The data points for the control spinner and for the cells maintained for
varying amounts of time in culture were obtained during exponential
growth, at which time the growth rate and specific productivity are constant,
and cells are at a dynamic steady-state condition. The data points clustered in
the lower left-hand corner of Figure HI-52 were obtained from bioreactor
samples when the specific productivity was changing only very slowly (days
6-13), again a quasi-steady state condition. Here again, the intracellular
antibody content is proportional to the specific productivity, indicating
matched rates of antibody synthesis and secretion. In contrast, the specific
productivity at day 3 in the bioreactors was decreasing rapidly, and it appears
that the rate of synthesis of antibody was not balanced with the rate of
secretion, as the intracellular antibody is higher than expected (see Figure n-
52).
These data show that there is a coordinated downregulation of
immunoglobulin peptide production, which appears to be mediated by some
as yet unidentified condition associated with high cell density in the
perfusion bioreactor. The data in figures 111-50 and rn-51 also show that there
is no "excess" of heavy or light chains; the production of both is decreased in a
coordinated fashion.
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Figure III-52.
Intracellular Antibody Content as a Function of Specific Productivity
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Data shown in Figures I1-49 and I-8 were combined and regraphed.
The relative intracellular antibody content of samples labelled "Cells
grown by J. Morrill" was determined by Morrill (1991).
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5.2 Comparison of Intracellular IgG of Live and Dead
Cells in Bioreactors
In order to assess the contribution of intracellular fluorescence of dead
cells, a second staining protocol was used. The green fluorescense of both
viable and dead cells is measured when cells are permeabilized with ethanol
(see for example Figure III-46). Cells were double stained with ethidium
monoazide (EMA) and FITC-conjugated anti-H chain reagent to
simultaneously determine viability and intracellular antibody. EMA, which
fluoresces red, is excluded by live cells. Cells were first incubated with EMA,
fixed, and then permeabilized with 1% paraformaldehyde and stained for
intracellular antibody using the anti-H chain antibody reagent.
Paraformaldehyde permeabilization was used as ethanol washes out the
EMA. However, paraformaldehyde does not give 100% permeabilization of
the cells (Crissman et al., 1978), and therefore the values for percentage of cells
positive for intracellular antibody were corrected using the values obtained
with ethanol permeabilization for samples on each day.
Use of this protocol allowed me to distinguish four subpopulations of
cells within each sample: dead (EMA+) cells negative for intracellular
antibody, dead cells positive for intracellular antibody, live cells (EMA-)
negative for intracellular antibody, and live cells positive for intracellular
antibody.
Crossplots of red fluorescence (EMA) and green fluorescence (FITC) are
shown in Figures III-53a-f. Quadrant 1 in each figure represent dead cells
negative for intracellular antibody; quadrant 2, dead cells positive for
intracellular antibody; quadrant 3, dead cells negative for intracellular
antibody; and quadrant 4, live cells positive for intracellular antibody. The
characteristics of subpopulations of cells in each quadrant are labelled in panel
53b. Figure III-53a shows results of staining of Sp2/0 cells. As expected, all
cells are in quadrants 1 (dead cells) and 3 (live cells), and none are in
quadrants 2 and 4, where antibody-positive cells are located.
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Figure 111-53.
Crossplots of Cells Double-Stained for Viability and
Intracellular Antibody Content
Aliquots of 2 x 106 cells were collected, washed with PBS, and the cell pellets
were then incubated with ethidium monoazide (EMA) for twelve minutes on
ice. Treatment of cells with EMA was done by adapting a protocol obtained
from Stuart Connor of the Flow Cytometry Lab at MIT. A stock solution of
EMA at 0.1 mg/ml was aliquotted and stored at -200 C, and 20 gl was added to
cell pellets to a final concentration of 1 pg/2 x 106 cells. The EMA was
crosslinked by exposing samples to 10 minutes of white fluorescent light and
2 minutes of ultraviolet light, at a distance of 10 cm. Cells were then washed
with PBS, permeabilized with 1% paraformaldehyde in PBS for 30 minutes on
ice, washed with PBS, and then incubated with a 1/15 dilution of the anti (H)
Fab2' fragment of goat antihuman antibody conjugated to FITC (Jackson
Laboratories, Inc. W. Baltimore Pike, PA cat. # 109-096-098) for 30 minutes at
room temperature. Cells were then washed with PBS, suspended in 1 ml
PBS, and kept on ice until analyzed.
Samples were run on a Coulter Epics C (Coulter, Hialeah, FL) flow cytometer.
Green fluorescence (FITC) was measured with excitation at 488 nm and
bandpass emission measured at 530 nm. Sp2/0 cells were used to assess non-
specific binding of the FITC-conjugated antibody reagents. Flow cytometer
voltages were adjusted so that both the positive and negative sample peaks
were on scale. Red fluorescence (EMA) was measured with excitation at 488
nm and bandpass emission measured at 610 nm. Shown are crossplots of red
fluorescence (EMA) versus green fluorescence (antibody content).
a): Sp2/0 cells at low density (negative control); b): CLC LT14 cells at low
density (positive control); c): cells removed from reactor #4 on day 3; d):
cells removed from reactor #4 on day 6; e): cells removed from reactor #4 on
day 11; f): cells removed from reactor #4 on day 13.
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Figure III-53b shows control CLC LT14 cells. Also as expected, most of
the cells (68%) are in quadrant 4 (live, aby+). 21% of the cells are in quadrant 3
(live, aby-), and these represent cells which are truly antibody negative and
cells not permeabilized by the paraformaldehyde. Since 98% of all cells from
the same sample on the same day were aby+ when permeabilized with
ethanol, I made the assumption that the paraformaldehyde permeabilization
efficiency is the same for live and dead cells, and corrected all values to reflect
the % of cells positive for antibody on that day for that sample when
permeabilized with ethanol. These corrected values are shown in Table 111-8.
Figure III-53c shows cells removed from bioreactor #4 on day 3; and the
distributions of cells are quite similar to those for control cells except that the
green fluorescence of aby+ cells (quadrants 2 and 4) is reduced as compared to
the control cells. Figure I-53d shows cells at day 6, and the green
fluorescence of aby+ cells (quadrants 2 and 4) is reduced even further. Figures
III-53e and EI-53f show cells at day 11 and day 13. Here it can be seen that the
bulk of the cells are aby- (quadrants 1 and 3) and that the percentage of dead
cells (EMA+, quadrants 1 and 2) has increased to 17% at day 11 and 24% at day
13. The viability as judged by EMA staining was similar to viability as
measured by trypan blue staining.
A summary of this data is shown in Table 1I-8. The fraction of dead
cells positive for intracellular antibody (column 2) remained fairly constant at
6-12%, and did not increase with time in the bioreactor. In addition, the ratio
of live to dead cells within each category, namely aby+ and aby-, was roughly
the same on each day (compare columns 5 and 6). This indicates that there is
not differential "killing" of antibody positive cells, ie, that the death rate for
all cells is the same. It also indicates that the flow cytometry data shown in
Figures 111-45-47 is not skewed in any way, since the distributions of
intracellular antibody for both live and dead cells are similar.
197
M ' __ i
Table 111-8.
Intracellular Antibody Content of Viable and Nonviable Cells in Reactor #4
Data shown in Figure 1I-53 was analyzed.
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Sample Percentage of Cells in Each Category Ratios
Column 1 2 3 4 5 6
aby+ EMA- aby+ EMA+ aby- EMA- aby- EMA+ aby+ aby-
(live) (dead) (live) (dead) (live/dead)
Sp2/0 0 0 91 9 - -
Control 87 10 2 0.2 - -
(low density)
Bioreactor #4
Day 3 91 8 2 0.2 12 10
Day 6 79 12 8 1 7 7
Day 11 31 6 52 11 5 5
Day 13 18 6 58 18 3 3
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D. Reversibility of Downshift of Immunoglobulin Production
1. Comparison of Cells Maintained at High and Low Cell
Density in Batch Spinner Experiments
A number of experiments were performed to show that the
downregulation of immunoglobulin production was not due to a permanent
change undergone by the cells while growing in the reactors. An example of
such a permanent change is loss of the gene(s) for immunoglobulin
production and outgrowth of a nonproducer population, which could be
favored by the reactor environment.
To show that the downregulation of immunoglobulin production was
reversible, cells which had been removed from the perfusion reactors were
inoculated into batch spinners, and the growth and antibody production in
these batch spinners was compared to that of cells maintained in T-flasks at
low cell density for the same number of generations. Average specific
productivity was estimated over 2-3 days in exponential growth. This
procedure takes into account the fact that the productivity of these cells
declines with time in culture. For cells maintained at low cell density, the
specific productivity declines from 0.2 pg/c-hr by about a factor of 3 over a
period of 4 to 6 weeks.
The history of the cells inoculated into and removed from the reactors
is shown schematically in Figure III-54. One vial of cells was expanded into
spinner culture and used to inoculate the first three bioreactors, and also
maintained at low cell density by passaging in T-flasks. Cells for control
cultures were inoculated into 100 ml batch spinner cultures at 5 x 104 cells/ml
from T-flasks.
To account for loss in production of the cells at low cell density over
time, parallel cultures were run during the six weeks of the first set of
bioreactor runs (#1-3). About once a week duplicate, batch spinner cultures
were inoculated from cells maintained in T-flasks. The specific productivity
of the cells used to inoculate reactors #1-3, maintained at low cell density, is
shown in Figure 111-55. Time in culture is referenced to the day the first three
bioreactors were inoculated (see Figure 1-55).
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Figure III-54.
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Figure III-55.
Specific Productivity in Batch Spinners of Cells used to
Inoculate Bioreactors #1-3
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CLC LT14 cells from the same vial used to inoculate bioreactors #1-3
were maintained at low density in T-flasks. On the days indicated,
duplicate spinners were inoculated at 5 x 104 cells/ml into DMEM*
supplementea witn -'/o rHIS. -nhe specitic productivity ot each spinner
over days 0-3 was calculated using equation 11, and average specific
productivties of duplicates are shown. The open square shows the
average specific productivity of CLC LT14 cells from a new vial, also
measured in batch spinner culture.
The closed squares indicate cells maintained from the same vial that was used
to inoculate the bioreactors, and the open circle indicates the specific
productivity of cells from a fresh vial of cells. In one month of culture, the
specific productivity declined 3 fold from about 0.15 to 0.05 pg/cell-hr.
To test the productivity of cells that had been grown in the bioreactors,
cells frozen from bioreactor #1 were thawed, grown in T-flasks for about 5
days, and then inoculated into batch spinners. Figure I1-56 plots specific
productivity of each spinner set as a function of days in the bioreactor. Cells
frozen from bioreactor #1 on days 3, 7, and 21 were tested in one set
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(experiment 1), and cells from days 2, 10, and 20 were tested in another
(experiment 2). In Figure I-56, the specific productivity over 3 days of each
culture is plotted versus the day the sample was removed from the bioreactor.
The productivity decreased from about 0.16 to .04 pg/cell-h from day 2 to day
21, representing an overall loss in specific productivity of 75% over 3 weeks.
This is comparable to the loss in specific productivity observed in 4-5 weeks at
low cell density with the control cells (see Figure 111-55). The specific antibody
production in spinners of cells removed from reactor #1 on days 20 and 21was
much greater (qP = 0.05 pg/c-hr) than in the high cell density bioreactor (qP =
0.006 pg/c-hr).
Figure III-56.
Specific Productivity of Spinners Inoculated
with Cells Removed from Reactor #1 on the Days Indicated
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Cells removed from reactor #1 were frozen, thawed, and grown
in T-flasks at low density for approximately one week. Cells
frozen from reactor #1 on days 3, 7, and 21 were tested in parallel(Exp. 1), and cells frozen from reactor #1 on days 2, 10, and 20
were tested in parallel in a second experiment (Exp. 2). On the
days indicated, duplicate spinners were inoculated at 5 x 104
cells/ml into DMEM* supplemented with 5% FBS. The specific
productivity of each spinner over days 0-3 was calculated using
equation 11.
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It was possible, though unlikely, that cells recovered from frozen cell
pellets did not represent the population of cells inside the bioreactor, that, for
example, there could be two populations of cells in the bioreactors, a "low or
non-producing" subpopulation and the "normally producing"
subpopulation, and that the hypothetical "low producing" cells in the
bioreactor were not as resistant to freezing and thawing as the "normally
producing" cells.
This possibility was ruled out during the second set of bioreactor runs
(#4-6). A fresh vial of cells was expanded into spinner culture and used to
inoculate the three bioreactors, and also maintained at low cell density by
passaging in T-flasks. About every five days, cells were removed from the
bioreactors and directly inoculated into batch spinners. Control spinners were
inoculated from cells maintained in T-flasks at low cell density. Specific
productivity in the batch spinners was calculated over days 1-3, during
exponential growth.
Figure M-57 plots specific productivity of each spinner set as a function
of days in the bioreactor. Cells were removed from bioreactors on days 5, 10,
and 14, and inoculated directly into 100 ml batch spinners containing DMEM*
with 4% FBS at 5 x 104 c/ml. Day 0 (inoculum) cells were taken from the cells
expanded in spinners and inoculated into the bioreactors. The specific
productivities for spinners started on days 0, 5, and 10 are quite similar to the
controls for those days, ranging from 0.1 to 0.25 pg/c-hr. The specific
productivity data for spinners started on day 14 showed more scatter and
therefore were subject to a statistical test (Test of equality of Several Means)
(Hogg and Tanis, 1988) to determine if the qPs for cells removed from the
bioreactors are statistically different from those of the controls. This
calculation showed that the specific productivity of cells removed from the
bioreactors at day 14 are indistinguishable from the controls at the 95%
confidence limit.
Thus, these results show that cells removed from the bioreactors to low
density grow and secrete antibody normally and are in fact indistinguishable
from control cells grown for the same number of generations.
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Figure 111-57.
Comparison of Specific Productivity in Batch Spinners of Cells
Maintained at Low Density and Cells Removed from Bioreactors #4-6
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Cells were removed from reactors #4-6 on the days indicated and
inoculated into batch spinners at 5 x 104 cells/ml into DMEM*
supplemented with 4% FBS. Day 0 (inoculum) cells were taken
from the cells expanded in spinners and used to inoculate
reactors #4-6. In parallel with each set of spinners inoculated
from the reactors, CLC LT14 cells from the same lot used to
inocuate the reactors but maintained at low density were also
inoculated into batch spinners. The specific productivity over
days 1-3 was calculated using equation 11.
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2. Comparison of Plating Efficiency of Cells Maintained at
High and Low Cell Density
Cells were also cloned at limiting dilution to compare the distributions
of antibody productivity and the plating efficiency of cells grown in
bioreactors or maintained at low cell density.
Samples of cells frozen and later thawed from bioreactor #1 were
cloned and the supernatants screened for antibody production. Samples from
bioreactor #1 from days 3, 7 and 21 were plated at 0.2 cells/well, and the
plating efficiency ranged from 38 to 88 percent. After 13 days, supernatants
from clones were removed, and assayed for antibody concentration by Morrill
(1990), using a software program (Assayzap). Figure HI-58 shows the
distribution of titers in clones from the three samples. The percent of clones
is plotted versus antibody concentration (glg/ml) in the supernatant, in 0.5
gg/ml intervals. The interval labelled "10" includes all supernatants with
monoclonal antibody concentrations of 6 to 10 gg/ml.
Table 11-9 lists number of clones tested, and mean and median
antibody concentrations. As a control for this cloning experiment, a stock
culture maintained at low density in T-flasks prior to cloning, of age between
the day 7 and day 21 samples, was also tested and results are shown in Table
111-9.
The distribution at day 3 is the broadest, containing no zero producing
clones. Ten percent of day 3 supernatants contained >6 gg/ml antibody. The
distributions of days 7 and 21 are skewed to lower secreting clones, however
greater than 95% of the clones produced antibody. For day 21 no clones with
titers of greater than 5 Cgg/ml were found. The median antibody
concentrations deceased three fold from day 3 to day 21. This three fold
decrease corresponds to the three fold decrease in specific productivity
observed in the batch spinners experiments. Once again, the decrease in
production ability declines with increasing age of the cells. The data
summarized in the histogram below confirm that the majority of the cells
secrete antibody and show that the overall population decreases in
production ability, as opposed to the appearance of non-secreting mutants.
205
OM E1 I' I II ·'
Figure 111-58.
Antibody Titers of Clones from Cells Removed from Reactor #1
on Days 3, 7, and 21 and Plated at Limiting Dilution
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Samples of cells frozen and later thawed from bioreactor #1 were
cloned and the supernatants screened for antibody production.
Samples from bioreactor #1 from days 3, 7 and 21 were plated at 0.2
cells/well, and the plating efficiency ranged from 38 to 88 percent. CLC
LT14 cells maintained at low density were also plated in parallel with
these cultures (data shown in Table IE-9). After 13 days, supernatants
from clones were removed, and assayed for antibody concentration by
Morrill (1990), using a software program (Assayzap).
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Table 111-9.
Mean and Median Antibody Concentration for Clonal Populations
Days in Total Days # of Mean IgG Median IgG
Bioreactor in culture clones (gg/ml) (9pg/ml)
3 14 65 3.3 2.9
7 18 129 2.4 2.0
21 32 122 1.1 1.0
Stock 24 97 2.0 1.7
Samples of cells frozen and later thawed from bioreactor #1 were
cloned and the supernatants screened for antibody production.
Samples from bioreactor #1 from days 3, 7 and 21 were plated at 0.2
cells/well, and the plating efficiency ranged from 38 to 88 percent. CLC
LT14 cells maintained at low density were also plated in parallel with
these cultures. After 13 days, supernatants from clones were removed,
and assayed for antibody concentration by Morrill (1990), using a
software program (Assayzap). Some of this data is shown in Figure II-
58.
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Frame and Hu (1990) also found a decrease in specific productivity in
hybridomas as a function of time in culture. They cloned cells removed from
cultures at several time points at limiting dilution and assayed clone
supernatants, and found that the fraction of producing cells decreased from
98% to about 50% over 60 days in culture. For the hybridoma they used, it
appeared that rather than a shift of the population towards lower
productivity, as seen for the CLC LT14 cells, they observed the appearance of a
non-antibody producing subpopulation.
The results presented in Figure 1I-58 and Table nI-9 indicate that the
antibody secretion patterns of clones recovered from cells frozen and later
thawed from bioreactor #1 were the same as those of cells maintained at low
cell density in T-flasks. Therefore, only the colony-forming potential of cells
removed directly from bioreactors #4-6 was compared to that of cells
maintained at low cell density in T-flasks. Cells were plated at limiting
dilution on days 0, 5, 7 and 12 (0.3 c/well on days 0, 5, and 7 and 1 c/well on
day 12). Colony formation was scored at day 14. The absolute plating
efficiencies for cells removed from the bioreactors on the days indicated as
compared to control cells from T-flasks are summarized in Figure M-59. The
plating efficiencies, calculated using the viable cell number, ranged from 12 to
54%. The low absolute plating efficiency observed for all cells plated on day 12
most likely is due to a suboptimal incubator condition (such as a change in
pH or temperature). However, it can be seen that the range of plating
efficiencies of the controls are quite similar to those of cells removed from the
bioreactors, suggesting that a similar fraction of cells grown either at high
density or low density are capable of colony formation.
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Figure 11-59.
Plating Efficiency of Cells Removed from Bioreactors #4-6 on the Days
Indicated as Compared to Cells Maintained at Low Density
*0
0 2 4 6 8 10 12
Time - Days in Bioreactor
Cells were removed from reactors #4-6 and plated at limiting dilution
on days 0, 5, 7 and 12 (0.3 c/well on days 0, 5, and 7 and 1 c/well on day
12). On each day when cells from the reactors were plated, CLC LT14
cells maintained at low density were also plated. Plating efficiency per
viable cell (P.E.) was calculted using the following formula: P. E. = -
In(empty wells/total wells) / (cell/well plated) x 100. Colony formation
was scored at day 14.
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3. Recovery of Productivity Measured by Flow Cytometry
A third method of assessing reversibility is to use flow cytometry to
measure the intracellular IgG content of cells. The intracellular
immunoglobulin content of the cells correlates with specific productivity, as
cells with a high specific productivity have a high intracellular
immunoglobulin content and those at low productvity (from bioreactors)
have a low intracellular immunoglobulin content (discussed in detail in
Section m.C.5.2). Cells were permeabilized and stained with fluorescein-
conjugated antibodies to the IgG produced by the cells, and the fluorescent
intensity, a measure of the intracellular IgG content, was measured via flow
cytometry.
To assess reversibility, cells were removed from bioreactors #4-6 on day
9, when the specific productivity had declined from 0.15 pg/c-hr to 0.02 pg/c-
hr in reactors #4 and #5, and to 0.04 pg/c-hr in #6, placed into batch spinners at
2 x 105 c/ml, and then subject to flow cytometry after 1 and 2 days. Cells were
stained with FITC-conjugated Fab2' portion of each of the three goat
antihuman antibodies, anti (H+L), anti (H), and anti (L). Control (high-
producing cells maintained in T-flasks) and non-antibody producing Sp2/0
cells (negative staining control) were also stained simultaneously on each
day.
Results of flow cytometric analyses for cells removed from reactors #4
are shown in Figures 111-60 through 111-62. Relative cell number is plotted as a
function of fluorescent intensity (log green fluorescence). Since the FITC-
conjugated antibody was in excess, the fluorescent intensity is proportional to
the intracellular IgG content. Figure 111-60 shows results of staining with the
anti (H+L) antibody reagent, Figure III-61 shows results of staining with the
anti(H) antibody reagent,and Figure III-62 shows results of staining with the
anti (L) antibody reagent. Panel a in each figure shows Sp2/0 cells (negative
control), panel b high-producing control cells (positive control), and panel c
cells from reactor #4 at day 10. Panels d and e show cells removed from
reactor #4 and placed into a batch spinner after one (d) and two (e) days at low
density.
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Figure III-60.
Intracellular Antibody Content of Cells Removed from Bioreactor #4 and
Stained with anti-(H+L) FITC-conjugated Antibody Reagent
Aliquots of 2 x 106 cells were collected by centrifugation, washed with ice-cold
PBS, permeabilized with 70% ethanol in PBS for 30 minutes on ice, washed
with PBS, and then incubated with 150 il of a 1/15 dilution of one of three
Fab 2' fragments of goat antihuman antibodies conjugated to fluorescein
(FITC) for 30 minutes at room temperature. Cells were then washed with
PBS, resuspended in 1 ml PBS, and kept on ice until analyzed. Previous
titrations ensured that the FITC-conjugated antibody reagent was in excess at a
1/15 dilution. The anti (H+L) FITC-conjugated antibody reagent was obtained
from Jackson Laboratories, Inc. W. Baltimore Pike, PA (cat. # 109-096-088).
Samples were run on a Coulter Epics C (Coulter, Hialeah, FL) flow cytometer.
Green fluorescence (FITC) was measured with excitation at 488 nm and
bandpass emission measured at 530 nm. The voltages were adjusted so that
Sp2/0 cells (negative control) and CLC LT14 cells maintained at low density(positive control) were both on scale. The negative cutoff cursor was set so
that >99% of the Sp2/0 cells' green fluorescence fell into the left hand region
of the histogram. Each histogram shows relative cell number versus the log
of green fluorescence. Sp2/0 cells and CLC LT14 control cells were run with
samples on each day, but only one set is shown. Cells were removed from
reactor #4 on day 9 and placed into a batch spinner at 2 x 105 cells/ml into
DMEM* supplemented with 4% FBS.
a): Sp2/0 cells stained with anti (H+L) FITC reagent; b): CLC LT14 cells
stained with anti (H+L) FITC reagent (positive control); c): cells removed
from reactor #4 on day 10 stained with anti (H+L) FITC reagent; d): cells
removed from reactor #4 after one day of growth at low density, stained with
anti (H+L) FITC reagent; e): cells removed from reactor #4 after two days of
growth at low density, stained with anti (H+L) FITC reagent;
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b) Control cells
Log Green Fluorescence
c) Bioreactor cells on day 10
Log Green Fluorescence
d) Cells in spinner after 1 day
Log Green Fluorescence
Log Green Fluorescence
e) Cells in spinner after 2 days
Log Green Fluorescence
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Figure I1-61.
Intracellular Antibody Content of Cells Removed from Bioreactor and
Stained with anti-(H) FITC-conjugated Antibody Reagent
Staining and flow cytometry was as described for Figure m-60, except that
samples and positive and negative controls were stained with the FITC-
conjugated reagent specific for the heavy chain (Jackson Laboratories, Inc. W.
Baltimore Pike, PA, cat. # 109-096-098).
a): Sp2/0 cells stained with anti (H) FITC reagent; b): CLC LT14 cells stained
with anti (H) FITC reagent (positive control); c): cells removed from reactor
#4 on day 10 stained with anti (H) FITC reagent; d): cells removed from
reactor #4 after one day of growth at low density, stained with anti (H) FITC
reagent; e):* cells removed from reactor #4 after two days of growth at low
density, stained with anti (H) FITC reagent;
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Figure III-62.
Intracellular Antibody Content of Cells Removed from Bioreactor and
Stained with anti-(L) FITC-conjugated Antibody Reagent
Staining and flow cytometry was as described for Figure I-60, except that
samples and positive and negative controls were stained with the FITC-
conjugated reagent specific for the light chain (Jackson Laboratories, Inc. W.
Baltimore Pike, PA, cat. # 109-096-097).
a): Sp2/0 cells stained with anti (L) FITC reagent; b): CLC LT14 cells stained
with anti (L) FITC reagent (positive control); c): cells removed from reactor
#4 on day 10 stained with anti (L) FITC reagent; d): cells removed from
reactor #4 after one day of growth at low density, stained with anti (L) FITC
reagent; e):* cells removed from reactor #4 after two days of growth at low
density, stained with anti (L) FITC reagent;
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a) Sp2/O cells
Log Green Fluorescence
c) Bioreactor cells on day 10
Log Green Fluorescence
d) Cells in spinner after 1 day
b) Control cells
Log Green Fluorescence
e) Cells in spinner after 2 days
Log Green Fluorescence Log Green Fluorescence
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When cells are removed from the environment of the perfusion reactors and
resuspended in fresh medium at low cell density, the intracellular IgG
content shows a bimodal distribution after one day (d) of growth, and
recovers to the same level seen in exponential growth after 2 days (e). The
cells removed from the bioreactor are indistinguishable from control cells
after two days at low cell density (compare panels b and e in each figure).
Results for cells removed from reactors #5 and #6 were similar (data not
shown).
The shift of these cells to high fluorescence is quite striking, and occurs
over about 2-2.5 generations. It can be seen that the entire population of cells
shifts to high fluorescence. This rapid and complete shift to high intracellular
IgG disproves the hypothesis of outgrowth of a clonal subpopulation.
These results again indicate that the downregulation of antibody
production observed in the bioreactors is reversible, and that the time constant
of this shift is on the order of 2 days, or about 2.5 generations.
To summarize: The cells which have been grown at high cell density in
bioreactors have been tested for growth and antibody production in batch
spinners. At high cell density, in the bioreactors, these cells have shown a
decline in antibody productivity which is reversible, as shown by recovery of
specific productivity in batch spinners identical to that of cells continually
maintained at low cell density. In addition, the ability to form clones, a more
stringent measure of viability than growth in batch spinners, is the same for
cells plated from bioreactors at high cell density and cells plated from stocks
continually maintained at low cell density in T-flasks.
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IV. Discussion
A. Growth and Non-growth-associated Immunoglobulin
Production
The production kinetics of the CLC LT14 cell line in batch culture are
growth-associated, that is, immunoglobulin production is highest during
exponential growth (results shown in Section III.A.1). Kinetics of this type
have been observed for many hybridomas grown in batch culture (see for
example Miller et al., 1988; Tharakan and Chau, 1986b). For example, Miller et
al. (1988) grew an Sp2/0-derived mouse hybridoma producing an IgG2a in
batch culture, and found that specific antibody production was highest over
the first three days at the highest growth rate. The specific productivity in
batch culture decreased from 1.46 pg/c-hr during exponential growth at a
growth rate of 0.052 hr-1 (doubling time of 13.3 hours) to 0.83 pg/c-hr during
stationary phase at a growth rate of 0.021 hr-1 (doubling time of 33 hours).
However, since conditions in batch culture are constantly changing,
they are not appropriate determining the relationship between the growth
rate and specific productivity. Quasi-steady-state conditions exist only during
exponential growth during batch culture, which is why I have used the
specific rate of production during exponential growth in spinners to compare
the specific productivities of cells removed from the bioreactors to those of
cells maintained at low cell density.
Many other groups have found that the rates of antibody secretion are
nearly constant throughout a batch culture, even when the viable cell
concentration is rapidly decreasing (Reuveny et al., 1985; Merten et al., 1985;
Boraston et al., 1984; Leno et al., 1991). Possible reasons for this phenomenon
are that the cells release surface bound or intracellular antibody as they are
dying, or that intracellular antibody from lysed cells is released into the
supernatant.
In order to determine the relationship between the growth rate and
specific productivity, cells are grown in continuous culture so that steady-state
conditions are obtained. In continuous culture, medium is added and
medium containing cells is withdrawn at the same rate, allowing
achievement of a steady state, where the growth rate is equal to the dilution
rate. This type of culture is termed chemostat culture. Varying the medium
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feed allows control of the specific growth rate, and the cell density may be
controlled by designing the medium so that a single nutrient or metabolite is
limiting. In a turbidostat, the medium feed is adjusted to maintain a constant
cell density so that the growth rate of the cells is near or at the maximum.
When I grew cells in semi-continuous culture at different levels of
dissolved oxygen, I found that production was not growth-associated (see
Section I.A.2). Instead, specific productivity increased 2-fold as the doubling
time increased, from about 0.05 pg/c-hr at a doubling time of 15 hours to 0.11
pg/c-hr at a doubling time of 19.5 hours. At a doubling time of 30.8 hours, the
specific productivity decreased to 0.093 pg/c-hr. Since these doubling times
were obtained by growing cells at different levels of dissolved oxygen, it is not
possible to tell if the primary cause of the increased productivity is due to the
effect of oxygen on cell metabolism or due to the increased doubling time.
In the perfusion cultures, the growth rate did not appear to change
significantly as the cell density increased (see section III.B.2). However, the
aim of those experiments was not to examine the effect of growth rate on
productivity, but rather to examine the effect of cell density on productivity.
In order to examine the effect of growth rate on productivity, it would
be necessary to modify the perfusion bioreactor to include a separate bleed
stream to allow for removal of cells from the bioreactor. This would allow
the cell density to be varied independently of the dilution rate, at a constant
growth rate. This can be done by varying the rates of removal from the cell
separator and the bleed stream. This type of experiment would answer the
question of whether the decline in specific productivity is dependent on cell
density, as the data strongly implies, or due to a change in the growth rate.
A number of workers (Reuveny et al., 1986b; Miller et al., 1988; Merten
et al., 1985; Ramirez and Mutharasan, 1990; Ray et al., 1989) have reported that
in continuous culture antibody production is negatively associated with the
growth rate, with higher specific rates of antibody secretion at slower growth
rates.
Miller et al. (1988) grew an Sp2/0-derived mouse hybridoma producing
an IgG2a in continuous culture at dilution rates from 0.013 to 0.055 hr-1. In
continuous culture, the specific productivity was 0.60 pg/c-hr at a growth rate
of 0.022 hr-1 (doubling time of 31.5 hours) and decreased to 0.30 pg/c-hr at a
growth rate of 0.056 hr-1 (doubling time of 12.4 hours). From the continuous
culture data, it may be seen that the specific productivity is negatively growth
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associated. Analysis of only the batch data (discussed above), however, would
have lead to the conclusion that the specific productivity is growth associated.
Miller et al. (1988) also found that the specific productivity in continuous
culture was constant at pH 7.1-7.4, but increased by a factor of three at pH 6.8,
which was quite unfavorable to growth. They suggest that the increase in
specific productivity at low pH and low growth rates is due to stress, and
perhaps associated with induction of heat shock proteins.
Ramirez and Mutharasan (1990), using a murine hybridoma grown in
semi-continuous culture and found that the specific productivity per viable
cell increased two-fold as the growth rate decreased from 0.035 hr-1 to 0.02 hr-1
(doubling time 19.8 to 34.7 hours). The specific productivity increased by
another factor of two as the growth rate decreased to 0.011 hr-1 (doubling time
63 hours). Their results are similar to those of Miller et al. (1988).
Ray et al. (1989) grew a murine hybridoma at dilution rates from 0.01 to
0.04 hr-1. Specific productivity was 1.5 pg/c-hr at a dilution rate of 0.01
(doubling time 31.5 hours), increased to 2.5 pg/c-hr at a dilution rate of 0.02
(doubling time 27.7 hours), and then decreased to 1.2 pg/c-hr at dilution rates
of 0.025-0.04 hr-1 (doubling times between 22.4 and 17.3 hours). It appears that
above a critical growth rate, antibody productivity decreased with increasing
growth rate.
There has been much speculation as to the possible mechanisms for
increased specific productivity at slower growth rates. Miller et al. (1988)
suggested that increased productivity at low growth rates and unfavorable pH
could be due to stress, which is known to induce the synthesis of heat shock
proteins. One of the members of the family of heat shock proteins is heavy
chain binding protein (Bip), which is thought to have a role in protein
folding, retention, and assembly. Bip is a 78 kd protein resident in the ER
(Haas and Wabl, 1983; Bole et al., 1986; Munro and Pelham, 1986) and nascent,
unfolded, or unassembled proteins, including immunoglobulin heavy
chains, are transiently complexed with Bip (Bole et al., 1986; Gething et al.,
1986). It is conceivable that in the presence of elevated levels of Bip,
immunoglobulin processing rates are enhanced, leading to increased rates of
secretion.
It has also been suggested that the enhanced rates of antibody
production at slower growth rates is due to an increase in the number of cells
in G1 phase. A number of workers have also shown that immunoglobulin
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synthesis and secretion are cell-cycle dependent (discussed in Section I.D.2). A
number of investigators have reported that the maximum rate of
immunoglobulin synthesis occurs in late G1 or early S phase (Byars and
Kidson, 1970; Al-Rubeai and Emery, 1990) and is 2-3 fold that seen during
mitosis. The time required for a cell to complete the S, G2, and M phases
remains approximately constant independent of the growth rate, with the
length of the G1 phase increasing with a decrease in the growth rate (Alberts
et al,, 1983a). Thus, at increased doubling times, a larger fraction of cells is in
G1 phase, when the rate of antibody secretion is at a maximum, and a smaller
proportion of cells is in mitosis, when the rate of antibody secretion is lowest.
Antibody production may, however, also be influenced be the
particular nutrient that was growth limiting in a particular system, and on
whether growth was substrate or waste product limited (Birch et al., 1985). For
example, Birch et al. (1985) grew a murine hybridoma line (NB1) in
continuous culture at growth rates from 0.02 to 0.042 hr-1 (doubling times
from 34.7 to 16.5 hours). Specific antibody production at a growth rate of 0.02
hr-1 was 0.3 pg/c-hr when the limiting nutrient was either glutamine,
glucose, or oxygen. At a growth rate of 0.042 hr-1, the specific productivity
increased to 0.38 pg/c-hr when glutamine was the limiting nutrient, but
decreased to 0.22 pg/c-hr when either glucose or oxygen were the limiting
nutrients.
In contrast to results suggesting that specific productivity is negatively
associated with the growth rate, Robinson and Memmert (1991) showed that
the specific rate of antibody production increased with the growth rate. They
grew a recombinant Sp2/0-derived transfectoma (ATCC 1581) in continuous
culture in serum-free medium at dilution rates ranging from 0.21 to 1.02
volumes/day. The growth rate at these dilution rates varied from 0.016 hr-1
to 0.042 hr-1 (doubling times 43.8 to 16.3 hours). Specific productivity of the
recombinant immunoglobulin was strictly growth-associated, with the qP
increasing linearly with the growth rate. The specific productivity increased
from 0.58 pg/c-hr to 3.17 pg/c-hr, a 5.4 fold increase.
These production kinetics are quite distinct from those observed for
hybridomas, but obviously all recombinant cell lines do not show these types
of production kinetics, as I showed that specific productivity in semi-
continuous culture for recombinant C46 cells was not growth-associated.
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In a hybridoma, the genes for heavy and light immunoglobulin chain
are in the same configuration as in a plasma cell or a myeloma, while for a
transfectoma, the H and L genes are part of a plasmid which is stably
integrated into the host cell line. The regulation of exogenously introduced
immunoglobulin genes has been shown to be differently regulated than
endogenous immunoglobulin genes (Hendricks et al., 1989).
For example, Hendricks et al. (1989) compared the level of endogenous
transcription from the light chain gene of myeloma line J558L to that of a
immunoglobulin gene transfected into these cells. The transfected J558L cells
contained one correctly integrated copy of the plasmid, but the level of RNA
produced from the plasmid was only about 25% of the amount transcribed
from the endogenous lambda gene. Nuclear runoff showed that transcription
from the plasmid was 38% of that of the endogenous lambda gene; thus, the
difference in the level of mRNA was largely attributable to a difference in
expression. They suggest that the difference in expression may be due to the
different chromosomal locations of the endogenous and transfected
immunoglobulin sequences, as chromosomal location may affect
transcription (Hendricks et al., 1988).
Classical microbiology divides production into "growth associated" and
"non-growth associated". Some products are synthesized in a growth
associated fashion, such as vitamins and amino acids (Wang et al., 1979),
while others, such as many antibiotics, notably penicillin, are synthesized
primarily at very low growth rates, 75-80% less than the maximum growth
rate during exponential growth (Demain et al., 1983). Ludeking and Piret
(1959) found that the rate of product formation in fermentations could be
described by:
qP = ag + (43)
In this model, a is the factor for growth-associated antibody production
(pg/cell), g is the growth rate (hr-1), and 3 is the growth-independent portion
of antibody production (pg/cell-hr). For products which are totally growth-
associated, 0 is zero; for products which are totally non-growth associated, a is
zero. This model predicts that there is a linear relationship between specific
productivity and the growth rate.
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Figure IV-1 shows specific productivity in continuous culture plotted
as a function of growth rate and doubling time for a number of
immunoglobulin-producing cell lines. Data from the literature, as well as my
results with the C46 cells, have been summarized in Figure IV-1. The data
obtained by Robinson and Memmert (1991) are the only set where antibody
production is clearly growth-associated and fit the model of Ludeking and
Piret. All of the other data (1-6 in the figure legend) indicate that specific
productivity increases with decreased growth rate but show a non-linear
relationship between antibody production and the growth rate, and thus do
not fit the model developed by Ludeking and Piret.
Interestingly, there is only a 2-4 fold variation in specific productivity
for the hybridomas and transfectoma (1-6 in the figure legend) where
productivity is not growth-associated over a wide range of doubling times (for
example from 12.3 to 30.2 hours (1 in the figure legend)). Robinson and
Memmert (1991) (7 in the figure legend) found a 5.4-fold variation in specific
productivity when the doubling time varied from 16.3 to 43.8 hours.
The fact that a number of cell lines show only a 2-5 fold variation in
specific productivity suggests, but does not prove, that the 10-20 fold decrease
in the rate of antibody production observed in the perfusion bioreactors
(Section m.B.3) is not due to a phenomenon related to a possible decrease in
the growth rate.
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Figure IV-1.
Specific Rates of Antibody Production in Continous Culture
as a Function of Growth Rate
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B. Long-term Stability of Immunoglobulin Production
We have observed that the specific productivity of the CLC LT14 cells
declines 3-fold over a period of one month in culture. Instability of
hybridomas in long-term culture is quite common, and has been observed by
many others.
The rate of loss of monoclonal antibody production has been reported
at 10-2-10-5 per cell-generation (Galfrd et al., 1980; Gardner et al., 1985). Jick and
Wabl (1987) measured the rate of mutation for gt chains in a pre-B cell line,
18-81, and found that large deletions in the constant region arose at a rate of
1.7 x 10-5 per cell generation and small deletions at a rate of 1.4 x 10-7. In
previous work (Wabl et al., 1985; Meyer et al., 1986) they had determined that
the rate of mutation at the variable segment in this cell line was 10-5 per base
pair per cell generation.
Baumal et al. (1973) measured the rate of loss of H and L chain synthesis
in several IgG-producing myeloma lines and clonal derivatives. In MPC 11
cells, they found the rate of loss of H chain production, where cells went from
H+L+ to L+ to be 1.1 x 10-3 per cell per generation. A similar rate of loss of
heavy chain production (1 x 10-3 per cell-generation) was found for P3 cells,
derived from the MOPC 21 myeloma. Loss of both H and L chain synthesis
was measured at 0.4 x 10-3 per cell-generation in an MPC 11 clone, and at 2 x
10-3 per cell-generation for C1 cells, derived from the X5563 myeloma.
However, the rates of mutation to resistance to 6-thioguanine and a
number of other drugs were less than 10-6 per cell-generation in MPC-11 cells.
This suggests that the rates of mutation in immunoglobulin genes are at least
three orders of magnitude higher than the rate of mutation at other loci.
Irreversible loss of production in hybridoma cells over time has been
seen by a number of workers (Lee and Palsson, 1990; Tharakan and Chau,
1986a; Heath et al., 1990; Zurawski et al., 1978; Frame and Hu, 1990; Hiller et al.,
1991; our unpublished data). The irreversibility, although not always
characterized, suggests that loss of production is due to gene loss and/or
random mutations. Even if the genes for mAb production are not lost, the
loss of mAb secretion by some other mechanism leads to an accumulation of
non-antibody producing cells in cultures over time. Loss of antibody
production can additionally confer a selective growth advantage leading to a
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very rapid loss in productivity. Frame and Hu (1991) isolated a nonproducing
clone obtained in continuous culture (see below) and found that its
maximum growth rate was about 20% higher than that of the parental
population of producing hybridomas.
Loss of antibody production over time was seen by Frame and Hu
(1990) for two murine hybridoma lines producing IgG. In one line, specific
productivity in continuous culture dropped 4-6 fold over 75 days, and the
fraction of nonproducers, as assessed by cloning at limiting dilution rose to
30-50%. The specific productivity per producing cell remained approximately
constant. In the second hybridoma, the specific productivity dropped 6 fold
over 35 days in continuous culture. The mechanism(s) involved in loss of
productivity were not investigated.
Tharakan and Chau (1986a) saw a decline in antibody production in a
murine hybridoma (NS6.3) producing IgM in long term semi-continuous
culture. After 60 days in culture, the percentage of cells secreting antibody had
decreased to only 10%, as shown by a plaque assay.
One group (Schmid et al., 1990) saw a decline in productivity over a 10
month period using an Sp2/0-derived hybridoma, coupled with an increase
in the maximum cell density in batch culture. Initially, the maximum
amount of monoclonal antibody secreted in a batch culture was 180 ug/ml,
and the maximum cell viable density 9 x 105 c/ml. After ten months in
culture, the maximum amount of monoclonal antibody secreted was 75
ug/ml, but the maximum viable cell density had increased five fold to 4.8 x
106 c/ml. In addition, the kinetics of antibody production in the culture
changes. Initially specific productivity was better at low growth rates (non-
growth associated production in batch culture) than at high growth rates,
while after ten months cells produced better at a high growth rate (growth
associated production in batch culture). The mechanism(s) involved in loss
of productivity were not investigated.
The overgrowth of producer by nonproducer cells is dependent on the
frequency with which nonproducers arise, and the growth rate of
nonproducers as compared to nonproducers. In most cases, nonproducers
eventually take over, but in some cases, a balanced population of producers
and nonproducers is obtained (Gardner et al., 1985; Altshuler et al., 1986).
The loss of antibody production may be affected by different culture
methods. For example, Ozturk and Palsson (1990) saw loss of productivity in
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the murine hybridoma line 167.4G5.3 when grown with 1.25% FBS over a
period of four months, but no loss when grown supplemented with 5%
serum.
Another mode of loss of antibody production is a decline in the rate of
antibody synthesis for all cells in a population, rather than the outgrowth of
nonproducing cells. We have found that for clone CLC LT14, derived from
the C46 transfectoma, the population as a whole produces less antibody per
cell. Over a period of one month, the specific rate of antibody production
drops 2-3 fold, but no nonproducing cells are seen. Analysis of cells cloned
from cultures of different ages showed that the average immunoglobulin
titers in wells of clones decreased, and that the distribution of clones was
skewed towards lower immunoglobulin production (Section III.C.2). The
intracellular antibody content, measured by flow cytometry, also showed a
shift of the whole population towards lower antibody per cell (Morrill, 1990).
The decrease in antibody production observed in the CLC LT14 cells is
thus not due to loss of immunoglobulin genes, but due to some other
event(s).
The average amount of heavy and light chain immunoglobulin
mRNA per cell also decreased as a function of time in culture (Section m.D.2).
James and Bell (1987) have reviewed some of the causes of loss of antibody
production. Reasons for the loss of antibody production other than loss of
immunoglobulin genes are the absence of receptors for growth and
differentiation factors (Melamed et al., 1985), defects in the synthetic
machinery (Kozbor and Croce, 1985; Teng et al., 1985), defects in the secretory
machinery of the cell (Kozbor and Croce, 1985), or the failure or loss of
regulatory genes or another regulatory defect (Kozbor and Croce, 1985; Teng et
al., 1985) such as lack of nuclear factor KB in a myeloma (Atchison and Perry,
1987). Mutations leading to decreased synthesis of regulatory factors, such as
nuclear factor IcB, or point mutations in the regulatory sequences in the
immunoglobulin genes, such as the promoter or enhancer could cause the
decreased transcription and synthesis of immunoglobulin which we have
observed in long-term culture.
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C. Immunoglobulin mRNAs
The synthesis of immunoglobulin is proportional to the steady-state
levels of immunoglobulin mRNAs (Cowan and Milstein, 1974; Gilmore-
Hebert and Wall, 1979; Perry and Kelley, 1979; Schibler et al., 1978).
Absolute amounts of heavy and light chain mRNAs present in
myeloma cells have been measured by Schibler et al. (1978) and Gilmore-
Hebert and Wall (1979). Measurement of the absolute amounts of
immunoglobulin heavy and light chain RNAs was done via solution
hybridization by Schibler et al. (1978) in MPC-11 myeloma cells, which
produce IgG2b. From the solution hybridization data, and assuming a value
of 20 pg RNA/cell, they then estimated that there are about 30,000 heavy and
40,000 light cytoplasmic mRNAs, respectively. In addition, they characterized
the primary immunoglobulin RNAs and splicing intermediates, and found
that the primary heterogeneous nuclear (hn) H RNA transcript is 11 kb, and
the mature mRNA 1.8 kb, while the primary light chain transcript is 5.4 kb,
and the mature mRNA is 1.2 kb. In MPC-11 cells, immunoglobulin synthesis
represents approximately 20% of total cellular protein synthesis, and the L:H
ratio is about 1.7:1 (Laskov and Scharff, 1970). MPC-11 cells synthesize
immunoglobulin at a rate of about 2.5 pg/c-hr (Laskov and Scharff, 1974).
Gilmore-Hebert and Wall (1979) estimated that there are about 54,000
copies of K light chain mRNA per MOPC 21 myeloma cell. In these cells, IgG
represents approximately 25% of the total cell protein synthesized (Sherr and
Uhr, 1970), and immunoglobulin is synthesized at a rate of about 3 pg/c-hr.
The stability of immunoglobulin mRNAs has been measured by
following the decrease in immunoglobulin mRNAs or immunoglobulin
protein synthesis in the presence of inhibitors of RNA synthesis and also by
labelling cells with radioactive uridine. I measured the stability of
immunoglobulin mRNAs in the presence of actinomycin D, an inhibitor of
RNA synthesis. The observed half-life for both heavy and light chain
mRNAs was the same; about 3-4 hours during exponential growth.
Several groups have estimated the stability of immunoglobulin
mRNAs by by monitoring the production of immunoglobulin protein in the
presence of actinomycin D, an inhibitor of mRNA synthesis (Namba and
Hanaoka, 1969; Scharff and Laskov, 1970; Shutt and Krueger, 1972). These
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workers found that the half-lives of immunoglobulin heavy and light chain
mRNA were only 2-5 hours. Namba and Hanaoka (1969) used MOPC-31B
myeloma cells, with a doubling time of 30 hours, and estimated a half-life of
about 2-4 hours for both heavy and light chain mRNA. Shutt and Krueger
(1972) used MOPC 21 cells and estimated that the half-life for heavy and light
chain was about 2.5 hours. Scharff and Laskov (1970) found that half-life of
heavy and light mRNAs in MPC-11 tumors were 3-5 hours, but noted that the
actinomycin D was toxic to cells, and that the cell count decreased with a decay
rate only slightly slower than the mRNA half-life.
Bibila and Flickinger (1991) determined the halflives of heavy and light
mRNA in a murine hybridoma (9.2.27) synthesizing an IgG2a during
exponential growth and during stationary phase in batch culture by
incubating cells either with actinomycin D or (5,6)dichloro-benzimidazole
(DRB), another inhibitor of RNA synthesis. They found that the half-life of
heavy and light mRNAs in cells treated with actinomycin D were the same.
mRNA half-lives were about 3-5 hours growth rate of 0.05-0.06, during
exponential growth, and about 2 hours at a growth rate of 0.015 hr-1 in
stationary phase. They found that actinomycin D was toxic to the cells after
exposure longer than 3 hours. Using DRB, the half life of L mRNA during
exponential phase was 14.4 hours, H chain 12 hours; in stationary phase, L
and H half lives were both 6.2 hours.
JAck and Wabl (1988) studied immunoglobulin heavy chain (g) mRNA
stability in various cells representing various stages of B lymphocyte
differentiation, the pre-B, B, and plasma cell stages. They had previously
found that the transcription rates for the heavy chain mRNA were about the
same for the cells tested, and suggested that the increased level of heavy chain
mRNA at the plasma cell stage is due to increased stability. Using two
different inhibitors of RNA synthesis, actinomycin D or (DRB), the measured
half-lives of pL mRNA were about the same. Most of the pt chain mRNA was
gone after 4 hours of treatment in three pre-B cell lines; in two plasma cell
lines, MOPC-104E, and Sp7, the half-life of Ip chain was about 4 hours; for two
hybridomas, FH and KH, there was almost no decay of g chain after 7-8 hours.
Using DRB, clone FH, a hybridoma, showed a clear decrease in P. mRNA only
at 23 hours. They suggest that actively transcribed mRNAs may be protected
from degradation by RNAses.
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Cowan and Milstein (1974) measured the half-life of heavy and light
chain immunoglobulin mRNAs via UTP pulse-chase in mouse myeloma
MOPC 21, which has a doubling time of 24 hours. They found that both the
heavy and light mRNAs have half-lives of 12-14 hours, but they stated that
the range could be from 5-20 hours. Storb (1973) labelled myeloma P3K cells
(derived from MOPC 21) with uridine and found that the half-life for
cytoplasmic polyA+ RNA was 12.2 hours and the half-life for microsomal
polyA+ was 44.4 hours. Since approximately 50% of the microsomal polyA is
immunoglobulin mRNA in these cells (Storb, 1973), this suggests that
immunoglobulin mRNA is quite stable, in agreement with the data of Cowan
and Milstein.
A striking observation is that the measured stability of both H and L
immunoglobulin mRNAs is the same in all of the cell types in which it has
been measured. This suggests that the factor(s) regulating H and L
immunoglobulin mRNA stability are the same.
The discrepancy between stability estimates for immunoglobulin
mRNAs (half-lives varying from 3 to 23 hours) may be explained by 1)
variations between different cell lines, and 2) variations due to the different
experimental protocols employed (incubation with actinomycin D or DRB vs.
labelling with uridine). In particular, it has been shown that actinomycin D is
toxic to some cells, and this toxicity may result in an artificially low estimate
for mRNA stability.
I measured of the relative levels of immunoglobulin heavy and light
chain mRNAs in cells grown in perfusion bioreactors and in cells in batch
culture during exponential phase (results in Section mI.D.2). In the
bioreactors, the relative levels of both H and L mRNAs decreased to about 1/3
the level seen at time zero and then remained at this level even as the
specific productivity continued to decline, from 0.15 pg/c-hr at time zero to
0.02 pg/c-hr at the end of the experiment.
Measurements of immunoglobulin mRNAs during exponential
growth in batch culture of cells maintained in culture for different amounts
of time were also done. These showed that the decline in productivity as a
function of time was due to decreased steady-state mRNA levels. Cells after
one month, where the productivity had declined about 3-fold; had only about
1/2 the amounts of immunoglobulin mRNAs as cells where the specific
productivity was high. Thus, the amount of immunoglobulin secreted
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during exponential growth at low cell density is proportional to the amount
of immunoglobulin message, and the amount of immunoglobulin secreted at
high cell density (and low qP) in the perfusion bioreactors is less than what
would be expected, based on immunoglobulin message levels.
The relative amounts of immunoglobulin mRNAs have also been
measured as a function of time in batch cultures. Leno et al. (1991) measured
the relative levels of heavy and light chain mRNAs during growth of a
murine hybridoma in batch culture. The specific productivity was high until
day 2 at about 0.1 pg/c-hr and then declined to about 0.05 pg/c-hr at days 3 and
4. Specific productivity appeared to increase on day 5, when the viable cell
density dropped 90%, presumably due to release of antibody from dead cells.
Leno et al. did not find a correlation between specific productivity and
mRNA levels; light chain mRNA levels remained fairly constant throughout
the culture until the viable cell declined at the end of the culture (day 5), and
at that point dropped 7-fold. The levels of heavy chain mRNA were highest
at days 0 and day 3, about 1/2 this value at days 1, 2, and 4, and also declined 7-
10 fold at the end of the culture. If one makes the assumption that the
variation of heavy chain mRNA levels over days 0-4 is due to experimental
error, then it appears that the levels of immunoglobulin mRNAs are nearly
constant during exponential and stationary phase while the specific
productivity is 2-fold higher during exponential phase relative to stationary
phase.
Bibila and Flickinger (1991) also measured the relative levels of heavy
and light chain mRNAs during growth of a murine hybridoma in batch
culture and found that they did not correlate with specific productivity. The
levels of H and L mRNAs per cell remained constant during exponential
growth, and then declined by 1/3 during stationary phase, while the specific
productivity of these cells remained nearly constant during exponential and
stationary phases.
Hendricks et al. (1988) compared the level of endogenous transcription
from the light chain gene of myeloma line J558L to that of a immunoglobulin
gene transfected into these cells. They transformed the myeloma line J558L
with a plasmid containing the kappa immunoglobulin enhancer and
promoter, an intervening TPA sequence, and the kappa gene. The transfected
J558L cells contained one correctly integrated copy of the plasmid. They found
that the rate of transcription of the endogenous lambda gene of J558L cells was
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at the same rate as the endogenous kappa gene in MPC 11 cells. However, the
amount of mRNA produced from the integrated plasmid was about 25% of
the amount transcribed from the endogenous lambda gene. Nuclear runoff
showed that transcription from the plasmid was 38% of that of the
endogenous lambda gene; thus, the difference in the level of mRNA was
largely attributable to a difference in expression. They suggest that the
difference in expression may be due to the different chromosomal locations of
the endogenous and transfected immunoglobulin sequences, as
chromosomal location may affect transcription (Hendricks et al., 1988).
D. Polysome Distributions
Examination of polysome loading of immunoglobulin mRNAs
showed that the average polysome size for light and heavy chain mRNAs
decreased coordinately from full loading at high productivity. Comparison of
the heavy chain polysomes at high and low specific productivity shows a 7-
fold decrease in the fraction containing the polysomes with the most
ribosomes, and a 2.4-fold decrease in the two fractions containing 68% of the
H chain mRNA at high specific productivity. Comparison of the light chain
polysomes at high and low specific productivity shows a 9-fold decrease in the
fraction containing the polysomes with the most ribosomes, and a 2.6-fold
decrease in the two fractions containing 68% of the L chain mRNA at high
specific productivity.
The average polysome size for a-tubulin also decreased; comparison of
the light chain polysomes at high and low specific productivity shows a 11.6-
fold decrease in the fraction containing the polysomes with the most
ribosomes, and a 2.6-fold decrease in the two fractions containing 68% of the L
chain mRNA at high specific productivity.
I also estimated the average number of ribosomes associated with the
immunoglobulin and a-tubulin mRNAs, as described in Section III.C.3.
A comparison of the average number of ribosomes associated with
each mRNA on day 0 and day 4 in bioreactor #4 (condition of high
productivity) and on days 11 and 12 (condition of low specific productivity)
showed that there is a 1.4-fold reduction of the number of ribosomes
associated with the immunoglobulin light chain mRNA, a 2.3-fold reduction
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in the number of ribosomes associated with the immunoglobulin heavy
chain mRNA, and a 2.6-fold reduction in the number of ribosomes associated
with the a(-tubulin message. This, again, indicated that there was a reduction
in translation of message. Immunoglobulin heavy chain and a-tubulin
translation was reduced more than the immunoglobulin light chain.
In contrast to my results, others (Stevens, 1974; Nuss et al., 1975; Nuss
and Koch, 1976) have found that in myelomas, initiation of translation of H
and L chains is more efficient than the average cell mRNA; H and L chains
represent a larger fraction of newly synthesized protein when initiation is
nonspecifically decreased, such as in response to amino acid starvation, viral
infection, or slowed growth.
Stevens (1974) studied the translational control of antibody synthesis
using a mouse plasmacytoma cell (5563) grown in batch culture, and showed
that the translation of H and L chain is differentially regulated. The synthesis
of L chain is regulated in a coordinated fashion with total cellular protein
synthesis, while synthesis of H chain remained high even when total protein
synthesis decreased.
The rates of protein synthesis were measured after 1, 2, and 3 days in
culture. The rate of total protein synthesis at day 2 (stationary phase)
decreased 40% relative to day 1 (exponential growth); H chain synthesis
decreased 9% and light chain synthesis by 52%. By day 3, cells were in late
stationary phase and the rates of total protein and L chain synthesis decreased
80%; H chain synthesis decreased 50%. The decrease in L chain synthesis
resulted in a drop in the L:H chain ratio from 2.5:1 on day 1 to 1.2:1 by day
three.
In order to determine the mechanism of the decrease in protein and
immunoglobulin synthesis, Stevens (1974) measured the size distributions of
polysomes engaged in heavy and light chain synthesis by labelling cells with
35S methionine, fractionating cell extracts on a 12-40% linear sucrose gradient
and precipitating nascent heavy and light chain immunoglobulin
polypeptides from the collected fractions. For cells labelled in stationary
phase (day 2), radioactivity corresponding to heavy chain peptides was seen
over the whole gradient, with a peak corresponding to polysomes containing
14-18 ribosomes. Radioactivity corresponding to light chain peptides was also
seen over the whole gradient, with a small peak corresponding to polysomes
containing 3-4 ribosomes. The absorbance profiles at 260 nm showed that the
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majority of cellular mRNAs were associated with 2-4 ribosomes during
stationary phase.
Treatment of a portion of these cells with emetine, an inhibitor of
peptide elongation, and subsequent fractionation and precipitation was done
to allow an estimate of the maximum polysome size possible at a condition
where initiation is not limiting. Following treatment with emetine the
absorbance profile shifted to an average of 6-8 ribosomes/polysome,
suggesting that the majority of cellular mRNAs were initiated at only 50% of
the potential maximum rate during stationary phase. Treatment with
emetine did not change the polysome profile of the H chains, showing that
they were fully loaded during stationary phase. The L chain profile shifted
and L polysomes were now associated with 6-8 ribosomes. This suggested that
initiation of L chain synthesis during stationary phase was also only at 50% of
the maximum rate.
Thus, the 50% decrease in total protein and L chain synthesis during
stationary phase was due to decreased initiation, while synthesis of H chains
remained at the same level as during exponential phase. In late stationary
phase, when growth had ceased (day 3), total cellular protein synthesis, as well
as light and heavy chain synthesis was severely reduced by a decrease in both
initiation and elongation.
These results show that for this plasmacytoma, H and L synthesis are
differentially regulated. During exponential phase, H polysomes are
associated with 14-18 ribosomes, and L polysomes and cellular mRNAs are
associated with 6-8 ribosomes. During stationary phase, when growth is
slowed, both total cellular mRNA and light chain mRNA exhibit decreased
polysome loading to 2-4 and 3-4 ribosomes per polysome, while heavy chain
mRNA remains fully loaded with 14-18 ribosomes/polysome.
Stevens' findings provides a mechanistic explanation for the fact that
many hybridomas continue to synthesize immunoglobulins even during
stationary phase.
Nuss and Koch (1976) measured the rates of immunoglobulin and total
protein synthesis in myeloma MPC-11 cells, and found that the rates of
immunoglobulin synthesis were less affected than the rate of total protein
synthesis in cells exposed to hypertonic medium. Nuss and Koch incubated
cells in medium containing excess NaC1, which results in a selective and
reversible inhibition of polypeptide initiation. They found that under control
234
_ 
__ ~___I
conditions, the H and L chains accounted for 16% of total cellular 35S
incorporation. Upon exposure to hypertonic medium, total protein synthesis
was reduced by over 90%. However, L chain synthesis was reduced by only
70%, and H chain by 85%, and H+L protein rose to 31% of total cellular 35S
incorporation, with secretion of IgG continuing unimpaired. Nuss et al.
(1975) had previously shown that exposure of RNA virus-infected cells to
hypertonic growth medium had resulted in a similar selective inhibition of
host mRNA translation relative to viral mRNA translation, due to a
reduction in the rate of initiation of host mRNAs.
The relatively higher rates of initiation on immunoglobulin mRNAs
suggests that they are more efficient in initiation of translation, perhaps due
to an increased affinity for initiation factors or the 40S ribosomal subunit. In
addition, the results of Nuss and Koch may explain the finding that in some
hybridomas, specific rates of synthesis are higher at conditions of low pH and
increased osmolarity (Miller et al., 1988; Ozturk and Palsson, 1991).
While Stevens (1974) measured radioactivity incorporated into
immunoglobulin peptides, I measured mRNA via Northern blotting. Using
peptides to determine polysome loading may underestimate the amount of
mRNA associated with smaller peptides, as these are not
immunoprecipitated efficiently (Stevens, 1974). In agreement with the data of
Stevens (1974), I found that the average polysome size for the light chain was
smaller than for the heavy chain; this is expected because the light chain
mRNA is a smaller molecule. However, in contrast to his data, I found a
decrease in the average polysome size for both the heavy and light chain in
bioreactor samples at high cell density and low qP. This may reflect both
differences among cell lines (immunoglobulin synthesis in a plasmacytoma
as opposed to synthesis from transfected genes in a recombinant myeloma cell
line) and the fact that cells in the perfusion reactors at high density are not in
stationary phase, but rather at a condition of slowed, but continual, growth.
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E. Intracellular Immunoglobulin
The amount of intracellular immunoglobulin can be used to monitor
specific productivity. During exponential or balanced growth, intracellular
immunoglobulin pool size is proportional to the rate of immunoglobulin
synthesis. However, as discussed below, the intracellular immunoglobulin
pool is no longer proportional to specific productivity during the stationary
and decline phases of batch culture.
Laskov and Scharff (1974) measured the rates of immunoglobulin
synthesis and amounts of intracellular immunoglobulin in two clones
isolated from MPC 11 cells, clones I and II. Clone I contained 3.5 pg/cell
immunoglobulin and its specific rate of production was 2.5 pg/c-hr, while
clone II contained 6.0 pg/cell immunoglobulin and synthesized
immunoglobulin at a rate of 3.6 pg/c-hr. We have measured intracellular
immunoglobulin in CLC LT14 cells at 0.2 pg, and find a specific rate of
production of 0.2 pg/c-hr; Meilhoc et al. (1989) found that intracellular
immunoglobulin of a murine hybridoma (during exponential phase of
growth) was 0.5 pg/cell, and the rate of secretion was 0.4 pg/c-hr; Leno et al.
(1991) measured intracellular immunoglobulin and specific productivity
(during exponential growth) at 0.12 pg/cell and 0.10 pg/c-hr, respectively.
A number of other workers have used flow cytometry to monitor both
surface and intracellular IgG and several have correlated these measurements
with the changes in specific productivity observed during batch culture. I
measured the intracellular IgG content of cells removed from bioreactors and
cells in exponential phase at low cell density and was able to correlate
intracellular IgG with specific productivity during exponential growth at low
cell density and during quasi-steady-state conditions in the bioreactors.
During the shift from high to low specific productivity in the bioreactors (day
6), the intracellular IgG content of cells was much higher than predicted,
indicating that the rates of synthesis and secretion were not balanced (see
section m.D.4).
One of the earliest studies was by Altshuler et al. (1986), who measured
the RNA, DNA, and intracellular IgG via flow cytometry of hybridoma
cultures in exponential phase. They found a bimodal distribution of
intracellular IgG in two hybridoma lines. Dual-staining was used to examine
the relationship of intracellular IgG and DNA content, and they found that
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the bimodal IgG distribution was present throughout the entire range of DNA
contents, indicating that IgG content was not cell cycle dependent. Rather, the
low IgG content peak represents a non-producing subpopulation of cells, as
the peak for the low intracellular IgG overlapped with that of the negative
control (non-producing cells stained with the same antibody).
Meilhoc et al. (1989) studied the kinetics of antibody synthesis and
secretion via measurements of total cell-associated IgG (surface and
intracellular), surface IgG, and IgG secreted into the medium in batch cultures
of a murine hybridoma. Total IgG and IgG secreted into the medium was
measured by lysis of cells and quantitation via an Elisa assay, while surface
IgG was measured via labelling and flow cytometry. Two subpopulations of
cells, one with low and one with high surface immunofluorescence, were
observed, and the fraction of the subpopulation with low surface
immunofluorescence increased with time in batch culture.
Both mean surface immunofluorescence and total cell-associated IgG
showed similar kinetics in batch culture; both were high during the first 30
hours and then continually decreased with time in culture. Meilhoc et al.
(1989) observed a positive correlation between mean surface
immunofluorescence and total cell-associated IgG, but did not find any
correlation between specific productivity and mean surface
immunofluorescence. The percentage of total IgG which was intracellular vs.
surface IgG was not calculated for these cells.
In contrast to the results obtained by Meilhoc et al. (1989), McKinney et
al. (1991), using a murine hybridoma (ATCC HB124), found that the
percentage of cells positive for surface immunofluorescence was positively
correlated with specific productivity, and that surface IgG was not correlated
with intracellular IgG. In addition, they found that surface
immunofluorescence decreased with increasing antibody concentration in the
medium.
McKinney et al. (1991) also used surface immunofluorescence to sort
cells into 2 populations containing 4% of the cells with highest and lowest
surface immunofluorescence, and measured the specific productivity of each
sorted population, as well as the unsorted population, in batch cultures. The
intracellular IgG of all 3 populations was identical. The initial secretion rate
(day 0-1) was the same for the high surface immunofluorescence and
unsorted populations, and about 17% less for the low surface
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immunofluorescence population; however, the specific productivity over
days 1-3, and the final titers, were the same for all 3 populations. This
indicates that surface immunofluorescence is not necessarily a useful tool for
selecting higher producers.
Leno et al. (1991) examined the kinetics of cytoplasmic, secreted, and
membrane-bound antibody in batch cultures. The specific productivity was
high during the 46 hours of batch culture, peaking at 46 hours, and then
decreased about 2 fold as the cells entered stationary phase (up to 100 hours),
similar to the kinetics seen by us. The qP then increases at the end of the
culture, presumably due to antibody released by dead cells. Surface
immunofluorescence and cytoplasmic antibody levels showed similar
kinetics during the first 100 hours of culture. Cytoplasmic IgG peaked at 46
hours, and then decreased by about 2 fold by 100 hours. Cytoplasmic IgG was
correlated with qP during the first 100 hours, but not linearly; the qP decreased
before the cytoplasmic IgG decreased. This would suggest that during the
changes occurring as cells enter stationary phase, the rates of synthesis and
secretion are no longer balanced, and that the rate of secretion of antibody
decreases before its rate of synthesis is slowed.
Heath et al. (1990) measured intracellular IgG as a function of time in
batch cultures. They used a murine hybridoma (ATCC HB124) which
produces an IgG2a. This line exhibited a bimodal distribution of intracellular
IgG. Two peaks were always seen, one of low and one of high intracellular
IgG, and the percentage of cells exhibiting high intracellular IgG was
correlated by the authors with specific productivity. This cell line showed
linear decay of the percentage of hybridomas exhibiting high intracellular
antibody content with time, with a decrease from 71% at high fluorescence to
14% over a period of six weeks in culture, and a corresponding decrease in
specific productivity.
Heath et al. (1990) also compared cultures grown with 0.5%, 1%, 5.5%,
and 10% serum. Specific productivity and the percentage of cells exhibiting
high intracellular IgG were highest for cultures grown with 0.5% and 1%
serum. In a comparison of cultures grown in 10% serum or in a serum-free
medium, the specific productivity in serum-free medium was double that in
medium containing 10% serum. The percentage of cells exhibiting high
intracellular IgG was similar for both cultures at day 3, but increased for the
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culture in serum-free medium by day 5, again showing a positive correlation
of the percentage of cells with high intracellular IgG and specific productivity.
F. Cell Density Effects on Cellular Metabolism
I found that there was a cell-density-dependent decrease in the levels of
steady-state immunoglobulin mRNAs, a global decrease in the average
polysome size, and a 10-fold decrease in the amounts of intracellular
immunoglobulin as the specific productivity in the bioreactors was
downregulated 10-20 fold. These phenomena may well be caused by density-
dependent metabolic downregulation, which has been observed in a number
of systems.
Tyo (1991) measured the rates of amino acid uptake at high and low cell
density in the CLC LT14 cells and found that the uptake rates of essential
amino acids are decreased about 10-fold at high density. At low cell density, <
3 x 106 c/ml, the rates of amino acid uptake were about 10 times in excess of
the amounts of amino acids needed for de novo synthesis of protein and
nucleic acids. At high cell density, the rates of amino acid uptake were
matched to the amounts needed for the synthesis of these cellular
components.
Rates of protein synthesis and RNA synthesis in myeloma cells have
also been shown to decrease with increasing cell density. Shutt and Krueger
(1972) found that in MOPC 21 myeloma cells, RNA synthesis and protein
synthesis and secretion were dependent on cell density; the amount of
incorporation of radioactive amino acids and labelled uridine was high at cell
densities < 106 c/ml and minimal at 5 x 106 c/ml. Scharff et al. (1970) found
that in MPC-11 cells teased into suspension from solid tumors, protein and
RNA synthesis were a function of cell density and decreased with increasing
cell density.
van Venrooij et al. (1972) examined protein synthesis and polysome
distributions of exponentially growing Ehrlich ascites tumor cells in culture.
They found that omission of any one of the 13 amino acids caused an
immediate reduction in protein synthesis, on the order of 30% after one hour.
The reduction in protein synthesis was largely due to a decrease in the rate of
initiation of protein synthesis, as evidenced by a reduction in the average
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polysome size. The fraction of ribosomal RNA found in monosomes, which
are not associated with mRNA, increased from 5-10% to 25%. Omission of 2
or more amino acids gave a 45% reduction in the rates of initiation, and the
fraction of monosomes increased to 40%. Omission of glucose caused a
decrease in both initiation and elongation rates.
While Tyo (1991) found no evidence for amino acid limitation at high
cell density, it is possible that the decreased rate of amino acid uptake
observed at high cell density (Tyo, 1991) caused the intracellular concentration
of one or more amino acids to become rate-limiting and thus cause the
decrease in the rate of protein synthesis observed for immunoglobulin
peptides and a-tubulin which I observed.
It has also been shown that the rate of oxygen uptake in cells is cell-
density dependent.
Sand et al. (1977) found a strong dependence of the rate of oxygen
uptake on cell density for a suspension culture of lymphocytes. Cells were
harvested and resuspended in fresh medium. The rate of oxygen uptake was
found to decrease 10-fold with a 100-fold increase in cell density from 105 to
107 c/ml. This effect was not related to the dissolved oxygen tension, nor to
changes in the concentration of lactate or carbon dioxide. The authors
suggested that it was due to humoral factors produced by the cells.
Wohlpart et al. (1990) measured the oxygen uptake rate of a murine
hybridoma as a function of cell density and found that it decreased
exponentially as the cell density was increased from 105 to 107 c/ml by a factor
of 5. The rate of oxygen uptake was not dependent on the history of the cells,
but rather only the final cell density; either concentrating cells from a culture
at low density or diluting them from a culture at higher cell density gave the
same results.
To test the hypothesis that "humoral factors" secreted into the
medium, as suggested by Sand et al. (1977), mediated the decrease in oxygen
uptake, they centrifuged cells and resuspended them at varying cell densities
in conditioned medium. The conditioned medium had no effect on the
oxygen uptake rate; the oxygen uptake rate was the same at each density as
when fresh medium was used. This result suggests that cell-cell contact, even
in suspension cultures, may serve to regulate some aspects of cell
metabolism.
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Yamada et al. (1990) measured the oxygen uptake rate of MPC-11 cells
and a human hybridoma as a function of cell density. Cells were harvested in
exponential phase and resuspended in fresh medium at densities from 106 to
107 c/ml. A linear relationship between the oxygen uptake rate and cell
density was seen for both cell lines. The oxygen uptake rate of MPC-11 cells
decreased 6-fold when the density was increased from 1 to 6 x 106 c/ml and
about 10-fold for the human hybridoma line; 2 other B cell lines tested gave
similar results.
The decreased rates of amino acid uptake, oxygen uptake, and protein
and RNA synthesis seem to be a function of cell density. The question then
becomes: is cell-cell contact the underlying cause of this decrease in metabolic
rates?
Many adherent cells, such as 3T3 cells, cease growth upon confluence.
It has been shown (Whittenberger and Glaser, 1977) that the growth of 3T3
cells can be arrested by the addition of isolated plasma membranes. Stallcup et
al. (1984) found that membranes isolated from normal spleen or lymphoid
tumor cells could inhibit the growth of several murine tumor lines,
including a B cell hybridoma. The mechanism of action appeared to be due to
a decrease in the growth rate of the cells, rather than killing of cells, as cells
exposed to plasma membranes reached the same final viable cell densities as
control cultures grown without the addition of membranes. The addition of
100 Jg/ml of purified plasma membranes from lymphoid tumor cells caused
the doubling time of a hybridoma to increase from 12 to 17 hours. This
concentration of plasma membranes is equivalent to the amount recovered
from 2.5 x 107 cells. Growth inhibition was linear with the amount of plasma
membranes added.
It is possible that the growth rate of cells in the bioreactors was slowed
slightly, and mediated by cell-cell contact. Experiments to determine whether
membranes isolated from CLC LT14 cells can inhibit cell growth or antibody
production are in progress in our laboratory (Morrill, 1992).
Even though the amino acid uptake rates of cells, and their rates of
RNA and protein synthesis are slowed at high cell density, some groups have
shown that the specific productivity actually increases as the cell density
increases. However, in most of these cases, the growth rate decreased at high
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density, and so it is not possible to dissect the effect of growth rate from the
effect of cell density.
Several groups have, however varied the cell density and growth rates
independently of one another, in continuous culture combined with cell
recycle. Unfortunately, the cell densities investigated are < 5 x 106 viable
c/ml. Schmid et al. (1992) investigated growth and productivity in a murine
hybridoma (AB2-143.2) in continuous culture with and without cell recycle.
Without cell recycle, at a dilution rate of 0.017 hr -1, the viable cell density
obtained was 2 x 106 c/ml, and the doubling time was 28.2 hours. Specific
productivity was 0.89 pg/c-hr. They then increased the dilution rate 2.4 fold,
and adjusted the recycle rate to obtain the same doubling time. This resulted
in a 2.4 fold increase in viable cell density, with the specific productivity
remaining constant, indicating that at least in the range of 2-5 x 106 c/ml, cell
density did not affect the specific productivity.
Robinson et al. (1992) and Robinson and Memmert (1991) grew a
recombinant Sp2/0 transfectoma in continuous culture with and without cell
recycle. The degree of cell retention and total cell dilution rate were varied
using a fermentor equipped with a spin filter to remove cell-free medium
and a separate bleed stream to remove cells. When cells were maintained at a
growth rate of 0.023 hr-1 (doubling time 29.6 hours), the productivity was
constant and independent of the dilution as the viable cell density increased
from 0.5 to 3.9 x 106 c/ml. Again, varying the cell density up to 3.9 x 106 c/ml
did not affect the specific rate of antibody production.
Other groups have observed that specific productivity either increased
or remained constant with increasing cell density; however, the growth rate
decreased as the cell density increased, so the effect of growth rate and cell
density could not be independently assessed.
Reuveny et al. (1986b) compared the production of antibody in batch,
fed-batch, semicontinuous culture, and perfusion culture. They used a
murine hybridoma, VIII H-8, producing an IgG2a. The specific productivities
in batch, fed-batch, and semi-continuous culture were similar; productivity in
batch ranged from 0.38-0.58 pg/c-hr, while specific productivity in semi-
continuous culture ranged from 0.44-0.67 pg/c-hr. In perfusion culture, the
specific productivity was the same as in batch culture during exponential
growth up to 1-2 x 107 viable c/ml, but then increased to 0.71-1.25 pg/c-hr
during the time of approximately constant cell density. Thus, the
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combination of slow growth and high cell density appeared to increase
specific productivity by a factor of 2-3. In related work Velez et al. (1987), also
using a spin filter and the same cell line achieved a cell density of 5 x 107
viable c/ml. The specific productivity was about 1 pg/c-hr (ie no increase
over 2 x 107 viable c/ml). The authors suggest that the decrease in cell
metabolism under low-growth conditions and/or the secretion of a factor
stimulatory to antibody production which can accumulate to stimulatory
levels at high cell density may be the cause of the increase in specific
productivity.
Yamada et al. (1990) grew a human hybridoma in perfusion culture and
observed that the specific productivity increased as the growth rate of the cells
slowed above a density of 5 x 106 c/ml, from 0.125 to 0.21 pg/c-hr. They
suggest that this increase in productivity was partly due to accumulation of
immunoglobulin production stimulating factor, (IPSF), a growth factor
produced by these hybridomas, as well as human Namalwa cells, which
stimulates immunoglobulin production (Yamada et al., 1989). It is possible
that the increase in specific productivity observed at high cell density and
slowed growth conditions by Reuveny et al. (1986b).
van der Velden-de Groot et al. (1990) also grew a murine hybridoma in
a fermentor equipped with a spin filter, and obtained a maximum viable cell
density of 9.2 x 106 c/ml at a dilution rate of 0.5 v/day. Here, the specific
productivity remained constant during both the time of increasing cell
density and constant cell density, at about 1.4 pg/viable c-hr, remaining
proportional to the viable cell density.
G. Mechanisms Implicated in Downregulation of Protein Synthesis
Phosphorylation of the alpha subunit of initiation factor 2 (eIF-2a) has
been implicated as a mechanism leading to decreased protein synthesis in
cells exposed to amino acid starvation (Scorsone et al., 1987), serum
deprivation (Rowlands et al., 1988), glutamine starvation (Rowlands et al.,
1988), heavy metals (Hurst et al., 1987), heat shock (Rowlands et al., 1988;
Scorsone et al., 1987), differentiation signals (Konno et al., 1986), and to double-
stranded RNA (Petryshn et al., 1988). In cells infected with poliovirus
(Ransone and Dasgupta, 1988), adenovirus (Reichel et al., 1985) and influenza
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(Katze et al., 1988), different virally mediated mechanisms prevent
phosphorylation of eIF-2a, and viral protein synthesis is not inhibited.
One of the events in initiation of peptide synthesis is the binding of
eIF-2.GDP to the 60S ribosomal subunit. elF-2 consists of three subunits, a, f3,
and y. Under normal conditions of protein synthesis, the alpha subunit of
eIF-2 is not phosphorylated, and reversing factor (RF, eIF-2B) interacts with
the eIF-2.GDP 60S ribosomal complex. Catalytic recycling of eIF-2 is mediated
by guanine-nucleotide exchange factor (GEF) and RF. GEF displaces GDP from
eIF-2 and RF then promotes release of eIF-2 from the 60S ribosomal subunit
as a complex with itself (Matts et al., 1988).
Under conditions where protein synthesis is inhibited, a cellular
protein kinase, p68, is autophosphorylated, and this kinase then
phosphorylates elF-2a (Petryshn et al., 1988). Phosphorylation of eIF-2a causes
eIF-2.GDP to accumulate on 60S subunits due to impaired dissociation
normally mediated by RF, and eIF-2aP.GDP appears to bind and sequester RF.
In addition, eIF-2aP.GDP impairs the ability of GEF to displace GDP from eIF-
2.GDP by competition with eIF-2.GDP (Clemens et al., 1987).
In Ehrlich ascites tumor cells exposed to conditions resulting in
decreased protein synthesis, such as heat shock, serum deprivation,
glutamine deprivation, or amino acid starvation, GEF activity was reduced
and the level of phosphorylation of eIF-2a was increased (Rowlands et al.,
1988; Scorsone et al., 1987).
While cells at high density were not starved for amino acids or serum,
it is tempting to speculate that phosphorylation of eIF-2(a may be the
mechanism causing the downregulation of protein synthesis the we have
observed at high cell density. However, mechanisms other than
phosphorylation of eIF-2a may mediate a decrease in protein synthesis. For
example, Cox et al. (1988) observed that the rate of protein synthesis in skeletal
muscle decreased in 48 hour starved rats, as expected. This decrease in
protein synthesis was due largely to a decrease in peptide chain initiation;
however, they did not observe an increase in phosphorylation of eIF-2cx.
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V. Conclusions
In this thesis, I examined the molecular cascade of antibody production.
A cell-density-dependent decline in antibody productivity was observed at
high cell density. This decline in productivity arose from a simultaneous
decrease in transcription and translation of immunoglobulin mRNAs, which
led to decreased synthesis and secretion of immunoglobulin.
The molecular cascade of antibody production was examined in low
cell density cultures at high specific productivity, and in high cell density
cultures at high and low specific productivity, as well as during the transition
to low specific productivity. These results are summarized in Table V-1.
Table V-1. shows the relative amounts of immunoglobulin heavy and light
chain mRNAs, the average number of ribosomes per message, and the
relative intracellular immunoglobulin content of cells at conditions of high,
intermediate (in bioreactor samples labelled "transient") and low specific
productivity.
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Table V-1.
Summary of Data in Batch Spinners and Bioreactors
Condition viable Relative Average Relative Relative Actual
c/ml Steady-state # of Intracellular qP qP
x 106 mRNAs ribosomes IgG pg mAb pg mAb
on mRNA / c-hr / c-hr
H L H L H+L H L
Batch
culture 0.5- 1 1 16.6 13.5 1 1 1 1 0.20
exponential 1.2
growth
Bioreactor
(# 6) 2.22 n.d. 0.5 16.4 14.9 0.94 0.89 0.90 0.75 0.15
high qP
day 3-4
Bioreactor
(# 5) 3.29 0.4 0.5 8.3 10.9 0.67 0.54 0.54 0.25 0.05
transient
day 3-4
Bioreactor
(# 5) 7.14 0.4 0.5 n.d. n.d. 0.15 0.11 0.15 0.13 0.025
transient
day 6-7
Bioreactor
(# 5) 12.8 0.3 0.4 4.0 10.1 0.082 0.097 0.18 0.07 0.014
low qP
day 10-11
Bioreactor
(# 5) 13.1 0.3 0.5 10.1 9.2 0.091 0.094 0.03 0.06 0.012
low qP
day 12-13
Bioreactor
(# 1) 14.0 0.3 0.5 n.d. n.d, n.d. n.d. n.d. 0.015 0.003
very low qP
day 26
n.d. not done
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The conclusions of these studies are the following:
Molecular Cascade:
1. During growth in the bioreactors there is a novel, cell-density-
dependent decline in specific productivity in the perfusion bioreactors. The
specific productivity declined 10-15 fold from about 0.2 pg/c-hr to 0.02 pg/c-hr
as the cell density increased from 3 x 106 viable c/ml to 1 x 107 c/ml.
2. Molecular cascade analysis of cells at high specific productivity (during
exponential growth in batch spinners) and during days 0-3 in the perfusion
bioreactors, and at low specific productivity (at high cell density in the
perfusion bioreactors) showed that the steady-state levels of heavy and light
chain mRNAs decreased coordinately to 1/3 of the levels seen at high specific
productivity after 4-5 days and remained at these levels as the specific
productivity slowly decreased to less than 1/10 the levels during days 0-3.
3. Examination of polysome loading of immunoglobulin mRNAs
showed that the average polysome size for light and heavy chain mRNAs
decreased coordinately from full loading at high productivity. Comparison of
the heavy chain polysomes at high and low specific productivity shows a 7-
fold decrease in the fraction containing the polysomes with the most
ribosomes, and a 2.4-fold decrease in the two fractions containing 68% of the
H chain mRNA at high specific productivity. Comparison of the light chain
polysomes at high and low specific productivity shows a 9-fold decrease in the
fraction containing the polysomes with the most ribosomes, and a 2.6-fold
decrease in the two fractions containing 68% of the L chain mRNA at high
specific productivity.
The average number of ribosomes associated with the
immunoglobulin mRNAs decreased 1.5-fold for light chain mRNA and 2.3-
fold for heavy chain mRNA as the specific productivity decreased 10-15-fold.
4. The average polysome size for a-tubulin also decreased; comparison of
the light chain polysomes at high and low specific productivity shows a 11.6-
fold decrease in the fraction containing the polysomes with the most
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ribosomes, and a 2.6-fold decrease in the two fractions containing 68% of the
a-tubulin mRNA at high specific productivity.
The average number of ribosomes associated with the a-tubulin
message decreased 2.6-fold.
5. Measurements of total intracellular IgG at high and low specific
productivity mirrored the decline in specific productivity; the total specific
intracellular IgG at low specific productivity was 1/10 that at high specific
productivity. This demonstrated that the decline in specific productivity was
due to reduced synthesis of IgG.
6. The decrease in immunoglobulin synthesis is part of a global decrease
in protein synthesis at high cell density. Work by Tyo (1991) demonstrated
that the rates of amino acid uptake decreased 10-fold as the specific
productivity declined.
Growth and Antibody Production in Bioreactors
7. Cell growth was balanced by cell death and removal of cells. The
growth rate did not change appreciably as the cell density increased and the
specific productivity decreased. Doubling times calculated from cell cycle
distributions in bioreactors #4-#6 at high and low productivity #4-#6 (Morrill,
1991) were similar to those observed in batch spinners in exponential growth
(16-20 hours) when the specific productivity is high (0.2 pg/c-hr). The growth
rate was also estimated from measurements of live and dead cells in the
bioreactors and in the outlet stream. Estimated growth rates varied from
0.045-0.014 hr -1 (doubling times 15.5-48.4 hours) and were not correlated with
specific productivity.
8. Downregulation of antibody productivity was not reversed by either
doubling the serum in the medium nor by doubling the concentrations of p-
mercaptoethanol, cysteine, and methionine in the medium. Therefore, the
downregulation of antibody production was not due to a serum nutrient
limitation nor due to lack of sulfur-containing amino acids.
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9. Downregulation of antibody productivity is not due to lack of oxygen
supplied to cells in the bioreactor, nor due to anoxic conditions in the cell
separator, as oxygenation of the conical cell settler did not affect cell growth or
antibody production.
Reversibility of Downregulation of Antibody Production at High Density
10. The downregulation of immunoglobulin synthesis observed at high
cell density is reversible. Cells removed from bioreactors and placed at low
cell density show the same specific productivity, plating efficiency, and
intracellular IgG content as cell grown for the same number of generations at
low cell density. Recovery of high productivity occurs with a characteristic
response time of 2-3 doubling times.
Characterization of Longterm Decline in Productivity
11. These cells exhibit a decrease in specific productivity as a function of
time in culture. The specific productivity of CLC LT14 cells maintained at low
cell density decreases about 3-fold over a period of one month in culture. The
decline in specific productivity is due to a decline in productivity of all of the
cells in the population, and is not due to the accumulation of a subpopulation
of non-producing cells.
This decrease in specific productivity is mediated by an approximately
2-fold decrease in the steady-state levels of heavy and light chain mRNAs.
The decrease in mRNAs is not due to a change in the stability, as the rate of
degradation of H and L mRNAs does not change. Rather, there is decreased
production of message, indicating that the amount of immunoglobulin
synthesized is proportional to the amount of immunoglobulin mRNAs.
The decrease in specific productivity is due to decreased synthesis of
immunoglobulin, as intracellular immunoglobulin levels declined linearly
with specific productivity.
249
·_ ___I
VI. Suggestions for Future Research
This thesis represents the first complete characterization of the
molecular cascade of immunoglobulin synthesis at conditions of high and
low productivity. Nevertheless, there are several areas in which future
research would be useful in elucidating the mechanism of the decline in
productivity seen at high cell density, and which would indicate how the
specific productivity in culture might be improved.
1) Determine the cause of the downregulation of antibody production at
high density.
It would be very interesting to determine the molecular mechanism of
the density-dependent downregulation of protein and immunoglobulin
synthesis. In this thesis, the decline in specific productivity has been
characterized in terms of the intermediates in immunoglobulin synthesis.
This work also showed that the translation of a-tubulin, a housekeeping
protein, was reduced at high density. In addition, work by Tyo (1991) showed
that the rates of amino acid uptake decline 10-fold at high density.
Others have shown that the rates of amino acid and oxygen uptake are
decreased at high density, and one group has shown that a component of the
plasma membrane of the cell causes a decrease in the growth rate of cells in a
concentration-dependent fashion. Alternatively, cells may secrete a factor
which causes downregulation of growth and protein synthesis.
2) Examine the phosphorylation of initiation factor eIF-2 at conditions of
high and low productivity.
A number of groups (see Section IV.G) have shown that the observed
decrease in protein synthesis seen in response to amino acid starvation,
serum deprivation, and other physiological stresses resulting in decreased
protein synthesis is due to an increase in the phosphorylation of the a
subunit of eIF-2. The extent of eIF-2a phosphorylation could be compared in
lysates of cells from conditions of high and low specific productivity;
alternately, rates of translation in such lysates could be measured.
250
... 1
3) Determine how specific productivity is related to the growth rate.
Experiments in continuous culture at several dilution rates with
different limiting nutrients would answer the question of how the specific
productivity is related to the growth rate of the cells; whether specific
productivity is not growth-related, as suggested by the experiments in
semicontinuous culture at different levels of dissolved oxygen, or whether
the specific productivity is growth-related, as found by others (Robinson et al.,
1991) for another transfectoma.
4) Determine the effect of cell density, at a constant growth rate, on
specific productivity.
Using the information obtained in 1), the bioreactor design could then
be modified to include a separate bleed stream to allow for removal of cells
from the bioreactor. This would allow the cell density to be varied
independently of the dilution rate, at a constant growth rate. This can be
done by varying the rates of removal from the cell separator and the bleed
stream. This type of experiment would answer the question of whether the
decline in specific productivity is dependent on cell density, as the data
strongly suggests, or due to the buildup of a metabolite other than lactate or
ammonia, perhaps a growth factor secreted by the cells.
5) Improve the performance of the cell separation device.
In the perfusion experiments described, the culture volume was
maintained at a constant level by setting the flow rate of the outlet pump
slightly faster than that of the inlet pump. This caused bubbles of air to be
withdrawn from time to time through the cell separator, which disrupted the
laminar flow necessary for cell separation. Therefore, measurements of the
cell density in the outlet stream varied depending on how recently a bubble
had passed through the separator. This caused significant variations in the
calculated separation efficiency, leading to unreliable estimates of the growth
and death rates. Using a level control to set the volume above the intake to
the separator would ensure that the separation efficiency varied only with the
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flow rate, and would allow more accurate estimates of the separation
efficiency, and hence better estimates of the growth and death rates.
6) Measure the stability of the heavy and light immunoglobulin mRNAs at
high and low productivity in the bioreactor via uridine labelling or addition
of DRB.
The measurements of immunoglobulin mRNA stability using
actinomycin D done during exponential growth for cells maintained in
culture for periods of 1 week to one month indicate that the stability of
immunoglobulin mRNAs did not change. However, it is possible that
mRNA stability decreased at high cell density in the bioreactor, leading to
lower levels of steady-state mRNAs.
7) Use cloning at limiting dilution or a cell immobilization technique to
isolate higher-producing cells.
The flow cytometry data as well as cloning data indicate great
heterogeneity in the capacity of individual cells for immunoglobulin
synthesis and secretion. While some of this heterogeneity may be a function
of the position of cells in different phases of the cell cycle, it nevertheless
should be possible to select higher producing cells.
8) Modify the expression vectors for the immunoglobulin genes.
Rates of immunoglobulin synthesis in myeloma cells are about 10-fold
higher than the peak specific productivity of these cells. As protein synthesis
during balanced growth is roughly proportional to steady-state RNA levels, it
seems that increasing the amount of immunoglobulin RNA synthesized
should increase the amount of IgG synthesized and secreted. RNA synthesis
could be increased either via gene amplification, providing more copies of
DNA template, or by genetic manipulation of the promoter and
immunoglobulin-factor binding sequences to resemble those found in
myeloma cells.
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Appendix 1: BASIC Program used to calculate antibody concentrations
from Elisa data
10 REM Program to analyze Elisa data
11 REM ********Written by M. Tyo; modified for Elisa by C.
Buser************
REM converted to Macintosh BASIC by M. Tyo
REM updated 10/27/89 to include tabular form of output file
REM UPDATED 1/25/90 to have max absorbance at 2.5 AU
20 PRINT CHR$(12): REM clear screen
22 PRINT: PRINT: PRINT " This program is to analyze Elisa
data."
23 PRINT: PRINT "
entering <R>."
24 PRINT: PRINT "
plotting options."
PRINT:PRINT"
results"
PRINT "
You may have gaps in dataset by just
This program has data saving and
This program also permits the saving of
in tabular form."
30 DIM M(25,25)
33 DIM abb(25)
35 PRINT: PRINT: PRINT" Please pr
STANDARD"
40 PRINT: PRINT: INPUT" Is data fron
41 IF LEFT$(ans$,1)="y" OR LEFT$(ans$,1)="Y" TF
48 PRINT: PRINT: INPUT" How ma
rows";rows
49 IF rows>24 THEN PRINT CHR$(7);"
48
50 PRINT: PRINT: PRINT" Enter STA
concentration [8]";: INPUT s8
60 IF s8<0 THEN PRINT: PRINT: PRINT CHR$(7);"
STANDARD VALUE": GOTO 50
65 IF s8=0 THEN s8=8
70 PRINT: PRINT
80 zold=z: PRINT: PRINT: PRINT" H
significant [";z;"]";: INPUT z
85 IF z=0 THEN z=zold
90 IF z>12 OR z<2 THEN PRINT: PRINT CHR$(7);"
epare data for
n disk file [N]";ans$
[EN GOTO 4000
ny STANDARD
Too many rows": GOTO
NDARD
INVALID
[ow many dilutions are
INVALID
RESPONSE - RANGE IS 2-12": GOTO 80
100 PRINT: PRINT: PRINT "Enter data by ROWS"
110 FOR j = 1 TO rows: FOR I=1 TO z
120 PRINT "COLUMN";STR$(I);", ROW";STR$(j);" = ";: INPUT M(I,j)
130 NEXT I: PRINT CHR$(7): NEXT j
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140 PRINT: PRINT: PRINT " THIS IS YOUR DATASET"
150 PRINT"COL->";: FOR I=1 TO z: PRINT TAB((I*6)+2);LEFT$(STR$(I),6);:
NEXT I: PRINT: PRINT
160 FOR j = 1 TO rows
170 PRINT "ROW";RIGHT$(STR$(j),1);: FOR I = 1 TO z
180 IF M(I,j)=0 THEN 190
185 PRINT TAB(I*6);: PRINT USING "#.###";M(I,j);
190 NEXT I: PRINT: NEXT j
200 PRINT: INPUT " Plot any row [N]";ans$
202 IF LEFT$(ans$,1)="Y" OR LEFT$(ans$,1)="y" THEN 5110
PRINT: PRINT: PRINT " THIS IS YOUR DATASET'
PRINT"COL->";: FOR I=1 TO z: PRINT TAB((I*6)+2);LEFT$(STR$(I),6);:
NEXT I: PRINT: PRINT
FOR j = 1 TO rows
PRINT "ROW";RIGHT$(STR$(j),1);: FOR I = 1 TO z
IF M(I,j)=0 THEN GOTO There
PRINT TAB(I*6);: PRINT USING "#.###";M(I,j);
There: NEXT I: PRINT: NEXT j
209 PRINT: PRINT: INPUT " Make Corrections [N]";ans$
210 IF LEFT$(ans$,1)="Y" OR LEFT$(ans$,1)="y" THEN 230
215 PRINT: PRINT: INPUT" Save this file [Y]";ans$
216 IF LEFT$(ans$,1)="N" OR LEFT$(ans$,1)="n" THEN GOTO 280
220 GOSUB 5000: GOTO 280
230 PRINT: INPUT " ROW, COLUMN TO EDIT",j,I
240 IF j<1 OR j>rows THEN PRINT: PRINT CHR$(7);"
INVALID ROW VALUE - RANGE 1 TO";rows: GOTO 230
250 IF I<1 OR I>z THEN PRINT: PRINT CHR$(7);" INVALID
COLUMN VALUE - RANGE 1 TO";z: GOTO 230
260 PRINT: PRINT " NEW VALUE FOR ROW",j;", COLUMN";I;:
INPUT M(I,j)
270 GOTO 140
280 N=0: SX=0: SX2=0: SY=0: SY2=0: SXY=0
290 FQ=0: FOR 1=1 TO z: FOR j=1 TO rows: X=I: IF M(I,j)=0 THEN FQ=1:
GOTO 310
295 Y=M(I,j): REM *** makes for regression
300 SX=SX+X: SX2=SX2+X*X: SY=SY+Y: SY2=SY2+Y*Y: SXY=SXY+X*Y:
N=N+1
310 NEXT j: NEXT I
320 b=(SXY-(SX*SY/N))/(SX2-(SX*SX/N)): REM ***linear regression
formula
330 a=SY/N-b*SX/N
331 IF flag=0 THEN
PRINT: INPUT" Value for comparison [0.6]";mmm
IF mmm=0 THEN mmm=.6
PRINT:INPUT' Please enter filename to contain saved
results";filnam$
PRINT:PRINT "Please enter text to appear in save file
heading"
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PRINT "=>T ";
LINE INPUT head$
OPEN filnam$ FOR OUTPUT AS #9
PRINT#9,head$
PRINT#9,"Standard Data from ";fil$;" and equivalence
absorbance= ";mmm
END IF
340 Q=-(a-mmm)/b : REM **********************
350 IF flag=0 THEN QO=Q
360 R=(N*SXY-SX*SY)/ (SQR((N*SX2-SX*SX)*(N*SY2-SY*SY)))
370 r2=R*R
380 PRINT: PRINT" R-SQUARED =";LEFT$(STR$(r2),5)
390 IF flag>0 THEN
PRINT
PRINT " SAMPLE CONCENTRATION
=";LEFT$(STR$(2A (Q-Q0)*s8),6)
PRINT
PRINT "Notes for save file ( 15 character max) =>";
INPUT "", note$
note$=LEFT$(note$,15)
PRINT#9,fil$;
PRINT#9, TAB(10)-note$;
PRINT#9,TAB(25);
PRINT#9,USING "##.##";2A (Q-Q0)*s8;
PRINT#9,TAB(40);
PRINT#9,USING ".###";r2;
PRINT#9,TAB(50);
PRINT#9,USING "#.###";a;
PRINT#9,TAB(60);
PRINT#9,USING "#.####";b
GOTO 430
ELSE
PRINT#9, "Standard r2 =";r2,"A=";a,"b=";b
PRINT#9,""
PRINT#9,"":PRINT#9,"":PRINT#9,"FILENAME";TAB(12);"NOTES";T
AB(25);"Conc'n";TAB(42);"R2";TAB (52);"A";TAB(62);"B"
END IF
410 PRINT: PRINT: PRINT" Please prepare data for SAMPLES":
PRINT: PRINT
411 flag=flag+l
412 PRINT: PRINT: INPUT" Is data from disk file [N]";ans$
414 IF LEFT$(ans$,l)="y" OR LEFT$(ans$,1)="Y" THEN GOTO 3000
415 PRINT: PRINT: INPUT " How many SAMPLE rows";rows
416 IF rows<1 THEN PRINT CHR$(7): PRINT: PRINT"
Invalid response": GOTO 415
419 IF rows>24 THEN PRINT CHR$(7);" Too many rows": GOTO
415
420 flag = flag+1: GOTO 80
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430 flag=flag+l
435 PRINT: PRINT: INPUT" MORE SAMPLES FROM THIS PLATE
[Y]";ans$
440 IF LEFT$(ans$,l)="n" OR LEFT$(ans$,1)="N" THEN 450
441 PRINT: PRINT: INPUT " Is data from disk file [N]";ans$
442 IF LEFT$(ans$,1)="y" OR LEFT$(ans$,1)="Y" THEN GOTO 3000
445 oldrows=rows: PRINT: PRINT: PRINT " How many SAMPLE
rows [";rows;"]";: INPUT rows
446 IF rows>24 THEN PRINT CHR$(7);" Too many rows": GOTC
445
447 IF rows=0 THEN rows=oldrows
448 GOTO 80
450 PRINT: PRINT: INPUT" CALCULATE DATA FROM
ANOTHER PLATE [N]";ans$
460 IF LEFT$(ans$,1)="Y" OR LEFT$(ans$,l)="y" THEN flag=0: GOTO 40
CLOSE #9
GOTO 6000
3000 PRINT: PRINT: INPUT " What is name of disk file you wish to
recall";fi$
3010 OPEN fi$ FOR INPUT AS #2
3020 INPUT#2,s8: INPUT#2,rows: INPUT#2,z
3030 FOR I=1 TO z
3040 FOR j=1 TO rows
3050 INPUT#2,M(I,j)
3060 NEXT j: NEXT I
3070 CLOSE#2
3080 GOTO 140
4000 PRINT: PRINT: INPUT " What is name of disk file you wish to
recall";fil$
4010 OPEN fil$ FOR INPUT AS #2
4020 INPUT#2,s8: INPUT#2,rows: INPUT#2,z
4030 FOR I=1 TO z
4040 FOR j=1 TO rows
4050 INPUT#2,M(I,j)
4060 NEXT j: NEXT I
4070 CLOSE#2
4080 GOTO 140
5000 PRINT: PRINT: INPUT " Filename to save to";fil$
5005 IF fil$="" THEN PRINT: PRINT: PRINT CHR$(7);" Excuse
me. I missed that": GOTO 5000
5010 OPEN fil$ FOR OUTPUT AS #1
5020 PRINT#1,s8: PRINT#1,rows: PRINT#1,z
5030 FOR I=1 TO z
5040 FOR j=1 TO rows
5050 PRINT#1,M(I,j)
5060 NEXT j: NEXT I
5070 CLOSE#1
5080 RETURN
5110 PRINT: INPUT " Which row to plot";brow
)
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5111 IF brow>rows OR brow<l THEN PRINT CHR$(7);"INVALID ROW!!":
GOTO 5110
PRINT: PRINT
5140 FOR xb=l TO z
5145 IF M(xb,brow)>0 THEN yb=(abb(xb)-least) ELSE yb=0
5150 IF M(xb,brow) <>0 THEN PRINT xb;TAB(5+M(xb,brow)/2.5*55);"*" ELSE
PRINT xb;TAB(5+M(xb,brow)/2*55);"o"
PRINT
5160 NEXT xb
5170 GOTO 200
6000 END
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Summary
Oxygen, although essential to the growth of mam-
malian cells in vitro and in vivo, has been widely
reported to be toxic at concentrations at or above the
oxygen concentration in culture medium equilib-
rated with air (approximately 200 uM). We were
therefore surprised to note that a diploid human
B-cell line (TK6) was able to proliferate normally
while exposed to 380 pM-oxygen. This observation
was extended to Vero (African Green monkey kid-
ney) cells, and Sp2/0-derived murine transfectomas
producing antibody. Using an experimental system
with a high capacity for oxygen transfer, we deter-
mined the growth rates of the three cell lines at
controlled oxygen concentrations ranging from
80 pM to 910 pM. Each of these cell types was able to
grow normally at oxygen concentrations up to
360-380 gM. At oxygen concentrations above 380 pM,
a significant increase in the apparent doubling
times of the cells was observed. No adverse effect of
oxygen on TK6 cell survival was seen for concen-
trations ranging from 60 pM to 410 pM. We conclude
that exponential growth at nearly maximum growth
rates was observed for Sp2/0-derived cells, TK6,
and Vero cells at constant oxygen concentrations up
to 400 pM (twice air saturation).
These findings have substantial implications for
process control in the production of cells and cell-
derived materials. The intrinsic oxygen transfer
rate of any cell culture vessel can be increased
severalfold by raising the oxygen gas concentration.
In practice, this should permit significant increases
in the operating cell density without the difficulty
and expense of oxygen control feedback loops.
Using this information it should be possible to
eliminate oxygen transfer as a limiting factor in
high-density cell culture technology.
Key words: oxygen, high cell density, lymphoblastoid cells,
Vero cells, Sp2/0 cells.
Introduction
Oxygen is an essential requirement for the normal growth
of mammalian cells, but concentrations in excess of
200 yM (160 mmHg partial pressure or 21 % oxygen in the
gas phase) have been reported to inhibit the growth and
metabolism of a number of cell types. Usually, cells are
grown in culture equilibrated with air (21 % gas-phase
oxygen). Under these conditions, the cells are exposed to
dissolved oxygen concentrations of 200 hUM or less. Cooper
et al. (1959) found that, while embryo rabbit kidnev cells
grew well at 210 yM-oxygen, their growth rate was halved
at just 230 lM, and concentrations of 240-285 yM were
'rapidly cytocidal'. Similarly, Balin et al. (1976) showed a
marked inhibition in WI-38 human diploid fibroblast
growth as the oxygen concentration was increased from
165 pM to 365 MM. Hyperatmospheric oxygen (465 MM)
was reported by Balin et al. (1978) to reduce the rate of
DNA synthesis and to delay mitosis in WI-38 cells.
However, Rueckert & Miller (1960) reported good HeLa
cell growth at 285 gM-oxygen.
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Some investigators have isolated subpopulations or
clones with a high tolerance for oxygen after a lengthy
period of adaptation to gradually increasing concen-
trations of oxygen. For example, Joenje et al. (1985)
reported that HeLa cells could grow in the presence of an
oxygen concentration of about 760 pm after a period of 21
months of adaptation.
Assays for plating efficiency also have been used to
investigate oxygen tolerance. Using a variety of human
and murine embryonic cell types, Bradley et al. (1978)
reported marked decreases in colony formation efficiency
as the oxygen concentration was increased from 6 0 yM to
170 MM. Taylor et al. (1974) found a tenfold increase in
WI-38 plating efficiency at 10Mm as compared with
190 pM. The plating efficiency of Vero cells was reported
to be unaffected in this range of oxygen concentrations.
The apparently narrow range of dissolved oxygen
concentration (between 40 yM and 140 MM) believed suit-
able for cell growth has had a pronounced effect on the
design of large-scale mammalian cell production devices.
At a density of 2x 107 cells ml - ', typical human cells will
mn ý E -I I I
consume 1-10 mmol oxygen I-1 h-' (Fleischaker & Sins-
key, 1981). The low solubility of oxygen in aqueous
medium (200 pM-oxygen at air equilibrium) relative to its
rate of consumption causes its rate of supply to be the
limiting factor for cell growth.
The oxygen transfer rate in a fermentor is described
OTR = KLa(Cgas - Cliq) ,
where OTR = oxygen transfer rate in lmol 02 1- 1 h-l;
KLa = mass transfer coefficient in h-'; Cga, = gas-phase
02 (equilibrium) concentration in pM; and Cliq = liquid-
phase 02 concentration in pM. This equation implies that
the OTR can be increased by either an increase in the
KLa or an increase in the driving force (Cgas-Cliq).
Dissolved oxygen concentrations are frequently ex-
pressed as the oxygen concentration in the liquid in
equilibrium with the partial pressure of oxygen in the gas
phase ('oxygen tension', p02). The gas POz may be
expressed asmmHg, where 760mmHg corresponds to
pure oxygen at I atmosphere, 150mmHg is the partial
pressure of oxygen in water vapor-saturated air, and
160mmHg is the partial pressure of oxygen in dry air.
Dissolved oxygen may also be expressed as the oxygen
concentration in the liquid in equilibrium with % oxygen
in the gas phase. Here, we define 100% as one atmos-
phere of pure oxygen. Thus, air is 21% oxygen.
We have estimated actual levels of dissolved oxygen in
media by calculating the reduction in solubility in me-
dium (due to salts) as compared to that in distilled water
using the technique of Schumpe et al. (1978). The
concentration of oxygen in medium in equilibrium with
dry air at 37 C is approximately 200 pM. Saturation of the
air with water vapor at 37 0C reduces the equilibrium
oxygen concentration to approximately 190 pM.
To overcome the limitation of the low solubility of
oxygen in culture medium, microbial fermentations are
typically aerated by direct sparging of air into the
fermentor. However, sparging of mammalian cell cul-
tures was reported by Kilburn & Webb (1968) and
Telling & Radlett (1970) to be detrimental to cell growth
rate, viability and maximum attainable cell density.
Handa et al. (1987) recently related this effect to bubble
size and frequency as well as cell type. Several alternative
means have been developed to improve the oxygen
transfer rate, including submerged silicone tubing (Tyo
& Wang, 1980; Kuhlmann, 1987), microporous tubing
(Lehmann et al. 1987), caged aeration (Whiteside et al.
1985), and fluorocarbon supports (Munder et al. 1971).
Most fermentor design in the past has centered on
increasing KLa (Spier & Griffiths, 1984; Aunins et al.
1986). The concentration of oxygen in the gas phase
(C,,), which is the driving force for oxygen transfer, has
usually been kept low at the onset of growth, in an effort
to avoid the putative deleterious effects of elevated
oxygen concentrations. For example, Fazekas de St.
Groth (1983) oxygenated hybridoma cultures using sur-
face aeration with a 10 % oxygen gas mixture. This poses
the problem of having reliable dissolved oxygen probes
and feedback systems to monitor oxygen levels. Our
observations suggest that some cell lines can tolerate
oxygen at elevated concentrations (above 200 pM, air
equilibrium); cultures could then be operated with an
elevated oxygen concentration in the gas phase (Cgas).
This would increase the driving force available during the
later stages of the culture, overcome the limitations of the
low solubility of oxygen in the medium, create a greater
oxygen transfer rate, and ultimately result in an increased
maximum cell density, without the necessity of utilizing
costly oxygen feedback control loops.
During unrelated studies on the effects of oxygen on
cell mutation rates, one of us (A.O.) observed that a
human B-cell line (TK6) was able to grow normally at
constant oxygen concentrations in the gas phase of 40 %,
that is, approximately 380 pM dissolved oxygen. Further-
more, these cells were able to grow with no toxic effects
(as determined by plating efficiency) at an oxygen
concentration of 410 /iM.
To see if this phenomenon was applicable to other cell
lines of importance in biotechnology, we investigated the
effects of high oxygen concentrations on Vero (African
Green monkey kidney) cells and murine cells transfected
with chimeric antibody genes (Sp2/0 derived). Vero cells
have widespread application in human virus vaccine
production, and hybridomas and transfectomas are of
central importance in the production of monoclonal
antibodies.
Materials and methods
Cells
TK6 is a diploid human lymphoblastoid cell line derived from
WI-L2 (Skopek et al. 1978). WI-L2 was originally isolated at
the Wistar Institute (Philadelphia, PA) from the lymphocytes of
a male donor. Vero cells are derived from African Green
monkey kidney and are a stable, diploid, anchorage-dependent
cell line obtained from the Institut Armand-Frappier (Laval,
Quebec). Murine cells, obtained from Centocor, Inc. (Mal-
vern, PA), are an Sp2/0-derived cell line, transfected with
chimeric mouse-human antibody genes, which secretes IgG
(Shaw et al. 1988).
Media
TK6 cells were grown in suspension in RPMI 1640, containing
2gl - 1 sodium bicarbonate, supplemented with 10% horse
serum. Vero cells were grown on DEAE-Sephadex microcar-
riers (Superbeads, Flow Laboratories, McLean, VA) in RPMI
1640 supplemented with 10 % horse serum. Sp2/0-derived cells
were grown in suspension in DMEM, containing 3-7g1-1
sodium bicarbonate, supplemented with 2mM-glutamine,
2mM-pyruvate, 50 ~M-p-mercaptoethanol, and 2-5% each of
horse serum and heat-treated fetal bovine serum. Media and
sera were obtained from Gibco Labs (Grand Island, NY), and
Hyclone (Logan, UT), respectively, and other media sup-
plements were obtained from Sigma (St Louis, MO).
Gas mixtures
Premade gas mixtures were obtained commercially (Granite
State Oxygen, Nashua, NH) or were made by combining
individual gases (Middlesex Welding Supply, Everett, MA).
Commercial gas mixtures contained 5% carbon dioxide, the
indicated proportion of oxygen, and the balance as nitrogen.
Gas mixtures from individual gas tanks were prepared by
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combining oxygen, air (21% oxygen), nitrogen and carbon
dioxide, using a mass flowmeter (Matheson Gas Products, East
Rutherford. NJ) to measure the flow rates. Dissolved oxygen
probes (Ingold, Waltham, MA) were used to measure the final
oxygen concentration in the medium equilibrated with each gas
mixture.
Methods
TK6 cells were grown in 500 ml modified Ball canning jars with
approximately 80cm of silicone rubber tubing (Cole-Parmer,
Chicago, IL), A inch inner diameter and j inch outer diameter,
coiled inside against the walls with the outlet venting to the
outside of the jar. Cells were counted and diluted daily to keep
them in exponential growth (cell densities between 3 10s to
9x 10' cells ml - ). Dry gas mixtures at a constant flow rate of
500mlmin - i were passed through the silicone tubing and
equilibrated with the medium. A Pasteur pipette and two
sections of tubing permitted sterile sampling and diluting via
siphoning. The KLa for oxygen transfer in this system was
2-5 h- . Cultures were grown at 370C with constant stirring.
Control cultures were grown without gas mixture being
pumped through the tubing. Under these conditions, the
oxygen levels in the control culture varied from 200 pM immedi-
ately following dilution to 50 Mm prior to dilution on the next
day. The pH of the medium varied daily from 6-9 to 7-4. No
differences in pH were found between the control cultures
growing without gas pumped through the tubing and the
cultures grown at constant oxygen concentrations.
Toxicity measurements were made either by a cloning assay
or by back extrapolation of growth curves after ceasing treat-
ment using the technique of DeLuca et al. (1983). Both
methods measure relative survival, and yielded the same
survival estimates when used concurrently after exposure of the
cells to high oxygen concentrations. In the cloning assay,
relative plating efficiency at 2-4 cells/well was measured using
96-well microtiter plates.
Stock Vero cells were grown on polystyrene roller bottles
(Coming), in RPMI 1640 supplemented with 10% horse
serum. Freshly trypsinized cells were resuspended in fresh
medium and counted using either a Coulter Counter or a
hemocvtometer. Viability was always in excess of 99% as
judged by Trypan Blue exclusion.
Cultures were inoculated at a cell density of 2-4x10 s
cells ml-1 with 4 gl-' of microcarriers in a volume of approxi-
mately 150 ml. Cultures were grown in spinner flasks having a
suspended magnetic stirrer and were sampled daily. The cell
density was enumerated by counting stained nuclei (Sanford et
al. 1951). The spinners were fed with fresh medium every 1-3
days, as needed to prevent medium acidification.
Control cultures were kept in a 37 C incubator with 5 %
CO 2. Experimental cultures were grown at a constant dissolved
oxygen level. Approximately 16 m of silicone rubber tubing
(Dow, Midland, MI), 0-058 inch inner diameter and 0"077 inch
outer diameter, was formed into a coil and placed inside the
spinner with the outlet venting to the headspace. The gas
mixture with the desired proportion of oxygen and 5 % COz was
first humidified by passage through a column of water at 370 C,
and then passed through the silicone tubing. Calculated oxygen
concentrations for these experiments were corrected for the
partial pressure of water vapor at 370C (47 mmHg). The oxygen
permeability of the tubing combined with surface aeration was
determined to have a KLa of about 10 h-1 for this system. As
was found for TK6 cultures, the pH was the same for control
Vero cell cultures and cultures grown at constant oxygen.
Sp2/0-derived cells were grown in the same spinners de-
scribed for Vero cells. Cells were inoculated from exponentially
growing stock cultures at 3x 10scellsml - l and diluted to
maintain the cell density between 3x 10s and 12x 10s cells ml-.
Spinners were sampled and the cells counted daily. Control
cultures were grown in a 370 C incubator with 5% CO z .Experimental culture oxygenation was as described for Vero
cells.
Results
TK6 lymphoblasts
We examined the growth and viability of TK6 cells over a
period of several days as a function of constant oxygen
concentrations ranging from 6 0 /M to 910t M. Control
cultures were grown under the same conditions without
regulation of the dissolved oxygen. The control vessels
were sealed and gas exchange arose solely by surface
aeration from headspace air. The oxygen concentration in
the control cultures varied from 200 pM immediately
following dilution of the cells to 50/M prior to dilution
the next day. Control cultures grew with a doubling time
of 14-15 h. Figure lA shows the growth curves of TK6
cells at various constant oxygen concentrations. Cell
cultures were diluted daily and the relative cumulative
cell number was plotted. TK6 cells grew between con-
stant 1 0 0 yM and 380 pM-oxygen with a doubling time of
15-16h. At constant oxygen concentrations of 6 0 M or
410OMM, cells grew with a doubling time of 18h. At
constant oxygen concentrations of 520 pM and 650 /M, the
apparent doubling times were 20 and 33 h, respectively.
We report the apparent doubling time of these cultures
because the information derived from the growth curves
alone does not allow us to distinguish between cytostatic
and cytotoxic effects of high oxygen concentrations. To
discriminate between these two possible effects, we
measured survival at different times during exposure,
either by a cloning assay or by back extrapolation of
growth curves after ceasing treatment. Table 1 shows the
relative survival (viability) of TK6 cells at various times
during growth at various constant oxygen concentrations.
No adverse effects of oxygen on relative survival were
detected for oxygen concentrations of 60 MM, 100 MM,
280MM, 3 80aM and 4 10MM. Thus, the inhibition of
growth seen at 4 10 pM (doubling time of 18 h) was not due
to cell killing. However, at constant oxygen concen-
trations of 5 2 0 pm and 650M M, survival of the cells
decreased to 50 % and 37 %, respectively, after 2 days of
exposure. This cvtotoxic effect thus contributed to an
apparent doubling time of 20 h and 33 h, respectively. At
these oxygen concentrations, survival remained approxi-
mately constant with continuous exposure for 4 days and
a partial recovery from the toxic effects of oxygen was
observed after 4 days (data not shown). During continu-
ous exposure to 910 /M-oxygen, a monotonic decrease in
survival was detected. After 24 h, 70 % of the cells were
viable and after 48 h, about 40 % of the cells were viable.
These toxic effects were not reversible with time, as cell
survival continued to decrease exponentially as a function
of time of exposure.
The apparent doubling time of TK6 cells as a function
of oxygen concentration is shown in Figure 2. These
values are derived from the data of Figure 1A and show a
plateau region between constant oxygen concentrations of
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Fig. 1. Growth curves at various oxygen concentrations. A. TK6 cells. (@) 80 pM (60 mmHg); (0) 100 pM (80 mmHg);
(A) 280 yM (215 mmHg); (A) 410 pM (310 mmHg); (M) 520 pM (425 mmHg); (0) 650 Mm (510 mmHg); (*) 910 pM
(720 mmHg). B. Vero cells. (0) No oxygen control; (0) 180i M (143 mmHg); (A) 360pM (285 mmHg); (A) 540 Mm
(428 mmHg); (0) 715 pm (570 mmHg). C. Sp2/0-derived cells. (0) No oxygen control; (0) 90 yM (71 mmHg); (A) 180 Mm
(143 mmHg); (A) 360 M (285 mmHg); (M) 540 MM (428 mmHg).
% Oxygen in gas at 1 atm.
0 10 20 30 40 50
60 and 280 p•. In this range of oxygen concentrations,
cells can grow with an approximate doubling time of
14-18 h (0-9-1-2 times the control with no gas), without
0 1 I I I I I I any e ffect on colony forming efficiency.
'ero cells
Growth of Vero cells in batch culture was examined for
oxygen concentrations between 180 LM and 715 /M. Con-
trol cultures were grown without regulation of oxygen
levels. Oxygenation was provided by surface aeration
from the headspace, which was open to the 5 % COz
incubator. The doubling time of control cultures ranged
f - 1 A1 3 .. l:l•DDT lgAA -,,:.. . .11
o IrIIr J LO to14 h using PIVIll It6,I mediumIII. tero ce s
grow at faster growth rates in other media such as
Leibovitz L-15 or Dulbecco's modified essential medium(data not shown). Figure 1B shows the growth curves for
o0 Vero cells at various constant oxygen concentrations, as
well as two control cultures without oxygen regulation.
Relative cell number was plotted as a function of time.
Th d bli ti 
t 180 M 45 h 
-
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ling times at 3 6 0 MM and 540 M were 48 and 68 h,
0 I I I I I I respectively. No significant growth was observed at
0 80 160 240 320 400 480 560 715 pM. The cells from the cultures grown without
Oxygen tension (mmHg) oxygen regulation (controls), as well as the cultures
I I I I I I I I grown at constant oxygen concentrations of 180 M and
0 100 200 300 400 500 600 700 360 /M appeared cytologically normal and were morpho-
Oxygen concentration (pM) logically indistinguishable (data not shown). In the
cultures grown at constant oxygen concentrations of
Apparent doubling time as a function of constant 540 pM and 715 Mm there were fewer microcarrier-at-
concentration. (0) TK6 cells; (0) Vero cells; tached cells and many cell fragments in the medium. The
p2/0-derived cells. 1 atmosphere = 101325 Pa. sample supernatants were clear for the controls and the
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Table 1. Percentage relative survival of TK6 cells
during growth at various constant oxygen
concentrations
Oxygen Days
concentration
(pM) 1 2 3 4
PE,GB PE,GB PE,GB
60 n.d. 86 98 107
nml n 2 n= l
PE PE.GB PE PE.CB
100 89 98 101 98
n - n= 2 n =l n I
PE,GB PE.GB PE,GB PE.GB
280 110 98 98 106
n -= n=
2  
n=l n =2
PE,GB PE.GB PE,GB PE,GB
380 96 96 98 100n-1 n- I n=l n=l
PEGB PE.GB PE,GB PE,GB
410 92 100 102 109
n =- l n = 2 n 2 n = 2
GB GB
520 n.d. 50 n.d. 40
n---1 n=l
PE.GB PE.GB
650 n.d. 37 n.d. 36
PE,GB PE.GB PE,GB
910 73 36 20 n.d.
n -10 l10 n- 3
Upper right corner: method used to measure relative survival; PE,
plating efficiency relative to control culture; GB, back extrapolation
of growth curves after ceasing treatment. The absolute plating
efficiency of control cultures was between 60 and 80%. Lower right
corner: n, number of replicate experiments. n.d., not determined.
cultures at 180 and 360 pM, indicating that very few, if
any, cells had detached. Since separate measurements of
colony forming efficiency were not performed we cannot
distinguish between cytostatic and cvtotoxic effects of
oxygen. Therefore, the cell counts may overestimate the
number of potential colony forming cells.
Figure 2 shows the apparent doubling time as a func-
tion of dissolved oxygen. Doubling times were estimated
for days 1-3 in culture. Both the maximum cell density
achieved and the growth rate during the exponential
phase were reduced at oxygen concentrations of 360 and
540 pM. Thus, the Vero cells appear to be somewhat more
sensitive to higher oxygen concentrations than the TK6
cells, but the relationship between dissolved oxygen and
minimum doubling times is similar. Thus it appears that
oxygen concentrations as high as 360 pM can be used for
fermentor growth of Vero cells.
Sp2/0-derived cells
Growth of Sp2/0-derived cells was examined at constant
oxygen concentrations ranging from 90p M to 540 pM.
Again, oxygenation of unregulated control cultures was
provided by surface aeration from the headspace, which
was open to the 5 % CO 2 incubator. The doubling time of
control cultures was 14-15h. Figure IC presents the
growth curves of the hybridomas at various concen-
trations of dissolved oxygen, shown as relative cumulat-
ive cell number. Doubling times were approximately
constant over a 5- to 7-day period for all cultures and were
calculated from growth data between days 1 and 5.
Doubling times for cultures at constant 90 pM-oxygen
were 14-15 h, identical to the control cultures. Doubling
times at 180 pM, 360 pm and 540OpM-oxvgen were
15"8-16-2, 19-5 and 31 h, respectively. The doubling
times as a function of the dissolved oxygen concentration
are shown in Figure 2. It can be seen that growth at
360 pM-oxygen was slightly slower in relation to that in
the control cultures. Doubling time as a function of
dissolved oxygen concentration essentially parallels the
results seen for TK6 and Vero cells.
Discussion
Oxygen transfer is frequently the limiting factor for scale-
up of animal cell culture processes. To assess the oxygen
tolerance of three different cell lines, we examined their
growth rates under a variety of controlled oxygen concen-
trations: Doubling times were used as the principal
indicators of the overall health of the cultures. We
observed that these cell lines could grow at or near their
maximum rates at concentrations of 300-400 pM-oxygen,
well in excess of air saturation (200 pM). Moreover, for all
these lines, continued exponential growth was seen at
concentrations up to 540 pM-oxygen.
The influence of dissolved oxygen on the plating
efficiency of TK6 human lymphoblasts permitted us to
distinguish the reversible effects of oxygen on cell growth
rates from its irreversible effects on cell survival. Ex-
posure of the cells to constant oxygen levels up to 410 pM-
oxygen did not affect cell survival. Oxygen levels of 520,
650 and 910j M did result in a loss of cell viability.
Interestingly, it appeared that cultures may regain faster
doubling times after 4 days at 520 pM or 650 pM-oxygen.
This point deserves further study.
The particular cell lines chosen for this investigation,
TK6 human lymphoblasts, Vero monkey cells and
Sp2/0-derived murine cells, were not chosen for their
oxygen tolerance and are not known to be unusually
tolerant of oxygen. Vero cells were chosen because of
their widespread use in the commercial production of
viral vaccines. Sp2/0 cells are frequently used as fusion
partners for hybridoma production and also as recipients
for transfection of antibody genes, and TK6 cells are used
in genetic toxicology. We were therefore surprised to note
that three different cell lines are capable of exponential
growth at near-maximum rates in the presence of oxygen
at twice the level of atmospheric saturation and four times
the level of 100 pM-oxygen generally:used as a set point for
mammalian cell fermentor oxygen regulation.
It is possible that widespread misconceptions concern-
ing oxygen intolerance arose from the fact that many early
investigators used normal cells, rather than established
cell lines, in their experiments. Established cell lines also
differ from normal cells in their metabolism; for
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example, thev exhibit enhanced glycolytic rates (Lanks &
Li, 1988). Cells reported to be sensitive to atmospheric
oxygen levels were either embryonic in origin (Cooper et
al. 1959) or were mortal diploid fibroblast strains (Balin
et al. 1976, 1978). However, those who investigated
HeLa cells (Rueckert & Mueller, 1960; Joenje et al. 1975)
reported cell growth up to 300 pM-oxygen. Now that
several established cell lines are licensed for the pro-
duction of vaccines and other products, a reconsideration
of oxygen tolerance for each cell line would be appropri-
ate.
Unlike many previous authors, who adjusted only the
oxygen content of the gas phase, we have taken special
care to control the dissolved oxygen content of the
medium in a well-mixed fermentor, as opposed to con-
trolling only the gas phase. It was pointed out by
McLimans et al. (1968) that cells grown in a stationary
monolayer culture (such as in a Petri dish) will establish a
diffusional concentration gradient of oxygen, resulting in
an oxygen concentration of nearly zero in the immediate
vicinity of the cells. Even well-mixed suspension systems
will exhibit significant differences between the oxygen
content of the headspace gas and that dissolved in the
medium, dependent on both the KLa and the oxygen
uptake rate. Through the use of a substantial quantity of
submerged silicone tubing for oxygen transfer (to obtain
a high KLa) and regular dilution of the experimental
cultures (to reduce the cell concentration and therefore
oxygen demand), we have minimized the gas-liquid
concentration gradient necessary to maintain the desired
oxygen concentration in the medium.
Our observations lead us to suggest that a simple
method of increasing oxygen transfer rate and fulfilling
the oxygen demand of the cells is to increase the oxygen
concentration in the gas phase. During cell growth, as the
cell density increases the oxygen concentration in the
liquid decreases. However, this decrease in oxygen con-
centration causes the rate of oxygen transfer to increase.
Therefore, as the cell density increases the oxygen
demand of the cells is continuously satisfied until the
cellular oxygen uptake rate exceeds the rate at which
oxygen can be supplied to the culture. However, through
the use of high oxygen concentrations in the gas phase,
the oxygen transfer rate can be several times higher than
that obtained using air alone. This allows cells to grow to
a higher density before the rate of oxygen transfer
becomes the limiting factor for cell growth.
A demonstration of the utility of our findings is shown
by considering two similar cell cultures in the following
example. We will assume that one fermentor is gassed
with air, and that the other is gassed with 42 % oxygen
gas. Neither vessel has an external oxygen controller.
Immediately after inoculation, the medium in both
vessels will be close to equilibrium with the gas phase.
The cells will grow exponentially in both cultures, and
the dissolved oxygen concentrations in both will fall until
the concentrations reach some final rate-limiting value
(assumed here for purposes of illustration to be 60 pM).
The oxygen uptake rate of Vero cells was determined to
be 0.24"x 10- 6 pmol oxygen cell- L h- (data not shown).
At a KLa of 10 h- 1 (obtainable using silicone tubing) and
a final liquid oxygen concentration of 60 pm, the oxygen
transfer rate attainable using air is 1400 pmoll - I h-
Therefore, gassing the culture vessel with air can permit
Vero cells to grow exponentially to a density of
5-8xl06cellsml - . On the other hand, if the other
culture vessel is gassed with an oxygen-enriched gas
mixture consisting of 42 % oxygen, the oxygen transfer
rate will be approximately 3400 pmol1-' h (again as-
suming a final liquid oxygen concentration of 60 pM).
This is sufficient to support exponential growth up to a
cell density of about 1-42x 107 cells ml - , representing a
2"4-fold increase over that obtainable through the use of
air alone. Of course, such a culture would also require
medium perfusion to attain such a high cell density.
In summary, the previously unrecognized abilitv of
human lymphoblasts, Vero cells and murine transfectoma
cells to grow exponentially in the presence of high
concentrations of oxygen enables the operation of a
culture vessel with either oxygen-enriched gas mixtures
or with air under pressure. This design provides a simple
way of increasing the maximum attainable cell density
and/or maximum culture size, without the expense andi
complication of oxygen control feedback loops. The use
of oxygen-enriched gas for aeration provides an attractive
alternative technique for the scale-up of high-density
mammalian cell cultures.
This work was supported by NIEHS grant NIH-S-P01-
ES00597, US DOE grant DE-F602-86-ER60448 and a Research
Agreement from Centocor Inc.
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Abstract
Culturing mammalian cells such as hvbridomas in continuous high cell density perfusion systems is
desirable because it allows increased volumetric productivity and decreased capital costs. However,
in many systems the specific productivity (mAb/cell-hr) drops off as the density increases to a 107
c/ml. We studied the molecular cascade of antibody production in high cell perfusion bioreactors in
order to begin to understand regulation of antibody production and examine the mechanism(s)
involved in the decrease in specific productivity. Sp2/0-derived transfectomas which secrete a
human-mouse chimeric IgG were grown to high cell density in perfusion bioreactors with a conical
lamellar cell settler to effect cell recycle. We used a kinetic model to calculate the growth and
death rates, and total (ug mAb/ml-hr) and specific (pg mAb/cell-hr) antibody production rates.
Steady-state levels of immunoglobulin heavy and light chain mRNA, and intracellular IgG were
measured using samples of cells removed from the bioreactors. In the bioreactors, a cell density of
107 viable cells/ml was achieved at a perfusion rate of 3 volumes per day, a condition where the
cells were not nutrient limited. The growth rate remained constant throughout the experiments at
about 0.029-0.035 hrr' and was balanced by cell death and removal of cells. Volumetric antibody
production increased from approximately 0.15 to 0.35 ug/ml-hr as the cell density approached 167
cells/ml. However, specific antibody production decreased from 0.15 pg/cell-hr at cell densities less
than 5 x 105 cell/ml to less than 0.01 pg/cell-hr at cell densities greater than 5 x 105 cell/ml, a 10 to
20-fold decrease in specific productivity. This decrease was accompanied by a 50-70% drop in both
immunoglobulin heavy and light chain mRNAs. Intracellular IgG content at high cell density
decreased by 90%. We showed that the downregulation of immunoglobulin production observed at
high cell density was reversible, as cells removed from the bioreactors and placed into low density
spinners regained their original level of productivity. The observation that immunoglobulin mRNAs
are decreased by only 50-70%, but that specific mAb productivity is decreased by more than 90%
suggests that the decrease in IgG production is both under transcriptional and translational control.
A
Introduction
Monoclonal antibodies have myriad public health applications, ranging from use in clinical
applications to anticancer therapy and treatment of septic shock. While the demand for monoclonal
antibodies for diagnostics is small, a few grams per year, the use of monoclonal antibodies for human
therapy requires large quantities of very pure antibodies, which may be conservatively estimated at 5-
50 kilograms/year for each therapeutic monoclonal antibody (1,2).
In addition, monoclonal antibodies used for human therapy must be such that they do not
provoke an immune response in patients. This requires that either the whole antibody or at least the
constant regions of the immunoglobulin heavy and light chains are of human origin, as the use of
murine monoclonal antibodies in clinical trials has resulted in the production of anti-idiotype
antibodies in patients (2,3,4). The construction of human-mouse chimeric antibodies has been reviewed
(5,6). Usually, the portion of an immunoglobulin gene encoding a human constant region is joined to a
murine variable region isolated from a hybridoma expressing mAb of the desired specificity, cloned
into an appropriate vector, and then transfected into a recipient non-producing myeloma line. This is
done for both the heavy and light chain genes.
The need for such large quantities of monoclonal antibodies dictates their production in cell
culture. While batch production has been sufficient to meet the demand for monoclonals in the past,
the only practical means for production of large quantities is via high cell density perfusion culture.
Production in high cell density perfusion culture is desirable for a number of reasons. It affords the
advantages of a reduction in the size of equipment needed, a reduction in the quantity of medium
needed, a decreased need for serum and/or growth factors, as well as continuous operation. These
advantages result in lower operating costs per unit of monoclonal antibody produced.
Perfusion culture systems for suspension cells may be classified as homogenous or
nonhomogeneous. Nonhomogeneous systems that have been used for monoclonal antibody production
include hollow fiber units (7,8,9) and stirred tank or expanded bed systems in which cells are grown
immobilized in encapsulated beads (10-13). In contrast, stirred tank fermentors fitted with either a cell
settler, a spin filter, or an external tangential flow system to allow retension/return of the cells in the
bioreactor are homogeneous and in general more amenable to scaleup. Systems employing a spin filter
to retain cells in the stirred tank, first described by Himmelfarb et al. (14), have been used successfully
for production of monoclonal antibodies (15,16). However, spin filters suffer from fouling and clogging
of the filter and loss of cell viability due to mechanical damaging of the cells.
Some of the design problems encountered with production of monoclonal antibodies at high cell
density include mass transfer limitations, removal of waste and ensuring adequate nutrient supply,
accumulation of dead cells, with the associated decrease in viability, and separation of cells from the
exit stream and returning them to the bioreactor. To address these, newer systems incorporate either a
cell settling tube (17) or conical cell separator (18-20) in the outlet flow. Since cells are differentially
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lost from the tank based on a combination of size and density, they are self-cleaning, as dead cells,
which are both smaller and lighter than live cells, are preferentially removed. In addition, these
systems have the advantage of requiring no moving parts or pumps which damage cells.
While much work has focused on analysis of nutrient uptake and production of metabolic
wastes, many fundamental question concerning changes in cell phsiology remain unanswered. One
question which has not been satisfactorily answered is how the growth rate and specific rate of
antibody production are related to each other, and what determines whether the specific productivity
increases or decreases as a function of viable cell density. A related topic is how one should understand
the great variability in specific antibody production rates, which vary by almost three orders of
magnitude (21,22), even among hybridomas with the same fusion partner. An additional point to
consider is the decline of specific productivity of cells sometimes seen in long-term culture, which can be
caused by outgrowth of low and/or nonproducing cells, or by poorly characterized environmental
changes associated with high density culture.
To begin to address some of these questions, we have characterized monoclonal antibody
production in both low density batch spinners and high density perfusion cell culture, and have
measured the concomitant changes of intracellular precursors, messenger RNA for the IgG heavy and
light chains, and intracellular antibody.
We studied growth and antibody production of Sp2/0-derived transfectomas at high cell
density and observed a reversible downregulation of specific antibody production (mAb/cell-hr) by a
factor of 10 to 15 at cell densities > 6 x 106 c/ml. The volumetric productivity, however, increased
during this time. The growth rate during downregulation remained constant at a doubling time of
approximately 20-24 hours, and the system was not nutrient limited. A viable cell density of 107
cells/ml was obtained at perfusion rates of 2.5-3.4 volumes/day. Measurements of cellular steady-state
levels of immunoglobulin heavy and light chain mRNA showed a 60-70% drop at the condition of low
productivity. Measurements of intracellular antibody showed a decrease of the same magnitude as the
decrease in specific productivity. These data suggest that the decrease in specific productivity is
partly transcriptionally regulated. The decrease in immunoglobulin production is partly accounted for
by a decrease in immunoglobulin mRNA, but there appears to be an additional coordinated
downregulation of immunoglobulin peptide production. This translational limitation may be mediated
by some as yet unidentified condition associated with high cell density in the perfusion bioreactor.
Materials and Methods
Cells
The antibody-producing cells are recombinant Sp2/0-derived cells transfected with chimeric
mouse-human antibody genes (23) and were obtained from Centocor, Inc. These cells secrete an IgG1
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(kappa light chain) directed against a determinant found on colorectal carcinomas (23). In the work
presented here, we used a subclone of this line isolated at MIT and designated CLC LT V-14. Sp2/0
cells are a non-antibody producing murine myeloma cell line and were also obtained from Centocor, Inc.
Medium and Serum
The medium used for all experiments was Dulbecco's Modified Eagle's Medium supplemented to
contain a total of 6 mM glutamine, 2 mM pyruvate, and 50 uM P-mercaptoethanol. This was designated
DMEM*. Fetal bovine serum (Hyclone) was heat treated at 56 OC for 30 minutes.
Culture Methods
Stock cells were grown in 75 cm 2 T-flasks in DMEM* supplemented with 5% fetal bovine serum
in a humidified incubator with a 8% CO 2 atmosphere. These were maintained in exponential growth
by dilution three times per week. These stock cultures were used to inoculate spinner flasks.
Bioreactors were inoculated from exponentially growing spinner cultures at approximately 5 x 105 c/ml.
Perfusion was initiated on day 2, and ramped to 3 volumes/day by day 6. A constant volume was
maintained by setting the outlet pump slightly faster than the inlet pump. Reactors were sampled
twice daily. Total cell density was enumerated using a Coulter Counter (Coulter Electronics). Viable
cell counts were estimated by Trypan Blue exclusion using a hemacytometer. Supernatants were
clarified by centrifugation and frozen at -20 oC for later analysis of antibody titers. Samples were
withdrawn daily from the exit flow and total and viable cell counts were determined as described
above.
Antibody Assay
Antibody titers were quantified via an Elisa sandwich assay, following a protocol obtained
from Centocor, Inc. (24). The absorbance at 405 nm was read on a plate reader. Absolute concentrations
of IgG were estimated by calculating a best fit line for the linear portion of each sample dilution and
for a human IgG standard run on the same plate, and calculating the concentration of IgG in the sample
relative to the standard at an absorbance of 0.8. All determinations were done at least in duplicate.
Flow Cytometry
Aliquots of 2 x 106 cells were permeabilized using 70% ethanol in phosphate buffered saline.
To assess intracellular antibody content, cells were incubated with a fluorescein-conjugated F(ab')2
fragment of goat anti-human IgG directed against human heavy and light chains. Samples were run on
a Coulter Epics C (Coulter, Hialeah, FL) flow cytometer, with excitation at 488 nm and bandpass
emission measured at 530 nm. Sp2 /0 cells were used to assess non-specific binding of the fluorescein-
conjugated antibody to the cells.
Molecular Methods
Total cellular RNA was isolated using the method of Chomczynski and Sacchi (25). Cells
removed from bioreactors were lysed directly into a solution of 4 M guanidinium thiocyanate, 25 mM
sodium citrate, pH 7.0, 0.5% sarcosyl, and 0.1 M 3-mercaptoethanol (25) and stored at -70 oC until RNA
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was isolated. RNA was quantified by measurment of the absorption at 260 nm, using the conversion of 1
A260 = 40 ug/ml RNA. Denaturing formamide/formaldehyde 1% agarose gels were prepared according
to standard methods (26) and loaded with 15 ug total RNA per lane. Gels were photographed and
then transferred to Gene Screen Plus (DuPont) nylon membranes, using the manufacturer's protocol (27).
Blots were baked for 2 hours at 80 oC in a vacuum oven, and irradiated for 7 minutes at 1.5 inches over
a U'V light table. Northern blots were probed with three different random-primed probes. A 1.4 kb
rat a-tubulin cDNA probe was obtained from Dr. Frank Solomon's laboratory at MIT. DNA probes for
the human constant regions of the heavy and light chain were obtained from Centocor, Inc. as pBR322
inserts in E. coli, and were isolated using standard methods. The heavy chain probe is a 75 kb
fragment encompassing the human IgG1 constant region, and the light chain probe consists of a 2.5 kb
fragment encompassing the human light chain (kappa) constant region. Probes were labelled using the
manufacturer's instructions using a 3 2P dCTP (3000 Ci/mmol) and a random priming kit (Amersham
1601Y). Hybridization buffer consisted of 1% SDS, 1 M sodium chloride, 10% dextran sulfate, and 100
ug/ml denatured salmon sperm DNA with 4 x 105 cpm probe/ml, and blots were hybridized overnight
at 60 oC following the Gene Screen Plus (27) protocol. Quantification of the signal intensity was done
using a Phosphor Imager (Molecular Dynamics, Sunnyvale, CA).
Bioreactor design
The bioreactor is shown schematically in Figure 1. Bioreactors were constructed by modifying a
250 ml spinner flask. Oxygenation was provided via gas passed through one meter of expanded PTFE
tubing (W.L. Gore and Associates, Inc.) coiled against the inside wall of the spinner and vented to the
headspace. Gas, initially air with 5% C02, and then 40% oxygen with 1% C02, was bubbled through
a column of water prior to entering the tubing in the bioreactor. One sidearm was fitted with a silicone
cork with two stainless steel tubes to allow for medium inflow and sampling. Cell recycle was via a
lamellar conical cell settler, constructed from four pyrex funnels, which has been described in detail
elsewhere (20). A second bioreactor was constructed with a modification of the conical cell separator,
which was aerated via thin walled silicon tubing coiled around the outer surfaces of the two innermost
funnels. The stem of the bottommost funnel was fitted into a teflon adaptor which had holes at the
bottom and held the stir paddle. Medium was pumped in and out using two peristaltic pumps. The
working volumes were 245 and 288 ml.
Results and Discussion
1. Growth and Antibody Production
Two bioreactors, designated #1 and #2, were run in parallel for 14 days. The design of both
reactors was identical except that the conical cell settler in #2 was oxygenated via silicon tubing. The
midia were identical until day 8, when the medium to #1 was changed from DMEM* supplemented
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with 4% fetal bovine serum (FBS) to DMEM* supplemented with 8% FBS. Viable cell densities and
percent viability are shown in figure 2. The viable cell density increased over days 0-9 and then
remained at approximately 107 viable c/ml from then on. Cell viability decreased from 96% at day 0
to about 70% after day nine, and remained constant. As indicated in figure 2, doubling the serum
concentration did not appear to have any effect on cell density or viability. Oxygenation of the cell
settler did not appear to have any discernible effect on growth or viability.
Perfusion to both bioreactors was initiated on day 2 and ramped to 3 volumes/day to #1 and 2.3
volumes/day to #2 over days 2-6, and held constant until day 10. The flow rate was then increased
slightly to 3.4 and 2.6 volumes/day on day 10. The slight difference in perfusion rate between the two
bioreactors did not appear to affect either cell density or viability. Previous work (28) with this
system had shown that there was no nutrient limitation due to lack of an amino acid or glutamine, and
that lactate levels at this perfusion rate remained below 20 mM (29).
A simple kinetic model was used to estimate the growth and death rates. The change in viable
cell density (Xv) as a function of time for this system is:
dXv Xv - aXv - evXvD
dt 1
Similarly, the change in the dead cell density (XD), ignoring cell lysis, is expressed as follows:
dX = aXv - eDXDDdt 2
where gt = growth rate (hr-1), a= death rate (hr-1 ), Xv, XD = viable, dead cell/ml,
e = separation ratio Xout/Xin for viable, dead cells, D = dilution rate (F/V),
F = flow rate (ml/hr), V = volume of the bioreactor (ml), JAapp = g - a, and
B = 'app - D (ev + ED).
We found values for ev of 0.01 to 0.03; that is, over 97% of the viable cells were retained in
the bioreactors. Values for ED showed more scatter, ranging from 0.08 to 0.67; most measurements were
at about 03. Thus, the dead (via trypan blue staining) cells were removed 3-10 times as efficiently as
the live cells.
Integration of equation 1 gives:
X, = Xv ° e(gtapp - EvD)At 3
which may be rearranged to solve for rapp.
Figure 1: Schematic of Bioreactor
Cell Growth and Viability in Perfusion Bioreactors
10
1
Viable
c/ml x 10^6
0 #1
n #2
0.
u
0
1
'0Io
100
Viability
.-. #2 1
-# 2
2 4 6 8 10 12 14 16
Cumulative Days
6
-w
Il
Figure 2:
* -
Scanged to
89/6 FBS
S1 ramping 3.0 v.l.day 3.4 va day FLOW#2 ramping 2.3vojday 2.6 MolIday
2
I • ,
I_~_ _ _ _ _ _
T I i l I I I I I I I I I I I i l i l l l
j
]I
Integration of equation 2 results in:
B ( XD -XDoe-eDDt)
Xvo e-EDDt ( eBt - 1 ) 4
By first calculating a and .app
, 
one can then estimate the actual growth rate g. When the growth
rates for #1 and #2 were calculated, we found that the actual growth rate did not change signiruficantly
over the course of the experiment, although the death rate a increased from almost zero to
approximately 0.03 hr-1. Doubling times (ln(2)/j.) were estimated at about 20-24 hours. These doubling
times were, however, slightly slower than the 16-20 hour doubling time observed in exponential phase
in batch spinner culture. It should be noted that these calculations are quite sensitive to small
variations in the retention efficiency, and probably underestimate the true growth rate for the
following reason. The level of medium in the reactors was maintained by setting the outlet flow
slightly faster than the inlet flow. This caused the pulling of a bubble of air through the cell settler,
temporarily disrupting the laminar flow, which in turn resulted in a temporarily much higher cell
density in the outlet stream.
We found that degradation of antibody in the medium is negligible (31), and modelled the
volumetric rate of antibody production as follows:
dAb = qp Xv - DAb
dt 5
where Ab = antibody concentration in fermentor (ug/ml)
qP = specific production rate (pg/cell - hr)
D = perfusion rate (F/V)
Equation 5 was solved to give:
= D[ Abt - Abto e-Dt ]
1 -e- Dt 6
and the specific rate of antibody production, qP is given by:
qP xl XvXv,tl - MXv,tO Xvto 7
The volumetric productivities (Qp) are shown in figure 3. The Qp remained fairly constant at
0.15 ug/ml-hr over days 2-6, and then increased to 0.3-0.4 ug/ml-hr at days 7-12, and decreased again at
7
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day 14. Specific productivities (qP) are shown in figure 4. These decreased quite dramatically from
0.15 pg/cell-hr at days 1-3 to 0.05 pg/cell-hr by day 4, and then slowly declined to less than 0.01
pg/cell-hr. Doubling the concentration of serum in the feed to #2 did not affect productivity. In
previous experiments (30), this drop in specific productivity was even more drastic, from about 0.25
pg/cell-hr to less than 0.001 pg/cell-hr. Thus, it can be seen that even though specific mAb production
rates decrease, the volumetric productivity may still rise.
Figure 3: Volumetric Antibody Production in Perfusion Bioreactors
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Figure 4: Specific Antibody Production in Perfusion Bioreactors
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2. Molecular Analysis
While analysis of antibody production rates indicates how the system as a whole is performing
and how much antibody the cells are secreting, it tells us nothing about specific events and control
points inside the cells. We analyzed the flow of macromolecules inside the cell in order to gain a more
complete picture of what is going on, with the eventual goal of identifying the rate limiting step in
antibody production for this system.
The flow of information in the production of antibody can be idealized as follows:
DNAH--> hnRNAH--> mRNAH--> H peptide-->
H2L2 -processed->H 2L2 secreted
DNAL-> hnRNAL--> mRNAL--> L peptide->
A change in any one molecular species will change all of those downstream of it. For example,
a decrease in the copy number, or a deletion in the DNA sequence encoding either the light or heavy
chain will result in a decrease in the amount of mRNA of that species, and thus, in specific mAb
production. Similarly, changes in the extracellular environment may change the growth rate of the
cells, which may result in either a decrease or increase in the amount of assembled antibody produced.
On the other hand, if there is a shortage of, for example, a nutrient, cellular resources may be shifted
towards production of essential housekeeping mRNAs and proteins and away from production of
nonessential mRNAs and proteins (such as antibodies).
To assess whether the decrease in specific antibody production was due to gene deletion, we
began by looking at the gene copy number. Analysis of DNA copy number via Southern blotting (31)
indicated that this subclone has about 2 copies each of the heavy and light chain gene integrated into
the genomic DNA. We have shown (31) that the copy number does not change with time in either
stock culture or bioreactor growth, and thus gene deletion is not the cause of the decline in specific
productivity.
The second step in information flow is transcription, consisting of initiation, elongation,
termination, splicing, polyA tail addition, and export from the nucleus to the cytoplasm (33). Since the
literature suggests that there are very few copies of heterogeneous nuclear RNA (32), and that it is
turned over very quickly, we focused on quantifying steady-state immunoglobulin mRNA levels, as the
level of mature mRNA template in the cytoplasm dictates the upper limit of the number of
polypeptide chains that may be made.
Analysis of cellular mRNA via northern blotting is shown in figures 5a and 5b. Figure 5a
shows RNA isolated from cells removed daily from the bioreactor and probed with mouse a-tubulin and
IgG light chain probes. Sizes were estimated by comparison with a synthetic marker (BRL) run on each
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gei. The tubulin mRNA is about 2.2 kb, and the light chain 1.2-1.4 kb. Figure 5b shows the same blot
after stripwashing and reprobed with a IgG heavy chain probe. The heavy chain mRNA is about 2.2
kb. The sizes of the immunoglobulin mRNAs agree with literature values (32).
Figures 5a and b: Northern Blot of mRNA Isolated from Cells in
Bioreactor on Indicated Days
a) Blot was probed with a-tubulin and IgG light chain probes.
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In order to estimate the the relative amounts of immunoglobulin per cell at various times during
the experiment, blots were quantified on a phosphor imager. The intensity of the tubulin signal was
used to normalize each lane for the amount of RNA loaded. As tubulin is an essential housekeeping
gene, the amount of tubulin mRNA per cell is regulated and remains fairly constant (3435). We have
also shown (31) that the amount of total RNA per cell remains fairly constant at about 20 pg/cell.
Thus, by normalizing using the tubulin signal, each lane represents an equal number of cells. The
amount of immunoglobulin mRNA per lane was then normalized to the average of the two day zero
sampies. The normalized values are depicted graphically in figure 6. It can be seen that the levels of
both heavy and light chain mRNA decrease as a function of time in the bioreactor. The level of light
chain mRNA decreases to about 30 to 40% of its original value, while the level of heavy chain mRNA
decreases to about 20-30% of its original value. These results indicate that at least part of the
decrease in specific productivity may be accounted for by the decrease in mRNA template available for
immunoglobulin peptide synthesis. However, other data (32) indicates that this level of mRNA is
available even when the specific productivity declines from about 0.01 pg/cell-hr (seen at day 14) to
0.001 pg/cell-hr. Therefore. we believe that the observed decrease in mRNA can not completely
account for the decline in specific productivity.
In depth analysis (32) of the immunoglobulin-producing cell line MPC-11 suggested that light
chain mRNA and peptide is in excess of heavy chain by about 2:1. An excess of light chain mRNA has
also been observed for a hybridoma cell line (36). Here we have observed the same phenomenon,
although judging from the difference in intensity observed, the ratio of LH mRNA is approximately 3-
4:1.
Figure 6: Cellular Immunoglobulin Heavy and Light Chain mRNA
During Growth In Bioreactor and Normalized to Day Zero
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We also examined the intracellular antibody content of these cells via staining for cytoplasmic
antibody and flow cytometry. Cells were removed from the bioreactors on days 3, 6, 10, and 13, and
stained for intracellular antibody content using a fluorescein-conjugated antibody specific for the human
heavy and light chain. Results of flow cytometry are shown in figures 7 and 8, with the x axis
showing green fluorescence (log scale) and the y axis number of cells. Figure 7a shows staining of Sp2/0.
These cells do not have any intracellular IgG and were used to determine the amount of nonspeciic
staining. The negative cutoff was set so that 99.9% of the Sp2/0 cells fell into the left region of figure
7a. Figure 7b shows stock "control" cells. These were exponentially growing cells from T-flasks which
had a specific productivity of 0.2 pg/cell-hr. Using the same cutoff as for the Sp2/0 cells, 95-99% of
the control cells are positive for intracellular antibody. Sp2/0 cells and control cells were run with
each set of samples from the bioreactor. Figures 8a and 8b show cells from day 3 and day 6. The
distribution of intracellular antibody observed in cells from the bioreactor on day 3 is nearly identical
to that of the control cells. On day 6, 97% of the bioreactor cells are positive for intracellular
antibody, but the distribution is skewed towards lower fluorescence. Figures 8c and 8d show cells from
days 10 and 13. It can be seen that there is quite a dramatic decline in intracellular antibody content.
On day 10, only 54% of the bioreactor cells were positive for intracellular antibody, and by day 13,
only 44% of the cells were positive. Similar results were obtained using two other fluorescein-
conjugated antibodies, one specific for the human IgG light chain and one for the Fc fragment (data not
shown).
Figures 7a and b and 8a-d show the intensities on a log scale. In order to quantify the
intracellular antibody content, this data was reanalyzed and the mean intensities were expressed as
linear, rather than logarithmic, means. Results of this data transformation indicate that by day 6,
the fluorescent intensity (a measurement of IgG content) had declined by 75%. On days 10 and 13, the
fluorescent intensity of cells from the bioreactor is only 15% of that of the controls. If one makes the
assumptions that the fluorescein-conjugated antibody is in excess, and that binding is proportional to
the intracellular antibody content, then one can see that this value corresponds quite well to the
specific antibody production rate. This suggests that there is a coordinated downregulation of
immunoglobulin peptide production. This translational limitation appears to be mediated by some as
yet unidentified condition associated with high cell density in the perfusion bioreactor.
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Figure 7a and b: Cytoplasmic Antibody Content of Cells Analyzed via
Flow Cytometry
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3. Analysis of Decline in Specific Productivity
We examined whether this downregulation of antibody production was reversible or permanent.
A permanent decrease in specific productivity of the population of cells in the reactor could be due to
outgrowth of non-producing mutants, while reversible downregulation suggests that there is an
inhibitory factor(s) produced at high density which mediates. If the downregulation was permanent,
then cells removed from the bioreactor and placed into spinners at low cell density should continue to
produce only at the low level.
Cells were removed from the bioreactor and inoculated into batch spinners at an initial cell
density of 5 x 104 c/ml. Stock "control" cells were also inoculated into spinners in parallel. These
spinners were sampled daily, and supernatants analyzed for IgG titer. Calculations of the specific
antibody production rates for "control" cells and cells removed from bioreactors showed that these were
indistinguishable. If the bioreactor imposed a condition to favor outgrowth of low or non-producing
cells, then this recovery of monoclonal antibody productivity would not be possible. Our current belief
is that the downregulation of antibody production is due to a change in the metabolism of the cells,
and experiments are in progress to test this hypothesis.
Conclusions
We have described growth and antibody production in a perfusion bioreactor employing a
conical cell settler to effect cell retension. A dynamic steady-state cell density of 107 viable cells/ml
was achieved, and growth was balanced by cell death and removal of cells. The volumetric
productivity increased with cell density, but specific productivity decreased with increasing cell
density from 0.15 pg/cell-hr to 0.01 pg/cell-hr. Analysis of steady-state immunoglobulin mRNAs
showed that the level of light chain mRNA decreased to about 30 to 40% of its original value, and the
level of heavy chain mRNA decreased to about 20-30% of its original value. Flow cytometry indicated
that the amount of intracellular antibody decreased by approximately 90%. Thus, the downregulation
of antibody production is partially transcriptionally regulated, but there is a second, as yet
unidentified control point mediating immunoglobulin peptide synthesis. We have also shown that the
downregulation of antibody production is reversible and is specifically mediated by condition(s) at high
cell density.
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